Go to PiHKAL • info home
Browse the short index of PiHKAL phenethylamines. Read book II of PiHKAL
Search for phenethylamines and related structures Beyond PiHKAL—Selected writings by Sasha and others. Explore phenethylamine structures and analogues
The essential oils and their amphetamine analogues How PiHKAL • info differs from the printed version
Go to TiHKAL • info home
References and bibliography: 1540 references found
Filter by: Type:
Author:
Journal:
From: To:
 
Sort by: Author then by: Author
Title Title
Publication Publication
Newest to oldest Newest to oldest
Oldest to newest Oldest to newest
Recently added first Recently added first

Fenderson5555. Synthesis of muscimol (Amanita Muscaria psychoactive component). 3483 kB.

Fenderson5555. Reactions in the synthesis of ketamine. 1379 kB.

Fenderson5555. Reactions in the synthesis of cocaine. 6072 kB.

Elliott, S; Evans, J. A 3-year review of new psychoactive substances in casework. Forensic Sci. Int., 1 Oct 2014, 243, 55–60. 1083 kB. doi:10.1016/j.forsciint.2014.04.017

Brandt, SD; King, LA; Evans-Brown, M. The new drug phenomenon. Drug Test. Anal., 1 Aug 2014, 6 (7–8), 587–597. 213 kB. doi:10.1002/dta.1686

Appendino, G; Minassi, A; Taglialatela-Scafati, O. Recreational drug discovery: natural products as lead structures for the synthesis of smart drugs. Nat. Prod. Rep., 1 Jul 2014, 31 (7), 880–904. 1202 kB. doi:10.1039/c4np00010b

Jovel, A; Felthous, A; Bhattacharyya, A. Delirium due to intoxication from the novel synthetic tryptamine 5-MeO-DALT. J. Forensic Sci., 1 May 2014, 59 (3), 844–846. 91 kB. doi:10.1111/1556-4029.12367

Sakai, R; Swanson, GT. Recent progress in neuroactive marine natural products. Nat. Prod. Rep., 1 Feb 2014, 31 (2), 273–309. 2059 kB. doi:10.1039/C3NP70083F

Haines-Saah, RJ; Johnson, JL; Repta, R; Ostry, A; Young, ML; Shoveller, J; Sawatzky, R; Greaves, L; Ratner, PA. The privileged normalization of marijuana use—an analysis of Canadian newspaper reporting, 1997–2007. Critical Public Health, 2014, 24 (1), 47–61. 191 kB. doi:10.1080/09581596.2013.771812

Nichols, DE; Fantegrossi, WE. Emerging designer drugs. In The Effects of Drug Abuse on the Human Nervous System; Madras, B; Kuhar, M, Eds., Elsevier, 1 Dec 2013; Vol. 19, pp 575–596. 427 kB. doi:10.1016/B978-0-12-418679-8.00019-8

Pal'chikov, VA. Morpholines. Synthesis and biological activity. Russ. J. Org. Chem., 1 Jun 2013, 49 (6), 787–814. 540 kB. doi:10.1134/S1070428013060018

Amsterdam, J; Nutt, D; Brink, W. Generic legislation of new psychoactive drugs. J. Psychopharmacol., 1 Mar 2013, 27 (3), 317–324. 411 kB. doi:10.1177/0269881112474525

Blunt, JW; Copp, BR; Keyzers, RA; Murray; Munro, HG; Prinsep, MR. Marine natural products. Nat. Prod. Rep., 1 Feb 2013, 30 (2), 237–323. 3410 kB. doi:10.1039/c2np20112g

Garcia-Mijares, M; Bernardes, AMT; Silva, MTA. Diethylpropion produces psychostimulant and reward effects. Pharmacol. Biochem. Behav., 1 Feb 2009, 91 (4), 621–628. 660 kB. doi:10.1016/j.pbb.2008.10.001

Stepens, A; Logina, I; Liguts, V; Aldiņš, P; Ekšteina, I; Platkājis, A; Mārtiņsone, I; Tērauds, E; Rozentāle, B; Donaghy, M. A Parkinsonian syndrome in methcathinone users and the role of manganese. N. Engl. J. Med., 6 Mar 2008, 358 (10), 1009–1017. 390 kB. doi:10.1056/NEJMoa072488

Görnemann, T; Jähnichen, S; Schurad, B; Latté, KP; Horowski, R; Tack, J; Flieger, M; Pertz, HH. Pharmacological properties of a wide array of ergolines at functional alpha1-adrenoceptor subtypes. Naunyn-Schmiedeberg's Arch. Pharmacol., 1 Jan 2008, 376 (5), 321–330. 303 kB. doi:10.1007/s00210-007-0221-3

Fierro, A; Osorio-Olivares, M; Cassels, BK; Edmondson, DE; Sepúlveda-Boza, S; Reyes-Parada, M. Human and rat monoamine oxidase-A are differentially inhibited by (S)-4-alkylthioamphetamine derivatives: Insights from molecular modeling studies. Bioorg. Med. Chem., 1 Aug 2007, 15 (15), 5198–5206. 1158 kB. doi:10.1016/j.bmc.2007.05.021

Reyes-Parada, M; Fierro, A; Iturriaga-Vásquez, P; Cassels, BK. Monoamine oxidase inhibition in the light of new structural data. Curr. Enz. Inhib., 2005, 1 (1), 85–95. 158 kB. doi:10.2174/1573408052952711

Peters, L; König, GM; Terlau, H; Wright, AD. Four new bromotryptamine derivatives from the marine bryozoans Flustra foliacea. J. Nat. Prod., 22 Nov 2002, 65 (11), 1633–1637. 67 kB. doi:10.1021/np0105984

Vallejos, G; Rezende, MC; Cassels, BK. Charge-transfer interaction in the inhibition of MAO-A by phenylisopropylamines—a QSAR study. J. Comput. Aided Mol. Des., 1 Feb 2002, 16 (2), 95–103. 103 kB. doi:10.1037/a0020827

Musshoff, F. Illegal or legitimate use? Precursor compounds to amphetamine and methamphetamine. Drug Metab. Rev., 2000, 32 (1), 15–44. 345 kB. doi:10.1081/DMR-100100562

Pietzsch, J; Scheunemann, M; Kretzschmar, M; Elz, S; Pertz, HH; Seifert, S; Brust, P; Spies, H; Syhre, R; Johannsen, B. Synthesis and autoradiographic evaluation of a novel high-affinity Tc-99m ligand for the 5-HT2A receptor. Nucl. Med. Biol., 1 Nov 1999, 26 (8), 865–875. 894 kB. doi:10.1016/S0969-8051(99)00058-X

Torres, MA; Rezende, MC; Cassels, BK. α1-Adrenergic and 5-HT2-serotonergic effects of some β-alkoxy-β-phenylethylamines on isolated rat thoracic aorta. Gen. Pharmac., 1 Jul 1998, 31 (1), 51–54. 169 kB. doi:10.1016/S0306-3623(97)00421-7

Reyes-Parada, M; Scorza, MC; Silveira, R; Dajas, F; Costa, G; Tipton, KF; Cassels, BK. Monoamine oxidase inhibitory effects of some 4-aminophenethylamine derivatives. Biochem. Pharmacol., 20 Apr 1994, 47 (8), 1365–1371. 570 kB. doi:10.1016/0006-2952(94)90335-2

Saez, P; Borges, Y; Gonzalez, E; Cassels, BK. α-Adrenergic and 5-HT2-serotonergic effects of some β-phenylethylamines on isolated rat thoracic aorta. Gen. Pharmac., 1 Jan 1994, 25 (1), 211–216. 472 kB. doi:10.1016/0306-3623(94)90035-3

Squella, JA; Cassels, BK; Arata, M; Bavestrello, MP; Nuñez-Vergara, LJ. Electrochemical oxidation of methylenedioxyamphetamines. Talanta, 1 Sep 1993, 40 (9), 1379–1384. 390 kB. doi:10.1016/0039-9140(93)80214-C

Squella, JA; Berguecio, MA; Hernández, A; Cassels, BK; Núñez-Vergara, LJ. Electrochemical study of some 2,5-dimethoxyamphetamine derivatives. J. Chim. Phys., 1992, 89, 669–679. 384 kB.

Gomez-Jeria, JS; Cassels, BK; Saavedra-Aguilar, JC. A quantum-chemical and experimental study of the hallucinogen (±)-1-(2,5-dimethoxy-4-nitrophenyl)-2-aminopropane (DON). Eur. J. Med. Chem., 1 Sep 1987, 22 (5), 433–437. 559 kB. doi:10.1016/0223-5234(87)90032-8

Gómez-Jeria, JS; Cassels, BK; Clavijo, R; Vargas, V; Quintana, R; Saavedra-Aguilar, JC. Spectroscopic characterization of a new hallucinogen: 1-(2,5-dimethoxy-4-nitrophenyl)-2-aminopropane (DON). Microgram, 1 Nov 1986, 19 (11), 153–161. 340 kB.

McLeod, WR; Sitaram, BR. Bufotenine reconsidered. Acta Psychiatr. Scand., 1 Nov 1985, 72 (5), 447–450. 263 kB. doi:10.1111/j.1600-0447.1985.tb02638.x

Baker, PB; Phillips, GF. The forensic analysis of drugs of abuse. A review. Analyst, 1 Jul 1983, 108 (1288), 777–807. 3771 kB. doi:10.1039/AN9830800777

Makriyannis, A; Knittel, J. Conformation studies on phenethylamine hallucinogens: The role of alpha alkyl substitution. In QuaSAR: Quantitative Structure Activity Relationships of Analgesics, Narcotic Antagonists, and Hallucinogens. NIDA Research Monograph 22; Barnett, G; Trsic, M; Willette, RE, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office, Washington, DC, 1978; Vol. 22, pp 464–478. 474 kB.

Giudicelli, JF; Richer, C; Berdeaux, A. Preliminary assessment of flutiorex, a new anorectic drug, in man. Br. J. Clin. Pharmac., 1 Feb 1976, 3 (1), 113–121. 1109 kB. doi:10.1111/j.1365-2125.1976.tb00578.x

Barfknecht, CF; Nichols, DE; Dunn, WJ. Correlation of psychotomimetic activity of phenethylamines and amphetamines with 1-octanol-water partition coefficients. J. Med. Chem., 1 Feb 1975, 18 (2), 208–210. 363 kB. doi:10.1021/jm00236a023

Nichols, DE. Potential psychotomimetics: Bromomethoxyamphetamines and structural congeners of lysergic acid. Ph. D. Thesis, University of Iowa, Iowa City, IA, 1 May 1973. 12963 kB.

Shaler, RC; Padden, JJ. Identification of hallucinogens in illicit seizures I: 2,5-dimethoxyamphetamine. J. Pharm. Sci., 1 Nov 1972, 61 (11), 1851–1855. 334 kB. doi:10.1002/jps.2600611142

Testa, B; Beckett, AH. Studies on the metabolism of diethylpropion. I. Analytical procedure. J. Chromatogr., 23 Aug 1972, 71 (1), 39–54. 1403 kB. doi:10.1016/S0021-9673(01)85688-0

Sepúlveda, S; Valenzuela, R; Cassels, BK. Potential psychotomimetics. New bromoalkoxyamphetamines. J. Med. Chem., 1 Apr 1972, 15 (4), 413–415. 356 kB. doi:10.1021/jm00274a022

Kapadia, GJ; Fayez, MBE. Peyote constituents: Chemistry, biogenesis, and biological effects. J. Pharm. Sci., 1 Dec 1970, 59 (12), 1699–1727. 3134 kB. doi:10.1002/jps.2600591202

Neville, GA. Gas chromatographic and nuclear magnetic resonance spectroscopic studies of 1,3-dimethylbarbiturates obtained by various methylation techniques. Anal. Chem., 1 Mar 1970, 42 (3), 347–351. 605 kB. doi:10.1021/ac60285a029

Bessho, K. Studies on pilocereine and related compounds. IV. Synthesis of o-methylisopilocereine. Chem. Pharm. Bull., 1963, 11 (12), 1491–1494. 329 kB. doi:10.1248/cpb.11.1491

Osmond, H. A review of the clinical effects of psychotomimetic agents. Ann. N. Y. Acad. Sci., 1 Mar 1957, 66, 418–434. 1193 kB. doi:10.1111/j.1749-6632.1957.tb40738.x

Zaehner, RC. The menace of mescalin. New Blackfriars, 1 Jul 1954, 35 (412–413), 310–323. 848 kB. doi:10.1111/j.1741-2005.1954.tb06115.x

Ziering, A; Berger, L; Heineman, SD; Lee, J. Piperidine derivatives. Part III. 4-Arylpiperidines. J. Org. Chem., 1 Nov 1947, 12 (6), 894–903. 637 kB. doi:10.1021/jo01170a022

Wallach, J; Kavanagh, PV; McLaughlin, G; Morris, N; Power, JD; Elliott, SP; Mercier, MS; Lodge, D; Morris, H; Dempster, NM; Brandt, SD. Preparation and characterization of the ‘research chemical’ diphenidine, its pyrrolidine analogue, and their 2,2-diphenylethyl isomers. Drug Test. Anal., 632 kB. doi:10.1002/dta.1689

Anon. Report on the risk assessment of 3,4-dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}benzamide (AH-7921), European Monitoring Centre for Drugs and Drug Addiction, May 2014.

Anon. Report on the risk assessment of 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one (MDPV), European Monitoring Centre for Drugs and Drug Addiction, May 2014.

Anon. Report on the risk assessment of 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine), European Monitoring Centre for Drugs and Drug Addiction, May 2014.

Anon. Report on the risk assessment of 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe), European Monitoring Centre for Drugs and Drug Addiction, Apr 2014.

Anon. Report on the risk assessment of 5-(2-aminopropyl)indole (5-IT), European Monitoring Centre for Drugs and Drug Addiction, Jan 2014.

Anon. Report on the risk assessment of GHB , European Monitoring Centre for Drugs and Drug Addiction, Jun 2002.

Anon. Report on the risk assessment of ketamine, European Monitoring Centre for Drugs and Drug Addiction, Jun 2002.

Simmler, LD; Rickli, A; Hoener, MC; Liechti, ME. Monoamine transporter and receptor interaction profiles of a new series of designer cathinones. Neuropharmacology, 1 Apr 2014, 79, 152–160. 787 kB. doi:10.1016/j.neuropharm.2013.11.008

Simmler, LD; Rickli, A; Schramm, Y; Hoener, MC; Liechti, ME. Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives. Biochem. Pharmacol., 15 Mar 2014, 88 (2), 237–244. 504 kB. doi:10.1016/j.bcp.2014.01.024

Hess, C; Ritke, N; Sydow, K; Mehling, L; Ruehs, H; Madea, B; Musshoff, F. Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. Drug Test. Anal., 20 Feb 2014. 451 kB. doi:10.1002/dta.1619

Uchiyama, N; Shimokawa, Y; Matsuda, S; Kawamura, M; Kikura-Hanajiri, R; Goda, Y. Erratum to: Two new synthetic cannabinoids, AM-2201 benzimidazole analog (FUBIMINA) and (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl)methanone (MEPIRAPIM), and three phenethylamine derivatives, 25H-NBOMe 3,4,5-trimethoxybenzyl analog, 25B-NBOMe, and 2C-N-NBOMe, identified in illegal products. Forensic Toxicol., 1 Jan 2014, 32 (1), 116–117. 258 kB. doi:10.1007/s11419-013-0219-0

Seely, KA; Patton, AL; Moran, CL; Womack, ML; Prather, PL; Fantegrossi, WE; Radominska-Pandya, A; Endres, GW; Channell, KB; Smith, NH; McCain, KR; James, LP; Moran, JH. Forensic investigation of K2, Spice, and “bath salt” commercial preparations: A three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Sci. Int., 10 Dec 2013, 233 (1–3), 416–422). 1346 kB. doi:10.1016/j.forsciint.2013.10.002

Iversen, L; Gibbons, S; Treble, R; Setola, V; Huang, X; Roth, BL. Neurochemical profiles of some novel psychoactive substances. Eur. J. Pharmacol., 30 Jan 2013, 700 (1–3), 147–151. 490 kB. doi:10.1016/j.ejphar.2012.12.006

Schmid, CL; Bohn, LM. Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a β-arrestin2/Src/Akt signaling complex in vivo. J. Neurosci., 6 Oct 2010, 30 (40), 13513–13524. 1534 kB. doi:10.1523/JNEUROSCI.1665-10.2010

Hammersley, R. Dangers of banning Spice and the synthetic cannabinoid agonists. Addiction, 1 Feb 2010, 105 (2), 373. 73 kB. doi:10.1111/j.1360-0443.2009.02845.x

Sedefov, R; Gallegos, A; King, L; Lopez, D; Auwärter, V; Hughes, B; Griffiths, P. Understanding the ‘spice’ phenomenon. Toxichem Krimtech, 2010, 77 (1), 29–45. 210 kB.

Wood, DM; Looker, JJ; Shaikh, L; Lidder, S; Ramsey, J; Holt, DW; Dargan, PI. Delayed onset of seizures and toxicity associated with recreational use of Bromo-dragonFLY. J. Med. Toxicol., 1 Dec 2009, 5 (4), 226–229. 732 kB. doi:10.1007/BF03178273

Wellman, PJ; Davis, KW; Clifford, PS; Rothman, RB; Blough, BE. Changes in feeding and locomotion induced by amphetamine analogs in rats. Drug Alcohol Depend., 1 Mar 2009, 100 (3), 234–239. 691 kB. doi:10.1016/j.drugalcdep.2008.10.005

Beug, MW; Shaw, M; Cochran, KW. Thirty-plus years of mushroom poisoning: Summary of the approximately 2,000 reports in the NAMA case registry. McIlvainea, 2006, 16 (2), 47–68. 158 kB.

Carroll, FI; Runyon, SP; Abraham, P; Navarro, H; Kuhar, MJ; Pollard, GT; Howard, JL. Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers. J. Med. Chem., 2 Dec 2004, 47 (25), 6401–6409. 121 kB. doi:10.1021/jm0401311

Adkins, EM; Barker, EL; Blakely, RD. Interactions of tryptamine derivatives with serotonin transporter species variants implicate transmembrane domain I in substrate recognition. Mol. Pharmacol., 1 Mar 2001, 59 (3), 514–523. 191 kB. doi:10.1124/mol.59.3.514

Tamiz, AP; Zhang, J; Flippen-Anderson, JL; Zhang, M; Johnson, KM; Deschaux, O; Tella, S; Kozikowski, AP. Further SAR studies of piperidine-based analogues of cocaine. 2. Potent dopamine and serotonin reuptake inhibitors. J. Med. Chem., 23 Mar 2000, 43 (6), 1215–1222. 263 kB. doi:10.1021/jm9905561

Gröger, D; Floss, HG. Biochemistry of ergot alkaloids – achievements and challenges. The Alkaloids: Chemistry and Biology, 1998, 50, 171–218. 2199 kB. doi:10.1016/S1099-4831(08)60043-7

Bailey, DJ; O’Hagan, D; Tavasli, M. A short synthesis of (S)-2-(diphenylmethyl)pyrrolidine, a chiral solvating agent for NMR analysis. Tetrahedron: Asymmetry, 9 Jan 1997, 8 (1), 149–153. 281 kB. doi:10.1016/S0957-4166(96)00495-8

Bal, TS; Gutteridge, DR; Johnson, B. Adverse effects of the use of unusual phenethylamine compounds sold as illicit amphetamine. Med. Sci. Law, 1 Jul 1989, 29 (3), 186–188. 886 kB. doi:10.1177/002580248902900303

Noggle, FT; DeRuiter, J; Long, MJ. Spectrophotometric and liquid chromatographic identification of 3,4-methylenedioxyphenylisopropylamine and its N-methyl and N-ethyl homologs. J. Assoc. Anal. Chem., 1986, 69 (4), 681–686. 274 kB.

Noggle, FT; Clark, CR; Davenport, TW; Coker, ST. Synthesis, identification, and acute toxicity of α-benzylphenethylamine and α-benzyl-N-methylphenethylamine. Contaminants in clandestine preparation of amphetamine and methamphetamine. J. Assoc. Anal. Chem., 1985, 68 (6), 1213–1222. 515 kB.

Tolkachev, ON; Voronin, VG; Preobrazhenskii, NA. Synthesis of bromo-substituted β-phenylethylamines. J. Gen. Chem. USSR, 1985, 28, 3345–3348. 183 kB.

Noggle, FT; Clark, CR. Identification of some benzodiazepines of forensic interest. J. Assoc. Anal. Chem., 1979, 62 (4), 799–807. 259 kB.

Bailey, K; Legault, D. Identification of analogs of the hallucinogen cyclohexamine. J. Assoc. Anal. Chem., 1979, 62 (5), 1124–1137. 512 kB.

Bailey, K; Gagné, DR; Legault, D; Pike, RK. Spectroscopic and chromatographic identification of dimethylamphetamines. J. Assoc. Anal. Chem., 1977, 60(3), 642–653. 381 kB.

Bailey, K; Gagné, DR; Pike, RK. Identification of some analogs of the hallucinogen phencyclidine. J. Assoc. Anal. Chem., 1976, 59 (1), 81–89. 353 kB.

Chilton, WS. The course of an intentional poisoning. McIlvainea, 1975, 2 (1), 17–18. 826 kB.

Snyder, SH; Unger, S; Blatchley, R; Barfknecht, CF. Stereospecific actions of DOET (2,5-dimethoxy-4-ethylamphetamine). Arch. Gen. Psychiat., 1 Jul 1974, 31 (1), 103–106. 642 kB. doi:10.1001/archpsyc.1974.01760130079013

Bailey, K; Legauld, D; Verner, D. Spectroscopic and chromatographic identification of dimethoxyamphetamines. J. Assoc. Anal. Chem., 1974, 57 (1), 70–78. 426 kB.

Bailey, K; Verner, D; Legault, D. Distinction of some dialkyl amides of lysergic and iso-lysergic acids from LCD. J. Assoc. Anal. Chem., 1973, 56 (1), 88–99. 513 kB.

Cooper, PD; Walters, GC. Stereochemical requirements of the mescaline receptor. Nature, 14 Jul 1972, 238 (5359), 96–98. 2681 kB. doi:10.1038/238096a0

Leminger, O. Příspěvek k chemii v jádře aIkoxylovaných p-fenoetylaminů - II. Chemický průmysl, 1972, 22, 553–557. 581 kB.

Snyder, SH; Weingartner, H; Faillace, LA. DOET (2,5-dimethoxy-4-ethylamphetamine), a new psychotropic drug. Arch. Gen. Psychiat., 1 Jan 1971, 24 (1), 50–55. 643 kB. doi:10.1001/archpsyc.1971.01750070052006

Violland, R; Violland-Duperret, N; Pacheco, H. Psychotropes potentiels. IX. Synthèse et structure de composés dérivant de l’amino-3 tétralol-1 et apparentés à divers psychotomimétiques. Bull. Soc. Chim. Fr., 1971, 1, 307–311. 312 kB.

Weingartner, H; Snyder, SH; Faillace, LA; Markley, H. Altered free associations: Some cognitive effects of DOET (2,5-dimethoxy-4-ethylamphetamine). Syst. Res., 1 Jul 1970, 15 (4), 297–303. 539 kB. doi:10.1002/bs.3830150402

Walters, GC; Cooper, PD. Alicyclic analogue of mescaline. Nature, 20 Apr 1968, 218 (5138), 298–300. 3141 kB. doi:10.1038/218298a0

Snyder, SH; Faillace, L; Hollister, L. 2,5-Dimethoxy-4-methyl-amphetamine (STP): A new hallucinogenic drug. Science, 3 Nov 1967, 158 (3801), 669–670. 520 kB. doi:10.1126/science.158.3801.669

Leete, E. Biosynthesis of the peyote alkaloids. The incorporation of tyrosine-2-C14 into mescaline and anhalonidine. J. Am. Chem. Soc., 1 Sep 1966, 88 (18), 4218–4221. 1135 kB. doi:10.1021/ja00970a020

Woolley, DW; Shaw, EN. Evidence for the participation of serotonin in mental processes. Ann. N. Y. Acad. Sci., 1 Mar 1957, 66 (3), 649–667. 946 kB. doi:10.1111/j.1749-6632.1957.tb40755.x

Jansen, MPJM. β-2,4,5-Trimethoxyphenylethylamine, an isomer of mescaline. Recl. Trav. Chim. Pays-Bas, 1931, 50 (4), 291–312. 1227 kB. doi:10.1002/recl.19310500403

Sanchez, MJSB. Sur un homologue de l’éphédrine. Bull. Soc. Chim. Fr., 1929, 45, 284–286. 600 kB.

Iversen, L; White, M; Treble, R. Designer psychostimulants: Pharmacology and differences. Neuropharmacology, 633 kB. doi:10.1016/j.neuropharm.2014.01.015

Hellot, J; Violland-Duperret, N; Pacheco, H. Psychotropes potentiels VI. Synthèse de nouveaux mescalinoïdes. Chimie Therapeutique, 1 Jan 1970, 5 (1), 55–64. 472 kB. HNMR, anal. chem. In French.

Nelson, ME; Bryant, SM; Aks, SE. Emerging drugs of abuse. Dis. Mon., 1 Mar 2014, 60 (3), 110–132. 524 kB. doi:10.1016/j.disamonth.2014.01.001

Glennon, RA. Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention. Advances in Pharmacology, 2014, 69, 581–620. 564 kB. doi:10.1016/978-0-12-420118-7.00015-9

Brandt, SD; Baumann, MH; Partilla, JS; Kavanagh, PV; Power, JD; Talbot, B; Twamley, B; Mahony, O; O’Brien, J; Elliott, SP; Archer, RP; Patrick, J; Singh, K; Dempster, NM; Cosbey, SH. Characterization of a novel and potentially lethal designer drug (±)-cis-para-methyl-4-methylaminorex (4,4′-DMAR, or ‘Serotoni’). Drug Test. Anal., 2014. 1068 kB. doi:10.1002/dta.1668

Venhuis, B; Keizers, P; Riel, A; Kaste, D. A cocktail of synthetic stimulants found in a dietary supplement associated with serious adverse events. Drug Test. Anal., 2014. 276 kB. doi:10.1002/dta.1664

Laussmann, T; Grzesiak, I; Krest, A; Stirnat, K; Meier-Giebing, S; Ruschewitz, U; Klein, A. Copper thiocyanato complexes and cocaine—a case of ‘black cocaine’ Drug Test. Anal., 2014. 709 kB. doi:10.1002/dta.1658

Wilkins, C. The interim regulated legal market for NPS (‘legal high’) products in New Zealand: The impact of new retail restrictions and product licensing. Drug Test. Anal., 2014. 396 kB. doi:10.1002/dta.1643

Wood, DM; Hill, SL; Thomas, SHL; Dargan, PI. Using poisons information service data to assess the acute harms associated with novel psychoactive substances. Drug Test. Anal., 2014. 395 kB. doi:10.1002/dta.1671

Haig, SD; Kelly, C; Morden, C. A report of an outbreak of toxicity from a novel drug of abuse: ERIC-3. Emerg. Med. J., 1 Jul 2013, 30 (7), 543–545. 90 kB. doi:10.1136/emermed-2012-201631

Moosmann, B; Hutter, M; Huppertz, LM; Ferlaino, S; Redlingshöfer, L; Auwärter, V. Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine. Forensic Toxicol., 1 Jul 2013, 31 (2), 263–271. 332 kB. doi:10.1007/s11419-013-0187-4

Paoli, GD; Brandt, SD; Wallach, J; Archer, RP; Pounder, DJ. From the street to the laboratory: Analytical profiles of methoxetamine, 3-methoxyeticyclidine and 3-methoxyphencyclidine and their determination in three biological matrices. J. Anal. Toxicol., 1 Jun 2013, 37 (5), 277–283. 264 kB. doi:10.1093/jat/bkt023

Socci, ME. Ingressus: The healing potentials of non-ordinary states of consciousness. M. A. Thesis, Pacifica Graduate Institute, Carpinteria, CA, 15 Mar 2013. 758 kB.

Gomes, MM; Dörr, FA; Catalani, LH; Campa, A. Oxidation of lysergic acid diethylamide (LSD) by peroxidises: a new metabolic pathway. Forensic Toxicol., 1 Jul 2012, 30 (2), 87–97. 632 kB. doi:10.1007/s11419-011-0131-4

Ross, S. Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies. Psychiatr. Clin. N. Am., 1 Jun 2012, 35 (2), 357–374. 436 kB. doi:10.1016/j.psc.2012.04.002

Gahr, M; Freudenmann, RW; Hiemke, C; Gunst, IM; Connemann, J; Schönfeldt-Lecuona, C. “Krokodil” – revival of an old drug with new problems. Subst. Use Misuse, 1 Jun 2012, 47 (7), 861–863. 141 kB. doi:10.3109/10826084.2012.669807

Lurie, Y; Gopher, A; Lavon, O; Almog, S; Sulimani, L; Bentur, Y. Severe paramethoxymethamphetamine (PMMA) and paramethoxyamphetamine (PMA) outbreak in Israel. Clin. Toxicol., 1 Jan 2012, 50 (1), 39–43. 93 kB. doi:10.3109/15563650.2011.635148

Tupper, KW. Ayahuasca, entheogenic education & public policy. Ph. D. Thesis, University of British Columbia, Vancouver, BC, 1 Apr 2011. 2119 kB.

Baggott, MJ. Other times I can barely see: The effects of hallucinogens on vision and attention. Ph. D. Thesis, University of California, Berkeley, CA, 2010. 3684 kB.

Tzschentke, TM; Christoph, T; Kögel, B; Schiene, K; Hennies, H; Englberger, W; Haurand, M; Jahnel, U; Cremers, TIFH; Friderichs, E; Vry, JD. (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel μ-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J. Pharmacol. Exp. Ther., 1 Oct 2007, 323 (1), 265–276. 662 kB. doi:10.1124/jpet.107.126052

Wark, C. A social and cultural history of the federal prohibition of psilocybin. Ph. D. Thesis, University of Missouri-Columbia, Columbia, MO, 1 Aug 2007. 2183 kB.

Daéid, NN; Waddell, RJH. The analytical and chemometric procedures used to profile illicit drug seizures. Talanta, 15 Aug 2005, 67 (2), 280–285. 81 kB. doi:10.1016/j.talanta.2005.05.018

Vallejos, G; Fierro, A; Rezende, MC; Sepúlveda-Boza, S; Reyes-Parada, M. Heteroarylisopropylamines as MAO inhibitors. Bioorg. Med. Chem., 15 Jul 2005, 13 (14), 4450–4457. 312 kB. doi:10.1016/j.bmc.2005.04.045

Camilleri, AM; Caldicott, D. Underground pill testing, down under. Forensic Sci. Int., 30 Jun 2005, 151 (1), 53–58. 96 kB. doi:10.1016/j.forsciint.2004.07.004

Caldicott, DGE; Edwards, NA; Kruys, A; Kirkbride, KP; Sims, N; Byard, RW; Prior, M; Irvine, RJ. Dancing with “death”: p-methoxyamphetamine overdose and its acute management. Clin. Toxicol., 1 Jan 2003, 41 (2), 143–154. 181 kB. doi:10.1081/CLT-120019130

Huang, X; Lawler, CP; Lewis, MM; Nichols, DE; Mailman, RB. D1 dopamine receptors. In International Review of Neurobiology; Bradley, R; Harris, R; Jenner, P, Eds., Academic Press, 1 Aug 2001; Vol. 48, pp 65–139. 5404 kB. doi:10.1016/S0074-7742(01)48014-7

Gulwadi, AG; Korpinen, CD; Mailman, RB; Nichols, DE; Sit, S; Taber, MT. Dinapsoline: Characterization of a D1 dopamine receptor agonist in a rat model of Parkinson’s disease. J. Pharmacol. Exp. Ther., 1 Feb 2001, 296 (2), 338–344. 271 kB.

Klee, H. Amphetamine use: crystal gazing into the new millennium: Part two – alternative paths. J. Subst. Use, 1 Jan 2001, 6 (2), 80–95. 323 kB. doi:10.1080/146598901300271086

Klee, H. Amphetamine use: crystal gazing into the new millennium: Part one – what is driving the demand? J. Subst. Use, 1 Jan 2001, 6 (1), 22–35. 285 kB. doi:10.1080/146598901750132063

Grob, CS. Deconstructing ecstasy: The politics of MDMA research. Addict. Res. Theory, 2000, 8 (6), 549–588. 2361 kB. doi:10.3109/16066350008998989

Hoffman, B; Cho, SJ; Zheng, W; Wyrick, S; Nichols, DE; Mailman, RB; Tropsha, A. Quantitative structure-activity relationship modeling of dopamine D1 antagonists using comparative molecular field analysis, genetic algorithms-partial least-squares, and K nearest neighbor methods. J. Med. Chem., 26 Aug 1999, 42 (17), 3217–3226. 216 kB. doi:10.1021/jm980415j

Scorza, C; Silveira, R; Nichols, DE; Reyes-Parada, M. Effects of 5-HT-releasing agents on the extracellular hippocampal 5-HT of rats. Implications for the development of novel antidepressants with a short onset of action. Neuropharmacology, 1 Jul 1999, 38 (7), 1055–1061. 108 kB. doi:10.1016/S0028-3908(99)00023-4

Doll, MK; Nichols, DE; Kilts, JD; Prioleau, C; Lawler, CP; Lewis, MM; Mailman, RB. Synthesis and dopaminergic properties of benzo-fused analogues of quinpirole and quinelorane. J. Med. Chem., 11 Mar 1999, 42 (5), 935–940. 107 kB. doi:10.1021/jm9804533

Lewis, MM; Watts, VJ; Lawler, CP; Nichols, DE; Mailman, RB. Homologous desensitization of the D1A dopamine receptor: Efficacy in causing desensitization dissociates from both receptor occupancy and functional potency. J. Pharmacol. Exp. Ther., 1 Jul 1998, 286 (1), 345–353. 312 kB.

Fromberg, E. Ecstasy: the Dutch story. J. Subst. Use, 1998, 3 (2), 89–94. 709 kB. doi:10.3109/14659899809053479

Baudot, P; Dresch, M; Dzierzynski, M; Vicherat, A. Identification de dérivés de la 3,4-méthylènedioxyamphétamine par couplage CPG-SM à piégeage d’ions et par RMN. Ann. Fals. Exp. Chim., 1 Oct 1996, 89 (937), 255–272. 912 kB.

Hodek, P; Strobel, HW. Synthesis and characterization of azidobenzphetamine analogs of the cytochrome P450 substrate benzphetamine. Bioorg. Chem., 1 Sep 1994, 22 (3), 253–267. 776 kB. doi:10.1006/bioo.1994.1019

Veress, T. Study of the extraction of LSD from illicit blotters for HPLC determination. J. Forensic Sci., 1 Sep 1993, 38 (5), 1105–1110. 348 kB. doi:10.1520/JFS13514J

Fuller, RW. Effects of p-chloroamphetamine on brain serotonin neurons. Neurochem. Res., 1 May 1992, 17 (5), 449–456. 906 kB. doi:10.1007/BF00969891

By, A; Neville, GA; Shurvell, HF. Fourier transform infrared/raman differentiation and characterization of cis- and trans-2,5-dimethoxy-4,β-dimethyl-β′-nitrostyrenes: precursors to the street drug STP. J. Forensic Sci., 1 Mar 1992, 37 (2), 503–512. 387 kB. doi:10.1520/JFS13258J

Owen, MLS; Baker, GB; Coutts, RT; Dewhurst, WG. Analysis of p-chloroamphetamine and a side-chain monofluorinated analogue in rat brain. J. Pharmacol. Methods, 1 Apr 1991, 25 (2), 147–155. 497 kB. doi:10.1016/0160-5402(91)90005-P

Dawson, BA. The use of nuclear magnetic resonance spectroscopy for the detection and quantitation of abused drugs. In The Analysis of Drugs of Abuse; Gough, TA, Ed., John Wiley & Sons, 1991; pp 283–309. 947 kB.

By, A; Ethier, JC; Lauriault, G; LeBelle, M; Lodge, BA; Savard, C; Sy, W; Wilson, WL. Traditional oriental medicines: I. Black Pearl: identification and chromatographic determination of some undeclared medicinal ingredients. J. Chromatogr., 1989, 469, 406–411. 353 kB. doi:10.1016/S0021-9673(01)96478-7

Schechter, MD. Amfonelic acid: Similarity to other dopamine agonists. Pharmacol. Biochem. Behav., 1 Feb 1987, 26 (2), 413–416. 315 kB. doi:10.1016/0091-3057(87)90138-9

McDonald, P; Martin, CF; Woods, DJ; Baker, PB; Gough, TA. An analytical study of illicit lysergide. J. Forensic Sci., 1 Jan 1984, 29 (1), 120–130. 493 kB. doi:10.1520/JFS11642J

Fuller, RW; Baker, JC; Perry, KW; Molloy, BB. Comparison of 4-chloro-, 4-bromo- and 4-fluoroamphetamine in rats: Drug levels in brain and effects on brain serotonin metabolism. Neuropharmacology, 1 Oct 1975, 14 (10), 739–746. 799 kB. doi:10.1016/0028-3908(75)90099-4

Fuller, RW; Perry, KW; Wong, DT; Molloy, BB. Effects of some homologues of 4-chloroamphetamine on brain serotonin metabolism. Neuropharmacology, 1 Jul 1974, 13 (7), 609–614. 490 kB. doi:10.1016/0028-3908(74)90050-1

Aceto, MD; Botton, I; Levitt, M; Martin, R; Bentley, HC; Speight, PT. Pharmacologic properties and mechanism of action of amfonelic acid. Eur. J. Pharmacol., 1 Jun 1970, 10 (3), 344–354. 631 kB. doi:10.1016/0014-2999(70)90206-2

Černý, A; Semonský, M. Ergot alkaloids. XXXIII. Epimerization of the simpler amides of d-lysergic, d-isolysergic and 1-methyl-d-lysergic acids. Collection Czechoslov. Chem. Commun., 1 Feb 1969, 34 (2), 694–698. 1938 kB. doi:10.1135/cccc19690694

Pletscher, A; Burkard, WP; Bruderer, H; Gey, KF. Decrease of cerebral 5-hydroxytryptamine and 5-hydroxyindolacetic acid by an arylalkylamine. Life Sci., 1 Nov 1963, 2 (11), 828–833. 226 kB. doi:10.1016/0024-3205(63)90094-8

Clarke, FH. cis- and trans-3-methyl-2-phenylmorpholine. J. Org. Chem., 1 Sep 1962, 27 (9), 3251–3253. 409 kB. doi:10.1021/jo01056a063

Leth-Petersen, S; Bundgaard, C; Hansen, M; Carnerup, MA; Kehler, J; Kristensen, JL. Correlating the metabolic stability of psychedelic 5-HT2A agonists with anecdotal reports of human oral bioavailability. Neurochem. Res., 625 kB. doi:10.1007/s11064-014-1253-y

Vollenweider, FX; Geyer, M; Greer, G. Acute psychological and neurophysiological effects of MDMA in humans. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 2001; Vol. 2, pp 53–63. 338 kB.

Gouzoulis-Mayfrank, E. Differential actions of an entactogen compared to a stimulant and a hallucinogen in healthy humans. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 2001; Vol. 2, pp 64–72. 261 kB.

Nichols, CD; Sanders-Bush, E. Serotonin receptor signaling and hallucinogen action. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 2001; Vol. 2, pp 73–79. 481 kB.

Nichols, DE. LSD and its lysergamide cousins. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 2001; Vol. 2, pp 80–87. 270 kB.

Krupitsky, EM; Burakov, AM; Romanov, TN; Grinenko, AY; Strassman, RJ. Ketamine-assisted psychotherapy (KPT) of heroin addiction: Immediate effects and six month follow-up. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 2001; Vol. 2, pp 88–101. 277 kB.

Horgan, J. The future of mind science. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 2001; Vol. 2, pp 1–5. 88 kB.

Perrine, DM. Visions of the night: Western medicine meets peyote 1887–1899. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 2001; Vol. 2, pp 6–52. 576 kB.

Shulgin, A. Forward. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 1998; Vol. 1, pp v–vi. 12 kB.

Walsh, R. New views of timeless experiences: Contemporary research on the nature and significance of transpersonal experiences. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 1998; Vol. 1, pp 62–64. 20 kB.

Krupitsky, EM; Grinenko, AY. Ten year study of ketamine psychedelic therapy (KPT) of alcohol dependence. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 1998; Vol. 1, pp 58–61. 36 kB.

Myers, LS; Watkins, SS; Carter, TJ. Flashbacks in theory and practice. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 1998; Vol. 1, pp 52–57. 39 kB.

Gouzoulis-Mayfrank, E; Hermle, L. Are the “entactogens” a distinct psychoactive substance class? In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 1998; Vol. 1, pp 46–51. 44 kB.

Nichols, DE. The medicinal chemistry of phenethylamine psychedelics. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 1998; Vol. 1, pp 40–45. 107 kB.

Geyer, MA. Why study hallucinogenic drugs in animals? In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 1998; Vol. 1, pp 33–38. 33 kB.

Grob, CS. Psychiatric research with hallucinogens: What have we learned? In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 1998; Vol. 1, pp 8–20. 66 kB.

McKenna, DJ; Callaway, JC; Grob, CS. The scientific investigation of Ayahuasca: A review of past and current research. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 1998; Vol. 1, pp 65–76. 70 kB.

Schultes, RE. Antiquity of the use of New World hallucinogens. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 1998; Vol. 1, pp 1–7. 48 kB.

Nichols, DE. Preface. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 1998; Vol. 1, pp vii. 11 kB.

Vollenweider, FX. Recent advances and concepts in the search for biological correlates of hallucinogen-induced altered states of consciousness. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 1998; Vol. 1, pp 21–32. 104 kB.

Martin, DA; Marona-Lewicka, D; Nichols, DE; Nichols, CD. Chronic LSD alters gene expression profiles in the mPFC relevant to schizophrenia. Neuropharmacology, 1 Aug 2014, 83, 1–8. 1213 kB. doi:10.1016/j.neuropharm.2014.03.013

Meyer, MR; Robert, A; Maurer, HH. Toxicokinetics of novel psychoactive substances: Characterization of N-acetyltransferase (NAT) isoenzymes involved in the phase II metabolism of 2C designer drugs. Toxicol. Lett., 5 Jun 2014, 227 (2), 124–128. 693 kB. doi:10.1016/j.toxlet.2014.03.010

Strike, C; Jairam, JA; Kolla, G; Millson, P; Shepherd, S; Fischer, B; Watson, TM; Bayoumi, AM. Increasing public support for supervised injection facilities in Ontario, Canada. Addiction, 1 Jun 2014, 109 (6), 946–953. 111 kB. doi:10.1111/add.12506

Banks, ML; Worst, TJ; Rusyniak, DE; Sprague, JE. Synthetic cathinones (“Bath salts”). J. Emerg. Med, 1 May 2014, 46 (5), 632–642. 791 kB. doi:10.1016/j.jemermed.2013.11.104

Gregg, RA; Rawls, SM. Behavioral pharmacology of designer cathinones: A review of the preclinical literature. Life Sci., 27 Feb 2014, 97 (1), 27–30. 249 kB. doi:10.1016/j.lfs.2013.10.033

ElSohly, MA; Gul, W; Wanas, AS; Radwan, MM. Synthetic cannabinoids: Analysis and metabolites. Life Sci., 27 Feb 2014, 97 (1), 78–90. 1531 kB. doi:10.1016/j.lfs.2013.12.212

Rapaka, RS; Purohit, V; Schnur, P; Rutter, J. Emerging trends in the abuse of designer drugs and their catastrophic health effects: Update on chemistry, pharmacology, toxicology and addiction potential. Life Sci., 27 Feb 2014, 97 (1), 1. 111 kB. doi:10.1016/j.lfs.2014.01.074

Järbe, TUC; Gifford, RS. “Herbal incense”: Designer drug blends as cannabimimetics and their assessment by drug discrimination and other in vivo bioassays. Life Sci., 27 Feb 2014, 97 (1), 64–71. 665 kB. doi:10.1016/j.lfs.2013.07.011

Halpin, LE; Collins, SA; Yamamoto, BK. Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine. Life Sci., 27 Feb 2014, 97 (1), 37–44. 507 kB. doi:10.1016/j.lfs.2013.07.014

Angoa-Pérez, M; Kane, MJ; Herrera-Mundo, N; Francescutti, DM; Kuhn, DM. Effects of combined treatment with mephedrone and methamphetamine or 3,4-methylenedioxymethamphetamine on serotonin nerve endings of the hippocampus. Life Sci., 27 Feb 2014, 97 (1), 31–36. 888 kB. doi:10.1016/j.lfs.2013.07.015

German, CL; Fleckenstein, AE; Hanson, GR. Bath salts and synthetic cathinones: An emerging designer drug phenomenon. Life Sci., 27 Feb 2014, 97 (1), 2–8. 390 kB. doi:10.1016/j.lfs.2013.07.023

Wiley, JL; Marusich, JA; Huffman, JW. Moving around the molecule: Relationship between chemical structure and in vivo activity of synthetic cannabinoids. Life Sci., 27 Feb 2014, 97 (1), 55–63. 865 kB. doi:10.1016/j.lfs.2013.09.011

Fantegrossi, WE; Moran, JH; Radominska-Pandya, A; Prather, PL. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: Mechanism underlying greater toxicity? Life Sci., 27 Feb 2014, 97 (1), 45–54. 1107 kB. doi:10.1016/j.lfs.2013.09.017

Felice, LJD; Glennon, RA; Negus, SS. Synthetic cathinones: Chemical phylogeny, physiology, and neuropharmacology. Life Sci., 27 Feb 2014, 97 (1), 20–26. 697 kB. doi:10.1016/j.lfs.2013.10.029

Dybdal-Hargreaves, NF; Holder, ND; Ottoson, PE; Sweeney, MD; Williams, T. Mephedrone: Public health risk, mechanisms of action, and behavioral effects. Eur. J. Pharmacol., 15 Aug 2013, 714 (1–3), 32–40. 837 kB. doi:10.1016/j.ejphar.2013.05.024

Eshleman, AJ; Wolfrum, KM; Hatfield, MG; Johnson, RA; Murphy, KV; Janowsky, A. Substituted methcathinones differ in transporter and receptor interactions. Biochem. Pharmacol., 15 Jun 2013, 85 (12), 1803–1815. 2164 kB. doi:10.1016/j.bcp.2013.04.004

Banks, ML; Blough, BE; Fennell, TR; Snyder, RW; Negus, SS. Role of phenmetrazine as an active metabolite of phendimetrazine: Evidence from studies of drug discrimination and pharmacokinetics in rhesus monkeys. Drug Alcohol Depend., 1 Jun 2013, 130 (1–3), 158–166. 520 kB. doi:10.1016/j.drugalcdep.2012.10.026

Stojanovska, N; Fu, S; Tahtouh, M; Kelly, T; Beavis, A; Kirkbride, KP. A review of impurity profiling and synthetic route of manufacture of methylamphetamine, 3,4-methylenedioxymethylamphetamine, amphetamine, dimethylamphetamine and p-methoxyamphetamine. Forensic Sci. Int., 10 Jan 2013, 224 (1–3), 8–26. 813 kB. doi:10.1016/j.forsciint.2012.10.040

Dargan, PI; Hudson, S; Ramsey, J; Wood, DM. The impact of changes in UK classification of the synthetic cannabinoid receptor agonists in 'Spice'. Int. J. Drug Policy, 1 Jul 2011, 22 (4), 274–277. 179 kB. doi:10.1016/j.drugpo.2011.02.006

Zhang, S; Fan, Y; Shi, Z; Cheng, S. DFT-based QSAR and action mechanism of phenylalkylamine and tryptamine hallucinogens. Chin. J. Chem., 1 Apr 2011, 29 (4), 623–630. 166 kB. doi:10.1002/cjoc.201190132

Sauer, C; Peters, FT; Staack, RF; Fritschi, G; Maurer, HH. Metabolism and toxicological detection of the designer drug N-(1-phenylcyclohexyl)-3-methoxypropanamine (PCMPA) in rat urine using gas chromatography-mass spectrometry. Forensic Sci. Int., 25 Oct 2008, 181 (1–3), 47–51. 188 kB. doi:10.1016/j.forsciint.2008.09.001

Feng, Z; Mohapatra, S; Klimko, PG; Hellberg, MR; May, JA; Kelly, C; Williams, G; McLaughlin, MA; Sharif, NA. Novel benzodifuran analogs as potent 5-HT2A receptor agonists with ocular hypotensive activity. Bioorg. Med. Chem. Lett., 1 Jun 2007, 17 (11), 2998–3002. 163 kB. doi:10.1016/j.bmcl.2007.03.073

Neuvonen, K; Neuvonen, H; Fülöp, F. Effect of 4-substitution on psychotomimetic activity of 2,5-dimethoxy amphetamines as studied by means of different substituent parameter scales. Bioorg. Med. Chem. Lett., 1 Jul 2006, 16 (13), 3495–3498. 111 kB. doi:10.1016/j.bmcl.2006.03.099

Milhazes, N; Calheiros, R; Marques, MPM; Garrido, J; Cordeiro, MNDS; Rodrigues, C; Quinteira, S; Novais, C; Peixe, L; Borges, F. β-Nitrostyrene derivatives as potential antibacterial agents: A structure-property-activity relationship study. Bioorg. Med. Chem., 15 Jun 2006, 14 (12), 4078–4088. 290 kB. doi:10.1016/j.bmc.2006.02.006

Ewald, AH; Fritschi, G; Bork, W; Maurer, HH. Designer drugs 2,5-dimethoxy-4-bromo-amphetamine (DOB) and 2,5-dimethoxy-4-bromo-methamphetamine (MDOB): studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass. Spectrom., 1 Apr 2006, 41 (4), 487–498. 244 kB. doi:10.1002/jms.1007

Kamata, T; Katagi, M; Kamata, HT; Miki, A; Shima, N; Zaitsu, K; Nishikawa, M; tanaka, E; Honda, K; Tsuchihashi, H. Metabolism of the psychotomimetic tryptamine derivative 5-methoxy-N,N-diisopropyltryptamine in humans: Identification and quantification of its urinary metabolites. Drug Metab. Dispos., 1 Feb 2006, 34 (2), 281–287. 427 kB. doi:10.1124/dmd.105.005835.

He, R; Kurome, T; Giberson, KM; Johnson, KM; Kozikowski, AP. Further structure-activity relationship studies of piperidine-based monoamine transporter inhibitors: Effects of piperidine ring stereochemistry on potency. Identification of norepinephrine transporter selective ligands and broad-spectrum transporter inhibitors. J. Med. Chem., 15 Dec 2005, 48 (25), 7970–7979. 173 kB. doi:10.1021/jm050694s

Jacob, MS; Presti, DE. Endogenous psychoactive tryptamines reconsidered: an anxiolytic role for dimethyltryptamine. Med. Hypotheses, 2005, 64 (5), 930–937. 162 kB. doi:10.1016/j.mehy.2004.11.005

Thakur, M; Thakur, A; Khadikar, PV. QSAR studies on psychotomimetic phenylalkylamines. Bioorg. Med. Chem., 15 Feb 2004, 12 (4), 825–831. 323 kB. doi:10.1016/j.bmc.2003.10.027

Michelot, D; Melendez-Howell, LM. Amanita muscaria: chemistry, biology, toxicology, and ethnomycology. Mycol. Res., 1 Feb 2003, 107 (2), 131–146. 337 kB. doi:10.1017/S0953756203007305

Ottaviano, V; Furnari, C; Rosati, F. Identification of di(β-phenylisopropyl)amine as the main ingredient in illicit amphetamine tablets. Ann. Ist. Super. Sanitá, 2002, 38 (3), 331–335. 125 kB.

Pertz, HH; Brown, AM; Gager, TL; Kaumann, AJ. Simple O-acylated derivatives of lysergol and dihydrolysergol-I: Synthesis and interaction with 5-HT2A, 5-HT2C and 5-HT1B receptors, and α1 adrenergic receptors. J. Pharm. Pharmacol., 1 Mar 1999, 51 (3), 319–330. 192 kB. doi:10.1211/0022357991772321

Woolverton, WL; Massey, BW; Winger, G; Patrick, GA; Harris, LS. Evaluation of the abuse liability of aminorex. Drug Alcohol Depend., 1 Dec 1994, 36 (3), 187–192. 711 kB. doi:10.1016/0376-8716(94)90144-9

Ask, A; Fagervall, I; Florvall, L; Ross, SB; Ytterborn, S. Selective inhibition of monoamine oxidase by p-aminosubstituted phenylalkylamines in catecholaminergic neurones. Neuropharmacology, 1 Jan 1986, 25 (1), 33–40. 1026 kB. doi:10.1016/0028-3908(86)90055-9

Aceto, MD; Rosecrans, JA; Young, R; Glennon, RA. Similarity between (+)-amphetamine and amfonelic acid. Pharmacol. Biochem. Behav., 1 Apr 1984, 20 (4), 635–637. 184 kB. doi:10.1016/0091-3057(84)90316-2

Glennon, RA; Rosecrans, JA; Young, R. Behavioral properties of psychoactive phenylisopropylamines in rats. Eur. J. Pharmacol., 17 Dec 1981, 76 (4), 353–360. 964 kB. doi:10.1016/0014-2999(81)90106-0

Cooper, PD. Stereospecific synthesis of cis- and trans-2-(3,4,5-trimethoxyphenyl)-cyclopropylamines. Can. J. Chem., 1 Dec 1970, 48 (24), 3882–3888. 452 kB. doi:10.1139/v70-653

Heim, R; Genest, K; Hughes, DW; Belec, G. Botanical and chemical characterisation of a forensic mushroom specimen of the genus psilocybe. J. Forensic Sci. Soc., 1 Jul 1966, 6 (4), 192–201. 2094 kB. doi:10.1016/S0015-7368(66)70336-3

Suter, CM; Weston, AW. Some fluorinated amines of the pressor type. J. Am. Chem. Soc., 1 Feb 1941, 63 (2), 602–605. 444 kB. doi:10.1021/ja01847a069

Marson, C; Schneider, S; Meys, F; Wennig, R. Structural elucidation of an uncommon phenylethylamine analogue in urine responsible for discordant amphetamine immunoassay results. J. Anal. Toxicol., 0000, 24 (1), 17–21. 509 kB. doi:10.1093/jat/24.1.17

Moosmann, B; Bisel, P; Auwärter, V. Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics. Drug Test. Anal., 429 kB. doi:10.1002/dta.1628

Wink, CSD; Meyer, GMJ; Wissenbach, DK; Jacobsen-Bauer, A; Meyer, MR; Maurer, HH. Lefetamine-derived designer drugs N-ethyl-1,2-diphenylethylamine (NEDPA) and N-iso-propyl-1,2-diphenylethylamine (NPDPA): Metabolism and detectability in rat urine using GC-MS, LC-MSn and LC-HR-MS/MS. Drug Test. Anal., 674 kB. doi:10.1002/dta.1621

Morris, H; Wallach, J. From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Drug Test. Anal., 942 kB. doi:10.1002/dta.1620

Uchiyama, N; Shimokawa, Y; Matsuda, S; Kawamura, M; Kikura-Hanajiri, R; Goda, Y. Two new synthetic cannabinoids, AM-2201 benzimidazole analog (FUBIMINA) and (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl)methanone (MEPIRAPIM), and three phenethylamine derivatives, 25H-NBOMe 3,4,5-trimethoxybenzyl analog, 25B-NBOMe, and 2C-N-NBOMe, identified in illegal products. Forensic Toxicol., 827 kB. doi:10.1007/s11419-013-0217-2

Kikura-Hanajiri, R; Uchiyama, N; Kawamura, M; Goda, Y. Changes in the prevalence of new psychoactive substances before and after the introduction of the generic scheduling of synthetic cannabinoids in Japan. Drug Test. Anal., 1438 kB. doi:10.1002/dta.1584

Blough, BE; Landavazo, A; Decker, AM; Partilla, JS; Baumann, MH; Rothman, RB. Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes. Psychopharmacology, 298 kB. doi:10.1007/s00213-014-3557-7

Hout, MCV. Kitchen chemistry: A scoping review of the diversionary use of pharmaceuticals for non-medicinal use and home production of drug solutions. Drug Test. Anal., 176 kB. doi:10.1002/dta.1622

Heim, R; Pertz, HH; Elz, MZS. Stereoselective synthesis, absolute configuration and 5-HT2A-receptor agonism of chiral 2-methoxybenzylamines. Arch. Pharm. Pharm. Med. Chem., Oct 2002, 335 (Suppl. 1), 82. 573 kB. Poster abstract

Heim, R; Pertz, HH; Elz, S. Partial 5-HT2A-receptor agonists of the phenylethanamine series: Effect of a trifluoromethyl substituent. Arch. Pharm. Pharm. Med. Chem., 3 May 2000, 333 (Suppl. 2), 45. 542 kB. Poster abstract

Heim, R; Elz, S. Novel extremely potent partial 5-HT2A-receptor agonists: Successful application of a new structure-activity concept. Arch. Pharm. Pharm. Med. Chem., Mar 2000, 333 (Suppl. 1), 18. 566 kB. Poster abstract

Lewin, AH; Seltzman, HH; Carroll, FI; Mascarella, SW; Reddy, A. Emergence and properties of spice and bath salts: A medicinal chemistry perspective. Life Sci., 27 Feb 2014. 673 kB. doi:10.1016/j.lfs.2013.09.026

Uchiyama, N; Matsuda, S; Kawamura, M; Kikura-Hanajiri, R; Goda, Y. Identification of two new-type designer drugs, piperazine derivative MT-45 (I-C6) and synthetic peptide Noopept (GVS-111), with synthetic cannabinoid A-834735, cathinone derivative 4-methoxy-α-PVP, and phenethylamine derivative 4-methylbuphedrine from illegal products. Forensic Toxicol., 1 Jan 2014, 32 (1), 9–18. 678 kB. doi:10.1007/s11419-013-0194-5

Shevyrin, V; Melkozerov, V; Nevero, A; Eltsov, O; Shafran, Y. Erratum to “Analytical characterization of some synthetic cannabinoids, derivatives of indole-3-carboxylic acid” [Forensic Sci. Int. 232 (2013) 1-10]. Forensic Sci. Int., 10 Oct 2013, 232 (1–3), 151–152. 634 kB. doi:10.1016/j.forsciint.2013.07.014

Kanu, AB; Brandt, SD; Williams, MD; Zhang, N; Hill, HH. Analysis of psychoactive cathinones and tryptamines by electrospray ionization atmospheric pressure ion mobility time-of-flight mass spectrometry. Anal. Chem., 17 Sep 2013, 85 (18), 8535–8542. 1636 kB. doi:10.1021/ac401951a

Gaujac, A; Ford, JL; Dempster, NM; Andrade, JB; Brandt, SD. Investigations into the polymorphic properties of N,N-dimethyltryptamine by X-ray diffraction and differential scanning calorimetry. Microchem. J., 1 Sep 2013, 110, 146–157. 1166 kB. doi:10.1016/j.microc.2013.03.009

Kelty, SF; Julian, R; Ross, A. Dismantling the Justice Silos: Avoiding the pitfalls and reaping the benefits of information-sharing between forensic science, medicine and law. Forensic Sci. Int., 10 Jul 2013, 230 (1–3), 8–15. 287 kB. doi:10.1016/j.forsciint.2012.10.032

Nieddu, M; Burrai, L; Pirisi, MA; Carta, A; Briguglio, I; Dessi, G; Boatto, G. Validated liquid chromatography-mass spectrometry method for the quantitation of N-substituted derivatives of 3,4-methylenedioxyamphetamine in rat urine. Forensic Toxicol., 1 Jul 2013, 31 (2), 204–211. 527 kB. doi:10.1007/s11419-013-0178-5

Mariotti, KC; Ortiz, RS; Souza, DZ; Mileski, TC; Fröehlich, PE; Limberger, RP. Trends in counterfeits amphetamine-type stimulants after its prohibition in Brazil. Forensic Sci. Int., 10 Jun 2013, 229 (1–3), 23–26. 987 kB. doi:10.1016/j.forsciint.2013.03.026

Heal, DJ; Smith, SL; Gosden, J; Nutt, DJ. Amphetamine, past and present—a pharmacological and clinical perspective. J. Psychopharmacol., 1 Jun 2013, 27 (6), 479–496. 740 kB. doi:10.1177/0269881113482532

Cameron, K; Kolanos, R; Vekariya, R; Felice, LD; Glennon, RA. Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of “bath salts,” produce opposite effects at the human dopamine transporter. Psychopharmacology, 1 Jun 2013, 227 (3), 493–499. 190 kB. doi:10.1007/s00213-013-2967-2

Power, JD; Clarke, K; McDermott, SD; McGlynn, P; Barry, M; White, C; O’Brien, J; Kavanagh, P. The identification of 4-methylamphetamine and its synthesis by-products in forensic samples. Forensic Sci. Int., 10 May 2013, 228 (1–3), 115–131. 1893 kB. doi:10.1016/j.forsciint.2013.02.039

Gil, D; Adamowicz, P; Skulska, A; Tokarczyk, B; Stanaszek, R. Analysis of 4-MEC in biological and non-biological material—Three case reports. Forensic Sci. Int., 10 May 2013, 228 (1–3), e11–e15. 554 kB. doi:10.1016/j.forsciint.2013.03.011

Rahman, AA; Daoud, MK; Dukat, M; Herrick-Davis, K; Purohit, A; Teitler, M; Amaral, AT; Malvezzi, A; Glennon, RA. Corrigendum to “Conformationally-restricted analogues and partition coefficients of the 5-HT3 serotonin receptor ligands meta-chlorophenylbiguanide (mCPBG) and meta-chlorophenylguanidine (mCPG)” [Bioorg. Med. Chem. Lett. 15 (2005) 3434-3438]. Bioorg. Med. Chem. Lett., 15 Oct 2012, 22 (20), 6526. 178 kB. doi:10.1016/j.bmcl.2012.08.076

Nichols, D. The costs of putting knowledge into the wrong hands. Sci. News, 26 Feb 2011, 179 (5), 32. 278 kB. doi:10.1002/scin.5591790529

Giorgioni, G; Claudi, F; Ruggieri, S; Ricciutelli, M; Palmieri, GF; Stefano, AD; Sozio, P; Cerasa, LS; Chiavaroli, A; Ferrante, C; Orlando, G; Glennon, RA. Design, synthesis, and preliminary pharmacological evaluation of new imidazolinones as L-DOPA prodrugs. Bioorg. Med. Chem., 1 Mar 2010, 18 (5), 1834–1843. 857 kB. doi:10.1016/j.bmc.2010.01.041

Westphal, F; Junge, T; Girreser, U; Jacobsen-Bauer, A; Rösner, P. “Badesalz” für die Nase—Fluormethcathinon neu auf dem Drogenmarkt. Toxichem Krimtech, 2010, 77 (2), 84–94. 355 kB.

Westphal, F; Junge, T; Jacobsen-Bauer, A; Rösner, P. Lefetamin-Derivate: alte Bekannte neu auf dem Drogenmarkt. Toxichem Krimtech, 2010, 77 (1), 46–58. 115 kB.

Westphal, F; Junge, T; Rösner, P; Girreser, U; Fritsch, R. Massenspektrometrische, infrarotspektroskopische und NMR-spekstroskopische Daten von Mephedron, Butylon und Methylon sowie einigen ihrer Derivate. Toxichem Krimtech, 2010, 77 (2), 95–116. 380 kB.

Cueva, JP; Nichols, DE. A novel and efficient synthesis of dihydrexidine. Synthesis, 1 Mar 2009, 2009 (5), 715–720. 127 kB. doi:10.1055/s-0028-1083359

Higashikawa, Y; Suzuki, S. Studies on 1-(2-phenethyl)-4-(N-propionylanilino)piperidine (fentanyl) and its related compounds. VI. Structure-analgesic activity relationship for fentanyl, methyl-substituted fentanyls and other analogues. Forensic Toxicol., 1 Jun 2008, 26 (1), 1–5. 283 kB. doi:10.1007/s11419-007-0039-1

Rasmussen, N. Making the first anti-depressant: Amphetamine in American medicine, 1929-1950. J. Hist. Med. Allied Sci., 1 Jul 2006, 61 (3), 288–323. 175 kB. doi:10.1093/jhmas/jrj039

Maroge, W; Bordelon, JA; Katz, JM; Zhivago, VR. Large fentanyl and MDA laboratory in Los Angeles, California. JCLIC, 1 Apr 2006, 16 (2), 12–13. 184 kB.

Blok, A; Cox, M; Ward, C. 4-Chlorodiphenylmethane, a precursor specific methylamphetamine manufacturing by-product. JCLIC, 1 Apr 2006, 16 (2), 14–20. 150 kB.

Cohen, WS. Ephedra used as a precursor in methamphetamine manufacturing. JCLIC, 1 Apr 2006, 16 (2), 21–22. 81 kB.

Meer, AP; Lock, E. Identification of 4-tert-butylamphetamine in clandestine amphetamine samples. JCLIC, 1 Apr 2006, 16 (2), 23–27. 51 kB.

Narcotics, BI; Affairs, LE. International narcotics control strategy report—2006. JCLIC, 1 Apr 2006, 16 (2), 3–12. 90 kB.

Carmo, H; Hengstler, JG; Boer, D; Ringel, M; Remião, F; Carvalho, F; Fernandes, E; Reys, LA; Oesch, F; Bastos, ML. Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human. Toxicology, 5 Jan 2005, 206 (1), 75–89. 273 kB. doi:10.1016/j.tox.2004.07.004

Rösner, P; Zechlin, L; Junge, T. N-Ethyl-2-(3,4-methylenedioxyphenyl)-propan-1-amin eine neue Designerdroge mit der Struktur eines beta-isomeren MDE. Toxichem Krimtech, 2003, 70 (2), 82–86. 42 kB.

Katagi, M; Tsuchihashi, H. Update on clandestine amphetamines and their analogues recently seen in Japan. J. Health Sci., 2002, 48 (1), 14–21. 181 kB. doi:10.1248/jhs.48.14

Ehlers, D; Schäning, J. Synthese von DOC (2,5-dimethoxy-4-chloramphetamin). Toxichem Krimtech, 2000, 68 (2), 62–68. 185 kB.

Rösner, P; Junge, T; Fritschi, G; Klein, B; Thielert, K; Kozlowski, M. Neue synthetische Drogen: Piperazin-, propicyclidin- und α-aminopropiophenonderivate. Toxichem Krimtech, 1999, 66 (2), 81–90. 1202 kB.

Dawson, BA; Black, DB; Lavoie, A; LeBelle, MJ. Nuclear magnetic resonance identification of the phenylalkylamine alkaloids of khat using a chiral solvating agent. J. Forensic Sci., 1 Jul 1994, 39 (4), 1026–1038. 453 kB. doi:10.1520/JFS13681J

Young, R; Glennon, RA. Cocaine-stimulus generalization to two new designer drugs: Methcathinone and 4-methylaminorex. Pharmacol. Biochem. Behav., 1 May 1993, 45 (1), 209–214. 224 kB. doi:10.1016/0091-3057(93)90110-F

Noggle, FT; DeRuiter, J; Coker, ST; Clark, CR. Synthesis, identification, and acute toxicity of some N-alkyl derivatives of 3,4-methylenedioxyamphetamine. J. Assoc. Off. Anal. Chem., 1987, 70 (6), 981–986. 1842 kB.

Clark, CC. The identification of methoxy-N-methylamphetamines. J. Forensic Sci., 1 Oct 1984, 29 (4), 1056–1071. 423 kB. doi:10.1520/JFS11772J

Makriyannis, A; Bowerman, D; Sze, PY; Fournier, D; Jong., APD. Structure activity correlations in the inhibition of brain synaptosomal 3H-norepinephrine uptake by phenethylamine analogs. The role of α-alkyl side chain and methoxyl ring substitutions. Eur. J. Pharmacol., 9 Jul 1982, 81 (2), 337–340. 313 kB. doi:10.1016/0014-2999(82)90454-X

Bailey, K; By, AW; Legault, D; Verner, D. Identification of the N-methylated analogs of the hallucinogenic amphetamines and some isomers. J. Assoc. Off. Anal. Chem., 1975, 58 (1), 62–69. 1987 kB.

Bailey, K; Beckstead, HD; Legault, D; Verner, D. Identification of 2-, 3-, and 4-methoxyamphetamines and 2-, 3-, and 4-methylamphetamines. J. Assoc. Off. Anal. Chem., 1974, 57 (5), 1134–1143. 2618 kB.

Bailey, K; Grey, AA. A conformational study of lysergic acid and iso-lysergic acid dialkylamides by proton magnetic resonance spectroscopy. Can. J. Chem., 1 Dec 1972, 50 (23), 3876–3885. 342 kB. doi:10.1139/v72-611

Matsuhiro, B; Furst, A. 2,3,6-Trimethoxynitrostyrene and its β-phenethylamine. J. Med. Chem., 1 Sep 1970, 13 (5), 973. 140 kB. doi:10.1021/jm00299a042

Clarke, EGC. The identification of amphetamine type drugs. J. Forensic Sci. Soc., 1 Jan 1967, 7 (1), 31–36. 770 kB. doi:10.1016/S0015-7368(67)70368-0

Gerdes, JM; Keil, RN; Shulgin, AT; Mathis, CA. ChemInform Abstract: High pressure nucleophilic fluoride-ion substitution reactions: Formation of fluoroalkylbenzenes. ChemInform, 3 Dec 1996, 27 (49), 1. 30 kB. doi:10.1002/chin.199649064

Moss, M. Book reviews: The Simple Plant Isoquinolines. Mycologist, 1 Nov 2006, 20 (4), 187. 39 kB. doi:10.1016/j.mycol.2006.09.008

Morris, H. Gaboxadol. Harper’s Magazine, 1 Aug 2013, 43–47. 572 kB.

Harms, A; Ulmer, E; Kovar, K. Synthesis and 5-HT2A radioligand receptor binding assays of DOMCl and DOMOM, two novel 5-HT2A receptor ligands. Arch. Pharm. Pharm. Med. Chem., 16 Jun 2003, 336 (3), 155–158. 69 kB. doi:10.1002/ardp.200390014

Anon. Personal communication of unpublished research. 6 Dec 2013.

King, LA. New phenethylamines in Europe. Drug Test. Anal., 20 Nov 2013. 472 kB. doi:10.1002/dta.1570

Robson, PJ. Therapeutic potential of cannabinoid medicines. Drug Test. Anal., Jan 2014. 150 kB. doi:10.1002/dta.1529

King, LA. Legal controls on cannabimimetics: An international dilemma? Drug Test. Anal., Jan 2014. 440 kB. doi:10.1002/dta.1510

Sekuła, K; Zuba, D. Structural elucidation and identification of a new derivative of phenethylamine using quadrupole time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom., 30 Sep 2013, 27 (18), 2081–2090. 2664 kB. doi:10.1002/rcm.6667

Herraiz, T; Brandt, SD. 5-(2-Aminopropyl)indole (5-IT): a psychoactive substance used for recreational purposes is an inhibitor of human monoamine oxidase (MAO). Drug Test. Anal., 20 Sep 2013. 567 kB. doi:10.1002/dta.1530

Poklis, JL; Nanco, CR; Troendle, MM; Wolf, CE; Poklis, A. Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Test. Anal., 2 Sep 2013. 292 kB. doi:10.1002/dta.1522

King, LA; Ujváry, I; Brandt, SD. Drug laws and the ‘derivative’ problem. Drug Test. Anal., 15 Aug 2013. 209 kB. doi:10.1002/dta.1523

Zuba, D; Sekuła, K. Identification and characterization of 2,5-dimethoxy-3,4-dimethyl-β-phenethylamine (2C-G)—A new designer drug. Drug Test. Anal., 1 Jul 2013, 5 (7), 549–559. 1611 kB. doi:10.1002/dta.1396

Zaitsu, K; Miyagawa, H; Sakamoto, Y; Matsuta, S; Tsuboi, K; Nishioka, H; Katagi, M; Sato, T; Tatsuno, M; Tsuchihashi, H; Suzuki, K; Ishii, A. Mass spectrometric differentiation of the isomers of mono-methoxyethylamphetamines and mono-methoxydimethylamphetamines by GC-EI-MS-MS. Forensic Toxicol., 1 Jul 2013, 31 (2), 292–300. 344 kB. doi:10.1007/s11419-013-0193-6

Pirisi, MA; Nieddu, M; Burrai, L; Carta, A; Briguglio, I; Baralla, E; Demontis, MP; Varoni, MV; Boatto, G. An LC-MS-MS method for quantitative analysis of six trimethoxyamphetamine designer drugs in rat plasma, and its application to a pharmacokinetic study. Forensic Toxicol., 1 Jul 2013, 31 (2), 197–203. 305 kB. doi:10.1007/s11419-012-0177-y

O’Connor, RE; Keating, JJ. Characterization of synthetic routes to ‘Bromo-DragonFLY’ and benzodifuranyl isopropylamine homologues utilizing ketone intermediates. Part 1: Synthesis of ketone precursors. Drug Test. Anal., 24 Jun 2013. 812 kB. doi:10.1002/dta.1504

Zuba, D; Byrska, B. Prevalence and co-existence of active components of ‘legal highs’ Drug Test. Anal., 1 Jun 2013, 5 (6), 420–429. 1294 kB. doi:10.1002/dta.1365

Stanczuk, A; Morris, N; Gardner, EA; Kavanagh, PV. Identification of (2-aminopropyl)benzofuran (APB) phenyl ring positional isomers in Internet purchased products. Drug Test. Anal., 1 Apr 2013, 5 (4), 270–276. 1304 kB. doi:10.1002/dta.1451

Kavanagh, PV; Angelov, D; O’Brien, J; Power, JD; McDermott, SD; Talbot, B; Fox, J; O’Donnell, C; Christie, R. The synthesis and characterization N-methyl-3-phenyl-norbornan-2-amine (Camfetamine™). Drug Test. Anal., 1 Apr 2013, 5 (4), 247–253. 1080 kB. doi:10.1002/dta.411

Pellegrini, M; Rotolo, MC; Marchei, E; Pacifici, R; Saggio, F; Pichini, S. Magic truffles or philosopher’s stones: a legal way to sell psilocybin? Drug Test. Anal., 1 Mar 2013, 5 (3), 182–185. 219 kB. doi:10.1002/dta.1400

Elliott, SP; Brandt, SD; Freeman, S; Archer, RP. AMT (3-(2-aminopropyl)indole) and 5-IT (5-(2-aminopropyl)indole): an analytical challenge and implications for forensic analysis. Drug Test. Anal., 1 Mar 2013, 5 (3), 196–202. 794 kB. doi:10.1002/dta.1420

King, LA. Legal classification of novel psychoactive substances: An international Comparison. In Novel Psychoactive Substances; Dargan, PI; Wood, DM, Eds., Elsevier, 2013; pp 3–27. 350 kB. doi:10.1016/B978-0-12-415816-0.00001-8

Zhang, Y; Woods, RM; Breitbach, ZS; Armstrong, DW. 1,3-Dimethylamylamine (DMAA) in supplements and geranium products: natural or synthetic? Drug Test. Anal., 1 Dec 2012, 4 (12), 986–990. 337 kB. doi:10.1002/dta.1368

Brandt, SD; Passie, T. Research on psychedelic substances. Drug Test. Anal., 1 Aug 2012, 4 (7–8), 539–542. 96 kB. doi:10.1002/dta.1389

Maher, HM; Awad, T; DeRuiter, J; Clark, CR. GC-MS and GC-IRD studies on brominated dimethoxyamphetamines: Regioisomers related to 4-Br-2,5-DMA (DOB). Drug Test. Anal., 1 Aug 2012, 4 (7–8), 591–600. 1532 kB. doi:10.1002/dta.409

Reitzel, LA; Dalsgaard, PW; Müller, IB; Cornett, C. Identification of ten new designer drugs by GC-MS, UPLC-QTOF-MS, and NMR as part of a police investigation of a Danish Internet company. Drug Test. Anal., 1 May 2012, 4 (5), 342–354. 538 kB. doi:10.1002/dta.358

Maher, HM; Awad, T; DeRuiter, J; Clark, CR. GC-MS and GC-IRD studies on dimethoxyphenethylamines (DMPEA): Regioisomers related to 2,5-DMPEA. J. Chromatogr. Sci., 1 Jan 2012, 50 (1), 1–9. 594 kB. doi:10.1093/chromsci/bmr013

Zaitsu, K; Katagi, M; Tatsuno, M; Sato, T; Tsuchihashi, H; Suzuki, K. Recently abused β-keto derivatives of 3,4-methylenedioxyphenylalkylamines: a review of their metabolisms and toxicological analysis. Forensic Toxicol., 1 Jul 2011, 29 (2), 73–84. 971 kB. doi:10.1007/s11419-011-0111-8

Nichols, DE. Dopamine receptor subtype-selective drugs: D1-like receptors. In The Dopamine Receptors, 2nd ed.; Neve, KA, Ed., Humana Press, 2010; pp 75–99. 850 kB. doi:10.1007/978-1-60327-333-6_4

Ennis, MD; Hoffman, RL; Ghazal, NB; Olson, RM; Knauer, CS; Chio, CL; Hyslop, DK; Campbell, JE; Fitzgerald, LW; Nichols, NF; Svensson, KA; McCall, RB; Haber, CL; Kagey, ML; Dinh, DM. 2,3,4,5-Tetrahydro- and 2,3,4,5,11,11a-hexahydro-1H-[1,4]diazepino[1,7-a]indoles: New templates for 5-HT2C agonists. Bioorg. Med. Chem. Lett., 21 Jul 2003, 13 (14), 2369–2372. 191 kB. doi:10.1016/S0960-894X(03)00403-7

Clare, BW. The frontier orbital phase angles: Novel QSAR descriptors for benzene derivatives, applied to phenylalkylamine hallucinogens. J. Med. Chem., 24 Sep 1998, 41 (20), 3845–3856. 239 kB. doi:10.1021/jm980144c

Dawson, BA; Black, DB; Sy, W; Graham, K. 13C NMR of some iodinated methoxy-amphetamines. Magn. Reson. Chem., 1 Sep 1994, 32 (9), 557–558. 171 kB. doi:10.1002/mrc.1260320913

Dawson, BA; By, AW; Avdovich, HW. 13C NMR of some aryl-methylated trans-β-methyl-β-nitrostyrenes. Magn. Reson. Chem., 1 Jan 1993, 31 (1), 104–105. 196 kB. doi:10.1002/mrc.1260310121

Dawson, BA; By, AW; Avdovich, HW. 13C NMR of some trans-alkoxy-β-methyl-β-nitrostyrenes. Magn. Reson. Chem., 1 Feb 1991, 29 (2), 188–190. 219 kB. doi:10.1002/mrc.1260290217

Dawson, BA; Girard, M; Kindack, D; Fillion, J; Awang, DVC. 13C NMR of lapachol and some related naphthoquinones. Magn. Reson. Chem., 1 Dec 1989, 27 (12), 1176–1177. 145 kB. doi:10.1002/mrc.1260271212

McKenna, DJ; Saavedra, JM. Autoradiography of LSD and 2,5-dimethoxyphenylisopropylamine psychotomimetics demonstrates regional, specific cross-displacement in the rat brain. Eur. J. Pharmacol., 13 Oct 1987, 142 (2), 313–315. 263 kB. doi:10.1016/0014-2999(87)90121-X

Neville, GA. High-resolution proton magnetic resonance spectra of morphine and its three O-acetyl derivatives. Magn. Reson. Chem., 1 Jan 1987, 25 (1), 31–35. 446 kB. doi:10.1002/mrc.1260250108

Glennon, RA; Young, R. MDA: A psychoactive agent with dual stimulus effects. Life Sci., 23 Jan 1984, 34 (4), 379–383. 283 kB. doi:10.1016/0024-3205(84)90627-1

Glennon, RA; Young, R; Rosecrans, JA. A comparison of the behavioral effects of DOM homologs. Pharmacol. Biochem. Behav., 1 Apr 1982, 16 (4), 557–559. 256 kB. doi:10.1016/0091-3057(82)90414-2

Sternbach, LH. The benzodiazepine story. J. Med. Chem., 1 Jan 1979, 22 (1), 1–7. 838 kB. doi:10.1021/jm00187a001

Kier, LB; Glennon, RA. Psychotomimetic phenalkylamines as serotonin agonists: An SAR analysis. Life Sci., 8 May 1978, 22 (18), 1589–1593. 238 kB. doi:10.1016/0024-3205(78)90053-X

Partyka, RA; Gylys, JA. Psychotomimetic agents. In Annual Reports in Medicinal Chemistry; Heinzelman, RV, Ed., Academic Press, 1974; Vol. 9, pp 27–37. 898 kB. doi:10.1016/S0065-7743(08)61425-6

Phillips, GF. Some chemical aspects of drug legislation. J. Forensic Sci. Soc., 1 Jan 1967, 7 (1), 17–30. 943 kB. doi:10.1016/S0015-7368(67)70367-9

Clarke, EGC. Instant nepenthe. J. Forensic Sci. Soc., 1 Jan 1967, 7 (1), 1. 76 kB. doi:10.1016/S0015-7368(67)70363-1

Clark, LC; Benington, F; Morin, RD. The effects of ring-methoxyl groups on biological deamination of phenethylamines. J. Med. Chem., 1 May 1965, 8 (3), 353–355. 389 kB. doi:10.1021/jm00327a016

Benington, F; Morin, RD; Clark, LC. Behavioral and neuropharmacological actions of N-aralkylhydroxylamines and their O-methyl ethers. J. Med. Chem., 1 Jan 1965, 8 (1), 100–104. 634 kB. doi:10.1021/jm00325a020

Benington, F; Morin, RD; Clark, LC. Synthesis of some vicinal trimethoxyphenyl derivatives of heterocyclic nitrogen bases. J. Org. Chem., 1 Nov 1960, 25 (11), 1912–1916. 668 kB. doi:10.1021/jo01081a022

Benington, F; Morin, R; Clark, LC. Mescaline analogs. X. 3,4-Dimethyl-, 3,4-dichloro- and 3,5-dimethoxy-4-methyl-β-phenethylamines. J. Org. Chem., 1 Nov 1960, 25 (11), 2066–2067. 286 kB. doi:10.1021/jo01081a626

Benington, F; Morin, RD; Clark, LC. Synthesis of some 5- and 6-chloro, 5-methyl, and 5,6,7-trimethyl derivatives of tryptamine. J. Org. Chem., 1 Sep 1960, 25 (9), 1542–1547. 857 kB. doi:10.1021/jo01079a020

Benington, F; Morin, RD; Clark, LC. Synthesis of 5,6,7-trimethoxy-2,3-dihydroindole and 6,7-dimethoxyindole. J. Org. Chem., 1 Jul 1959, 24 (7), 917–919. 393 kB. doi:10.1021/jo01089a006

Benington, F; Morin, RD; Clark, LC. Synthesis of O- and N-methylated derivatives of 5-hydroxytryptamine. J. Org. Chem., 1 Dec 1958, 23 (12), 1977–1979. 401 kB. doi:10.1021/jo01106a046

Benington, F; Morin, R; Clark, LC. Mescaline analogs. IX. Tetra- and pentamethyl-β-phenethylamines. J. Org. Chem., 1 Dec 1958, 23 (12), 2034–2035. 263 kB. doi:10.1021/jo01106a632

Benington, F; Morin, RD; Clark, LC. Mescaline analogs. VIII. Substituted 5-methoxy- and 5,6,7-trimethoxyindoles. J. Org. Chem., 1 Jan 1958, 23 (1), 19–23. 628 kB. doi:10.1021/jo01095a007

Morin, R; Benington, F; Clark, L. Synthesis of 5,6,7-trimethoxyindole possible intermediary metabolite of mescaline. J. Org. Chem., 1 Mar 1957, 22 (3), 331–332. 266 kB. doi:10.1021/jo01354a608

Benington, F; Morin, RD; Clark, LC. Mescaline analogs. VII. 3,4,5-Trimethyl-β-phenethylamine. J. Org. Chem., 1 Mar 1957, 22 (3), 332–333. 293 kB. doi:10.1021/jo01354a609

Benington, F; Morin, RD; Clark, LC. Mescaline analogs. V. p-Dialkylamino-β-phenethylamines and 9-(β-aminoethyl)julolidine. J. Org. Chem., 1 Dec 1956, 21 (12), 1470–1472. 295 kB. doi:10.1021/jo01118a038

Benington, F; Morin, RD; Clark, LC. Mescaline analogs. VI. Mescaline homologs. J. Org. Chem., 1 Dec 1956, 21 (12), 1545–1546. 282 kB. doi:10.1021/jo01118a635

Benington, F; Morin, RD; Clark, LC. Mescaline analogs. IV. Substituted 4,5,6-trimethoxyindoles. J. Org. Chem., 1 Oct 1955, 20 (10), 1454–1457. 278 kB. doi:10.1021/jo01127a026

Benington, F; Morin, RD; Clark, LC. Mescaline analogs. III. 2,4,6-Trialkyl- and 3,4-dihydroxy-5- methoxy-β-phenethylamines. J. Org. Chem., 1 Sep 1955, 20 (9), 1292–1296. 345 kB. doi:10.1021/jo01126a019

Benington, F; Morin, RD; Clark, LC. Mescaline analogs. II. Tetra- and penta-methoxy-β-phenethylamines. J. Org. Chem., 1 Jan 1955, 20 (1), 102–108. 534 kB. doi:10.1021/jo01119a017

Benington, F; Morin, RD; Clarke, LC. Synthesis of 4-hydroxy- and 4-ethoxy-3,5-dimethoxy-β-phenethylamines. J. Am. Chem. Soc., 1 Nov 1954, 76 (21), 5555–5556. 307 kB. doi:10.1021/ja01650a084

Benington, F; Morin, RD; Clark, LC. Mescaline analogs. I. 2,4,6-Trialkoxy-β-phenethylamines. J. Org. Chem., 1 Jan 1954, 19 (1), 11–16. 436 kB. doi:10.1021/jo01366a003

Nutt, DJ; King, LA; Nichols, DE. Effects of schedule I drug laws on neuroscience research and treatment innovation. Nat. Rev. Neurosci., 1 Aug 2013, 14 (8), 577–585. 472 kB. doi:10.1038/nrn3530

Ettrup, A; Holm, S; Hansen, M; Wasim, M; Santini, MA; Palner, M; Madsen, J; Svarer, C; Kristensen, JL; Knudsen, GM. Preclinical safety assessment of the 5-HT2A receptor agonist PET radioligand [11C]Cimbi-36. Mol. Imaging Biol., 1 Aug 2013, 15 (4), 376–383. 374 kB. doi:10.1007/s11307-012-0609-4

Paulke, A; Kremer, C; Wunder, C; Achenbach, J; Djahanschiri, B; Elias, A; Schwed, JS; Hübner, H; Gmeiner, P; Proschak, E; Toennes, SW; Stark, H. Argyreia nervosa (Burm. f.): Receptor profiling of lysergic acid amide and other potential psychedelic LSD-like compounds by computational and binding assay approaches. J. Ethnopharmacol., 9 Jul 2013, 148 (2), 492–497. 555 kB. doi:10.1016/j.jep.2013.04.044

Abdel-Hay, KM; DeRuiter, J; Clark, CR. GC-MS and GC-IRD studies on the six-ring regioisomeric dimethoxybenzylpiperazines (DMBPs). Drug Test. Anal., 1 Jul 2013, 5 (7), 560–572. 985 kB. doi:10.1002/dta.1417

Jensen, AA; Plath, N; Pedersen, MHF; Isberg, V; Krall, J; Wellendorph, P; Stensbøl, TB; Gloriam, DE; Krogsgaard-Larsen, P; Frølund, B. Design, synthesis, and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-d]azepin-3-ol analogues: Novel 5-HT2A/5-HT2C receptor agonists with pro-cognitive properties. J. Med. Chem., 14 Feb 2013, 56 (3), 1211–1227. 3506 kB. doi:10.1021/jm301656h

Currie, CL. Epidemiology of adolescent Salvia divinorum use in Canada. Drug Alcohol Depend., 1 Feb 2013, 128 (1–2), 166–170. 201 kB. doi:10.1016/j.drugalcdep.2012.08.008

Hanks, JB; Gonzá-Maeso, J. Animal models of serotonergic psychedelics. ACS Chem. Neurosci., 16 Jan 2013, 4 (1), 33–42. 950 kB. doi:10.1021/cn300138m

Páleníček, T; Fujáková, M; Brunovský, M; Horáček, J; Gorman, I; Balíková, M; Rambousek, L; Syslová, K; Kačer, P; Zach, P; Bubeníková-Valešová, V; Tylš, F; Kubešová, A; Puskarčíková, J; Höschl, C. Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats. Psychopharmacology, 1 Jan 2013, 225 (1), 75–93. 1079 kB. doi:10.1007/s00213-012-2797-7

Dabrowska, K; Bujalski, M. The legal highs problem in the Polish printed media—actors, claims, and its hidden meanings. Subst. Use Misuse, 1 Jan 2013, 48 (1–2), 31–40. 268 kB. doi:10.3109/10826084.2012.720336

Langer, N; Lindigkeit, R; Schiebel, H; Ernst, L; Beuerle, T. Identification and quantification of synthetic cannabinoids in 'spice-like' herbal mixtures: A snapshot of the German situation in the autumn of 2012. Drug Test. Anal., 2013. 1680 kB. doi:10.1002/dta.1499

Wallach, J; Paoli, GD; Adejare, A; Brandt, SD. Preparation and analytical characterization of 1-(1-phenylcyclohexyl)piperidine (PCP) and 1-(1-phenylcyclohexyl)pyrrolidine (PCPy) analogues. Drug Test. Anal., 2013. 874 kB. doi:10.1002/dta.1468

Barker, SA; Borjigin, J; Lomnicka, I; Strassman, R. LC/MS/MS analysis of the endogenous dimethyltryptamine hallucinogens, their precursors, and major metabolites in rat pineal gland microdialysate. Biomed. Chromatogr., 2013. 929 kB. doi:10.1002/bmc.2981

Coppola, M; Mondola, R. Bromo-DragonFly: Chemistry, pharmacology and toxicology of a benzodifuran derivative producing LSD-like effects. J. Addict. Res. Ther., 1 Oct 2012, 3 (4), 133. 1197 kB. doi:10.4172/2155-6105.1000133

Wood, DM; Dargan, PI. Use and acute toxicity associated with the novel psychoactive substances diphenylprolinol (D2PM) and desoxypipradrol (2-DPMP). Clin. Toxicol., 1 Sep 2012, 50 (8), 727–732. 117 kB. doi:10.3109/15563650.2012.716158

Chemel, BR; Bonner, LA; Watts, VJ; Nichols, DE. Ligand-specific roles for transmembrane 5 serine residues in the binding and efficacy of dopamine D1 receptor catechol agonists. Mol. Pharmacol., 1 May 2012, 81 (5), 729–738. 1213 kB. doi:10.1124/mol.111.077339

McIlhenny, EH; Riba, J; Barbanoj, MJ; Strassman, R; Barker, SA. Methodology for determining major constituents of ayahuasca and their metabolites in blood. Biomed. Chromatogr., 1 Mar 2012, 26 (3), 301–313. 557 kB. doi:10.1002/bmc.1657

Kusin, S; Tesar, J; Hatten, B; Horowitz, BZ; Hendrickson, R; Leman, R; Buser, G. Severe methemoglobinemia and haemolytic anemia from aniline purchased as 2C-E (4-ethyl-2,5-dimethoxyphenethylamine), a recreational drug, on the internet – Oregon, 2011. Morbidity and Mortality Weekly Report, 10 Feb 2012, 61 (5), 85–88. 273 kB.

Muzalevskiy, VM; Shastin, AV; Balenkova, ES; Haufe, G; Nenajdenko, VG. Synthesis of α-trifluoromethyl-phenethylamines from α-trifluoromethyl-β-aryl enamines and β-chloro-β-trifluoromethyl)styrenes. J. Fluorine Chem., 1 Dec 2011, 132 (12), 1247–1253. 413 kB. doi:10.1016/j.jfluchem.2011.06.030

McIlhenny, EH; Riba, J; Barbanoj, MJ; Strassman, R; Barker, SA. Methodology for and the determination of the major constituents and metabolites of the Amazonian botanical medicine ayahuasca in human urine. Biomed. Chromatogr., 1 Sep 2011, 25 (9), 970–984. 1030 kB. doi:10.1002/bmc.1551

Nutt, D. Perverse effects of the precautionary principle: how banning mephedrone has unexpected implications for pharmaceutical discovery. Ther. Adv. Psychopharmacol., 1 Apr 2011, 1 (2), 35–36. 63 kB. doi:10.1177/2045125311406958

Carroll, FI; Muresan, AZ; Blough, BE; Navarro, HA; Mascarella, SW; Eaton, JB; Huang, X; Damaj, MI; Lukas, RJ. Synthesis of 2-(substituted phenyl)-3,5,5-trimethylmorpholine analogues and their effects on monoamine uptake, nicotinic acetylcholine receptor function, and behavioral effects of nicotine. J. Med. Chem., 10 Mar 2011, 54 (5), 1441–1448. 1018 kB. doi:10.1021/jm1014555

Silverman, J. Addicted to getting drugs wrong. Br. Journal. Rev., 1 Dec 2010, 21 (4), 31–36. 177 kB. doi:10.1177/0956474810393603

Nutt, DJ; King, LA; Phillips, LD. Drug harms in the UK: a multicriteria decision analysis. Lancet, 6 Nov 2010, 376 (9752), 1558–1565. 343 kB. doi:10.1016/S0140-6736(10)61462-6

Ettrup, A; Palner, M; Gillings, N; Santini, MA; Hansen, M; Kornum, BR; Rasmussen, LK; Nagren, K; Madsen, J; Begtrup, M; Knudsen, GM. Radiosynthesis and evaluation of 11C-CIMBI-5 as a 5-HT2A receptor agonist radioligand for PET. J. Nucl. Med., 1 Nov 2010, 51 (11), 1763–1770. 548 kB. doi:10.2967/jnumed.109.074021

King, LA; Corkery, JM. An index of fatal toxicity for drugs of misuse. Hum. Psychopharmacol. Clin. Exp., 1 Mar 2010, 25 (2), 162–166. 95 kB. doi:10.1002/hup.1090

Oh, S; Kim, KS; Chung, Y; Shong, M; Park, SB. Anti-obesity agents: A focused review on the structural classification of therapeutic entities. Curr. Top. Med. Chem., 2009, 9 (6), 466–481. 438 kB. doi:10.2174/156802609788897862

Wood, DM; Button, J; Lidder, S; Ramsey, J; Holt, DW; Dargan, PI. Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-trifluoromethylphenyl)piperazine (TFMPP) and 1-benzylpiperzine (BZP). J. Med. Toxicol., 1 Dec 2008, 4 (4), 254–257. 334 kB. doi:10.1007/BF03161209

Kanai, K; Takekawa, K; Kumamoto, T; Ishikawa, T; Ohmori, T. Simultaneous analysis of six phenethylamine-type designer drugs by TLC, LC-MS, and GC-MS. Forensic Toxicol., 1 Nov 2008, 26 (2), 6–12. 406 kB. doi:10.1007/s11419-008-0041-2

Gambelunghe, C; Aroni, K; Rossi, R; Moretti, L; Bacci, M. Identification of N,N-dimethyltryptamine and β-carbolines in psychotropic ayahuasca beverage. Biomed. Chromatogr., 1 Oct 2008, 22 (10) 1056–1059. 140 kB. doi:10.1002/bmc.1023

Lidder, S; Dargan, PI; Sexton, M; Button, J; Ramsey, J; Holt, DW; Wood, DM. Cardiovascular toxicity associated with recreational use of diphenylprolinol (diphenyl-2-pyrrolidinemethanol [D2PM]). J. Med. Toxicol., 1 Sep 2008, 4 (3), 167–169. 164 kB. doi:10.1007/BF03161195

Thomsen, WJ; Grottick, AJ; Menzaghi, F; Reyes-Saldana, H; Espitia, S; Yuskin, D; Whelan, K; Martin, M; Morgan, M; Chen, W; Al-Shamma, H; Smith, B; Chalmers, D; Behan, D. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J. Pharmacol. Exp. Ther., 1 May 2008, 325 (2), 577–587. 491 kB. doi:10.1124/jpet.107.133348

Wood, DM; Warren-Gash, C; Ashraf, T; Greene, SL; Shather, Z; Trivedy, C; Clarke, S; Ramsey, J; Holt, DW; Dargan, PI. Medical and legal confusion surrounding gamma-hydroxybutyrate (GHB) and its precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4BD). QJM-Int. J. Med., 1 Jan 2008, 101 (1), 23–29. 98 kB. doi:10.1093/qjmed/hcm117

Smith, BM; Smith, JM; Tsai, JH; Schultz, JA; Gilson, CA; Estrada, SA; Chen, RR; Park, DM; Prieto, EB; Gallardo, CS; Sengupta, D; Thomsen, WJ; Saldana, HR; Whelan, KT; Menzaghi, F; Webb, RR; Beeley, NRA. Discovery and SAR of new benzazepines as potent and selective 5-HT2C receptor agonists for the treatment of obesity. Bioorg. Med. Chem. Lett., 1 Mar 2005, 15 (5), 1467–1470. 122 kB. doi:10.1016/j.bmcl.2004.12.080

Cami-Kobeci, G; Slatford, PA; Whittlesey, MK; Williams, JMJ. N-Alkylation of phenethylamine and tryptamine. Bioorg. Med. Chem. Lett., 1 Feb 2005, 15 (3), 535–537. 265 kB. doi:10.1016/j.bmcl.2004.11.050

Anon. Dr. Ecstasy. New York Times Magazine, 30 Jan 2005.

Bustamante, D; Diaz-Véliz, G; Paeile, C; Zapata-Torres, G; Cassels, BK. Analgesic and behavioral effects of amphetamine enantiomers, p-methoxyamphetamine and N-alkyl-p-methoxyamphetamine derivatives. Pharmacol. Biochem. Behav., 1 Oct 2004, 79 (2), 199–212. 404 kB. doi:10.1016/j.pbb.2004.06.017

Villalobos, CA; Bull, P; Sáez, P; Cassels, BK; Huidobro-Toro, JP. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes. Br. J. Pharmacol., 1 Apr 2004, 141 (7), 1167–1174. 271 kB. doi:10.1038/sj.bjp.0705722

Błachut, D; Czarnocki, Z; Wojtasiewicz, K. α-Phenylethylamine in illegally produced amphetamine. Forensic Sci. Int., 1 Dec 2001, 123 (2–3), 182–190. 171 kB. doi:10.1016/S0379-0738(01)00548-5

Boer, D; Gijzels, MJ; Bosman, IJ; Maes, RAA. More data about the new psychoactive drug 2C-B. J. Anal. Toxicol., 1 Jul 1999, 23 (3), 227–228. 190 kB. doi:10.1093/jat/23.3.227

Buttar, HS; Moffatt, JH; Foster, BC. Developmental toxicity of 4-substituted amphetamines in mice. Reprod. Toxicol., 1 Jul 1996, 10 (4), 301–310. 710 kB. doi:10.1016/0890-6238(96)00059-7

Cyr, TD; Dawson, BA; By, AW; Neville, GA; Shurvell, HF. Structural elucidation of unusual police exhibits. II. Identification and spectral characterization of N-(2-hydroxyethyl)amphetamine hydrochloride. J. Forensic Sci., 1 Jul 1996, 41 (4), 608–611. 360 kB. doi:10.1520/JFS13962J

Scorza, MC; Reyes-Parada, M; Silveira, R; Viola, H; Medina, JH; Viana, MB; Zangrossi, H; Graeff, FG. Behavioral effects of the putative anxiolytic (±)-1-(2,5-dimethoxy-4-ethylthiophenyl)-2-aminopropane (ALEPH-2) in rats and mice. Pharmacol. Biochem. Behav., 1 May 1996, 54 (2), 355–361. 504 kB. doi:10.1016/0091-3057(95)02149-3

LeBelle, MJ; Savard, C; Dawson, BA; Black, DB; Katyal, LK; Zrcek, F; By, AW. Chiral identification and determination of ephedrine, pseudoephedrine, methamphetamine and metecathinone by gas chromatography and nuclear magnetic resonance. Forensic Sci. Int., 28 Feb 1995, 71 (3), 215–223. 405 kB. doi:10.1016/0379-0738(94)01669-0

Dawson, BA; Black, DB; Cyr, TD; Ethier, J; By, AW; Beckstead, HD; Neville, GA. Structural elucidation of unusual police exhibits. I. Dimethpramide ('Dimetcarb'). Forensic Sci. Int., 28 Feb 1995, 71 (3), 169–179. 1376 kB. doi:10.1016/0379-0738(94)01664-X

Geertsen, S; Foster, BC; Cyr, DLWTD; Casley, W. Metabolism of methoxyphenamine and 2-methoxyamphetamine inP4502D6-transfected cells and cell preparations. Xenobiotica, 1995, 25 (9), 895–906. 731 kB. doi:10.3109/00498259509046661

Sy, W. Iodination of methoxyamphetamines with iodine and silver sulphate. Tetrahedron Lett., 24 Sep 1993, 34 (39), 6223–6224. 133 kB. doi:10.1016/S0040-4039(00)73715-4

LeBelle, MJ; Lauriault, G; Lavoie, A. Gas chromatographic-mass spectrometric identification of chiral derivatives of the alkaloids of KHAT. Forensic Sci. Int., 1 Sep 1993, 61 (1), 53–64. 900 kB. doi:10.1016/0379-0738(93)90249-A

Corrigall, WA; Coen, KM; Saouda, FM; Robertson, JM; Lodge, BA. Discriminative stimulus properties of substituted amphetamine derivatives. Pharmacol. Biochem. Behav., 1 Dec 1992, 43 (4), 1117–1119. 265 kB. doi:10.1016/0091-3057(92)90490-7

Lodge, BA; Duhaime, R; Zamecnik, J; MacMurray, P; Brousseau, R. New street analogs of phencyclidine. Forensic Sci. Int., 1 Jul 1992, 55 (1), 13–26. 529 kB. doi:10.1016/0379-0738(92)90090-J

Corrigall, WA; Robertson, JM; Coen, KM; Lodge, BA. The reinforcing and discriminative stimulus properties of para-ethoxy- and para-methoxyamphetamine. Pharmacol. Biochem. Behav., 1 Jan 1992, 41 (1), 165–169. 538 kB. doi:10.1016/0091-3057(92)90077-S

Sy, W. Iodination of aromatic amines with iodine and silver sulphate. Synth. Commun., 1992, 22 (22), 3215–3219. 433 kB. doi:10.1080/00397919208021135

Foster, BC; McLeish, J; Wilson, DL; Whitehouse, LW; Zamecnik, J; Lodge, BA. Biotransformation of tri-substituted methoxyamphetamines by Cunninghamella echinulata. Xenobiotica, 1992, 22 (12), 1383–1394. 765 kB. doi:10.3109/00498259209056689

Persons, PE; Mayer, JP; Nichols, DE; Cassady, JM; Smalstig, EB; Clemens, JA. Preliminary evaluation of 4-(2-N,N-dialkylaminoiethyl)indoles as potential dopamine agonists. Eur. J. Med. Chem., 1 Jun 1991, 26 (4), 473–475. 221 kB. doi:10.1016/0223-5234(91)90110-9

Foster, BC; Litster, DL; Lodge, BA. Biotransformation of 2-, 3-, and 4-methoxyamphetamines by Cunninghamella echinulata. Xenobiotica, 1991, 21 (10), 1337–1346. 553 kB. doi:10.3109/00498259109043208

By, AW; Dawson, BA; Lodge, BA; Neville, GA; Sy, W; Zamecnik, J. Synthesis and spectral properties of 2,5-dimethoxy-4-ethoxyamphetamine and its precursors. J. Forensic Sci., 1 Mar 1990, 35 (2), 316–335. 538 kB. doi:10.1520/JFS12833J

Awang, DVC; Dawson, BA; Neville, GA; Ekiel, I; Deslauriers, R; Smith, ICP. 13C-NMR of Rauwolfia alkaloids. J. Pharm. Biomed. Anal., 1990, 8 (1), 91. 76 kB. doi:10.1016/0731-7085(90)80012-E

Foster, BC; Nantais, LM; Wilson, DL; By, AW; Zamecnik, J; Lodge, BA. Fungal metabolism of 4-substituted amphetamines. Xenobiotica, 1990, 20 (6), 583–590. 510 kB. doi:10.3109/00498259009046873

Nichols, DE; Cassady, JM; Persons, PE; Yeung, MC; Clemens, JA; Smalstig, B. Synthesis and evaluation of N,N-di-n-propyltetrahydrobenz[f]indol-7-amine and related congeners as dopaminergic agonists. J. Med. Chem., 1 Sep 1989, 32 (9), 2128–2134. 1027 kB. doi:10.1021/jm00129a017

Sy, W; Lodge, BA. Iodination of alkylbenzenes with iodine and silver nitrite. Tetrahedron Lett., 1989, 30 (29), 3769–3772. 176 kB. doi:10.1016/S0040-4039(01)80650-X

Hashimoto, Y; Kawanishi, K; Moriyasu, M. Forensic chemistry of alkaloids by chromatographic analysis. In The Alkaloids: Chemistry and Pharmacology; Brossi, A, Ed., Academic Press Inc., 1988; Vol. 32, pp 1–77. 4312 kB. doi:10.1016/S0099-9598(08)60215-1

Baker, GB; Coutts, RT; Rao, TS. Neuropharmacological and neurochemical properties of N- (2-cyanoethyl)-2-phenylethylamine, a prodrug of 2-phenylethylamine. Br. J. Pharmacol., 1 Oct 1987, 92 (2), 243–255. 1932 kB. doi:10.1111/j.1476-5381.1987.tb11318.x

Clark, RD; Repke, DB. Some observations on the formation of 1-hydroxyindoles in the Leimgruber-Batcho indole synthesis. J. Heterocycl. Chem., 1 Jan 1985, 22 (1), 121–125. 334 kB. doi:10.1002/jhet.5570220130

Sy, W; By, AW. Nitration of substituted styrenes with nitryl iodide. Tetrahedron Lett., 1985, 26 (9), 1193–1196. 174 kB. doi:10.1016/S0040-4039(00)98431-4

Nichols, DE. The development of novel dopamine agents. In Dopamine Receptors; Kaiser, C; Kebabian, JW, Eds., American Chemical Society, Washington, DC, 29 Jun 1983; Vol. 224, pp 201–221. 1866 kB. doi:10.1021/bk-1983-0224.ch009

Bailey, K; Legault, D. 13C NMR spectra and structure of mono-, di- and trimethoxyphenylethylamines and amphetamines. Org. Magn. Resonance, 1 Jun 1983, 21 (6), 391–396. 680 kB. doi:10.1002/omr.1270210611

Bailey, K; Legault, D. Analysis of the 13C NMR spectra of mono- and dimethoxy-β-methyl-β-nitrostyrenes: Spectral assignments and conformation effects. Org. Magn. Resonance, 1 May 1981, 16 (1), 47–51. 604 kB. doi:10.1002/mrc.1270160113

Bailey, K; Legault, D. Analysis of the 13C-NMR spectra of mono- and dimethylamphetamines. Anal. Chim. Acta., 1 Jan 1981, 123, 75–82. 654 kB. doi:10.1016/S0003-2670(01)83160-3

Bailey, K; Legault, D. Carbon-13 nuclear magnetic resonance spectra of aminocyclohexanecarbonitriles and comparison with phencyclidine analogues. Org. Magn. Resonance, 1 Jan 1981, 15 (1), 68–71. 407 kB. doi:10.1002/mrc.1270150114

Legault, D. Investigation of the gas-liquid chromatographic separation of phencyclidine and some heterocyclic analogues by combined gas-liquid chromatography-mass spectrometry. J. Chromatogr., 19 Dec 1980, 202 (2), 309–312. 253 kB. doi:10.1016/S0021-9673(00)81744-6

Bailey, K; Legault, D. Identification of cyclohexamine, phencyclidine and simple analogues by carbon-13 nuclear magnetic resonance spectroscopy. Anal. Chim. Acta., 15 Jan 1980, 113 (2), 375–381. 571 kB. doi:10.1016/S0003-2670(01)93755-9

Bailey, K. Identification of a street drug as N-ethyl-1-phenylcyclohexylamine, a phencyclidine analog. J. Pharm. Sci., 1 Jun 1978, 67 (6), 885–886. 244 kB. doi:10.1002/jps.2600670649

Acheson, RM; Hunt, PG; Littlewood, DM; Murrer, BA; Rosenberg, H. The synthesis, reactions, and spectra of 1-acetoxy-, 1-hydroxy-, and 1-methoxy-indoles. J. Chem. Soc. Perkin Trans. 1, 1978, 1978 (10), 1117–1125. 1395 kB. doi:10.1039/P19780001117

Nichols, DE; Pfister, WR; Yim, GKW; Cosgrove, RJ. A new view of the structural relationship between LSD and mescaline. Brain Res. Bull., 1 May 1977, 2 (3), 169–171. 338 kB. doi:10.1016/0361-9230(77)90034-X

Bailey, K; Gagné, DR. Distinction of synthetic cannabidiol, cannabichromene, and cannabivarin by GLC using on-column methylation. J. Pharm. Sci., 1 Oct 1975, 64 (10), 1719–1720. 169 kB. doi:10.1002/jps.2600641033

Bailey, K; By, AW. The conformation of β-phenylethylamines in solution. Can. J. Pharm. Sci., 1975, 10 (1), 31–32. 117 kB.

Bailey, K; Boulanger, JG; Legault, D; Taillefer, SL. Identification and synthesis of di-(1-phenylisopropyl)methylamine, an impurity in illicit methamphetamine. J. Pharm. Sci., 1 Oct 1974, 63 (10), 1575–1578. 255 kB. doi:10.1002/jps.2600631017

Horn, AS. Structure-activity relations for the inhibition of catecholamine uptake into synaptosomes from noradrenaline and dopaminergic neurones in rat brain homogenates. Br. J. Pharmacol., 1 Feb 1973, 47 (2), 332–338. 903 kB. doi:10.1111/j.1476-5381.1973.tb08331.x

Short, JH; Dunnigan, DA; Ours, CW. Synthesis of phenethylamines from phenylacetonitriles obtained by alkylation of cyanide ion with Mannich bases from phenols and other benzylamines. Tetrahedron, 1973, 29 (14), 1931–1939. 791 kB. doi:10.1016/0040-4020(73)80127-9

Ho, B; Tansey, LW; Huang, J. Analogs of amphetamine. 6. 2,5-Dimethoxy-4-methyl- and 2,5-dimethoxy-α,4-dimethylphenylalanines. J. Med. Chem., 1 Nov 1971, 14 (11), 1132–1133. 349 kB. doi:10.1021/jm00293a036

Ho, B; Estevez, V; Tansey, LW; Englert, LF; Creaven, PJ; McIsaac, WM. Analogs of amphetamine. 5. Excretory metabolites of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) in rats. J. Med. Chem., 1 Feb 1971, 14 (2), 158–160. 371 kB. doi:10.1021/jm00284a019

Ho, B; Tansey, LW. Analogs of amphetamine. 4. Synthesis of metabolites of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM). J. Med. Chem., 1 Feb 1971, 14 (2), 156–157. 316 kB. doi:10.1021/jm00284a018

Antun, F; Smythies, JR; Benington, F; Morin, RD; Barfknecht, CF; Nichols, DE. Native fluorescence and hallucinogenic potency of some amphetamines. Experientia, 15 Jan 1971, 27 (1), 62–63. 248 kB. doi:10.1007/BF02137743

Warren, RJ; Begosh, PP; Zarembo, JE. Identification of amphetamines and related sympathomimetic amines. J. Assoc. Off. Anal. Chem., 1971, 54 (5), 1179–1191. 3851 kB.

Ho, B; Tansey, LW; McIsaac, WM. Derivatives of 2,5-dimethoxy-4-methylamphetamine (DOM). J. Med. Chem., 1 Sep 1970, 13 (5), 1022. 99 kB. doi:10.1021/jm00299a071

Ho, B; McIsaac, WM; An, R; Tansey, LW; Walker, KE; Englert, LF; Noel, MB. Analogs of α-methylphenethylamine (amphetamine). I. Synthesis and pharmacological activity of some methoxy and/or methyl analogs. J. Med. Chem., 1 Jan 1970, 13 (1), 26–30. 601 kB. doi:10.1021/jm00295a007

Farnsworth, NR. Hallucinogenic plants. Science, 6 Dec 1968, 162 (3858), 1086–1092. 1515 kB. doi:10.1126/science.162.3858.1086

Wiseman-Distler, MH; Sourkes, TL. The effect of 4-hydroxyindoles on the metabolism of 5-hydroxytryptamine (serotonin). Ann. N.Y. Acad. Sci., 1 Jan 1962, 96, 142–151. 458 kB. doi:10.1111/j.1749-6632.1962.tb50109.x

Smythies, JR. The stroboscope as providing empirical confirmation of the representative theory of perception. Br. J. Philos. Sci., 1 Feb 1956, 6 (24), 332–335. 504 kB. doi:10.2307/685413

Speeter, ME; Anthony, WC. The action of oxalyl chloride on indoles: A new approach to tryptamines. J. Am. Chem. Soc., 1 Dec 1954, 76 (23), 6208–6210. 416 kB. doi:10.1021/ja01652a113

Edmunds, R; Locos, O; Brown, D; Reynolds, D. Identification of the synthetic cannabinoid (1-(cyclohexylmethyl)-1H-indol-3-yl)(4-methoxynaphthalen-1-yl)methanone on plant material. Microgram J., 1 Jan 2013, 10 (1), 3–7. 470 kB.

Trachsel, D; Lehmann, D; Enzensperger, C. Phenethylamine: Von der Struktur zur Funktion, Nachtschatten Science, 1 Jan 2013. In German.

Casale, JF; Hays, PA. Characterization of eleven 2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (NBOMe) derivatives and differentiation from their 3- and 4-methoxybenzyl analogues—Part I. Microgram J., 1 Jan 2012, 9 (2), 84–109. 4601 kB.

Casale, JF; Hays, PA; Berrier, A. The characterization of 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine). Microgram J., 1 Jan 2012, 9 (1), 3–17. 1852 kB.

Casale, JF; Hays, PA. The characterization of α-pyrrolidinopentiophenone. Microgram J., 1 Jan 2012, 9 (1), 33–38. 1194 kB.

Casale, JF; Hays, PA. The characterization of etaqualone and differentiation from its 3- and 4-ethyl analogues. Microgram J., 1 Jan 2012, 9 (2), 47–51. 786 kB.

Donohue, KM; Steiner, RR. JWH-018 and JWH-022 as combustion products of AM2201. Microgram J., 1 Jan 2012, 9 (2), 52–56. 442 kB.

Fultz, BA; Mann, JA; Gardne, EA. Methamphetamine contaminated currency in the Birmingham, Alabama metropolitan area. Microgram J., 1 Jan 2012, 9 (2), 57–60. 209 kB.

Casale, JF; Hays, PA. The characterization of 6-(2-aminopropyl)benzofuran and differentiation from its 4-, 5-, and 7-positional analogues. Microgram J., 1 Jan 2012, 9 (2), 61–74. 1652 kB.

Casale, JF; Hays, PA. Differentiation of 3,4-dimethylmethcathinone (3,4-DMMC) from its dimethyl aryl-positional isomers. Microgram J., 1 Jan 2012, 9 (2), 75–83. 1330 kB.

Trachsel, D. Psychedelische Chemie, Nachtschatten Science, 1 Jan 2011. In German.

Bozenko, JS. The characterization of anastrozole. Microgram J., 1 Jan 2011, 8 (1), 12–15. 393 kB.

Kirby, DA. 4-Methoxyphencyclidine: An analytical profile. Microgram J., 1 Jan 2011, 8 (2), 39–42. 788 kB.

Casale, JF; Hays, PA. Characterization of 2β-(1,2,4-oxadiazol-5-methyl)-3β-phenyltropane (“RTI-126”). Microgram J., 1 Jan 2011, 8 (1), 3–11. 682 kB.

Lurie, IS; Bozenko, JS; Li, L; Miller, EE; Greenfield, SJ. Chiral separation of methamphetamine and related compounds using capillary electrophoresis with dynamically coated capillaries. Microgram J., 1 Jan 2011, 8 (1), 24–28. 786 kB.

Casale, EM; Casale, JF. Identification of levamisole and lidocaine acetylation reaction impurities found in heroin exhibits. Microgram J., 1 Jan 2011, 8 (1), 16–23. 1131 kB.

Smith, RM; Casale, JF. The mass spectrum of cocaine: Deuterium labeling and MS/MS studies. Microgram J., 1 Mar 2010, 7 (1), 16–41. 3202 kB.

Steiner, RR. A rapid technique for the confirmation of iodine and red phosphorus using direct analysis in real time and accurate mass spectrometry. Microgram J., 1 Mar 2010, 7 (1), 3–6. 327 kB.

Casale, JF; Nguyen, MC. N-Acetylbenzocaine: Formation via transacetylation of benzocaine and acetylsalicylic acid in a cocaine exhibit. Microgram J., 1 Mar 2010, 7 (1), 7–11. 1082 kB.

McGehee, MC. Etodolac: An analytical profile. Microgram J., 1 Jul 2008, 6 (3–4), 104–108. 65 kB.

Corbeil, EM; Casale, JF. Determination of cocaine in various South American commercial coca products. Microgram J., 1 Jul 2008, 6 (3–4), 109–113. 70 kB.

Jones, LM; Boudreau, DK; Casale, JF. “Crack” cocaine: A study of stability over time and temperature. Microgram J., 1 Jul 2008, 6 (3–4), 114–127. 496 kB.

Moore, JM; Casale, JF. The discoloration of illicit drug samples. Microgram J., 1 Jul 2008, 6 (3–4), 128–145. 256 kB.

Sarwar, M; Taylor, S; Majeed, I. A specific screening color test for diazepam. Microgram J., 1 Jul 2008, 6 (3–4), 63–71. 678 kB.

Boudreau, DK; Casale, JF. An in-depth study of Peruvian base llavada (“washed base”) technique for purification of crude cocaine base. Microgram J., 1 Jul 2008, 6 (3–4), 72–81. 278 kB.

Casale, JF; Corbeil, EM; Hays, PA. Identification of levamisole impurities found in illicit cocaine exhibits. Microgram J., 1 Jul 2008, 6 (3–4), 82–89. 216 kB.

Casale, JF; Orlando, PM; Colley, VL; Hays, PA. Identification of diltiazem impurities/artifacts during the analysis of illicit cocaine exhibits containing diltiazem. Microgram J., 1 Jul 2008, 6 (3–4), 90–103. 397 kB.

Anon. Microgram Journal, July–December 2008, U.S. Drug Enforcement Administration, 1 Jul 2008.

Anon. Microgram Journal, January–June 2008, U.S. Drug Enforcement Administration, 1 Jan 2008.

Rodriguez-Cruz, SE. Rapid screening of seized drug exhibits using desorption electrospray ionization mass spectrometry (DESI-MS). Microgram J., 1 Jan 2008, 6 (1–2), 10–25. 353 kB.

McGill, JW; Dixon, CA; Ritter, D; Sides, JD. Discovery of an interesting temperature effect on the sensitivity of cobalt thiocyanate test for cocaine. Microgram J., 1 Jan 2008, 6 (1–2), 26–35. 47 kB.

Kerr, SC; Casale, JF. The use of dipropionylmorphine as a structurally-related internal standard for gas chromatographic quantitation of heroin. Microgram J., 1 Jan 2008, 6 (1–2), 3–9. 69 kB.

Sanderson, RM. Identification of N-methylbenzylamine hydrochloride, N-ethylbenzylamine hydrochloride, and N-isopropylbenzylamine hydrochloride. Microgram J., 1 Jan 2008, 6 (1–2), 36–45. 495 kB.

Martinez, FS; Roesch, DM; Jacobs, JL. Isolation of methamphetamine from 1-(1′,4′-cyclohexadienyl)-2-methylaminopropane (CMP) using potassium permanganate. Microgram J., 1 Jan 2008, 6 (1–2), 46–54. 149 kB.

Anon. Microgram Journal, January–December 2007, U.S. Drug Enforcement Administration, 1 Jan 2007.

Panicker, S; Wojno, HL; Ziska, LH. Quantitation of the major alkaloids in opium from Papaver Setigerum DC. Microgram J., 1 Jan 2007, 5 (1–4), 13–19. 381 kB.

Fucci, N. Analysis of fatty acids in marijuana (Cannabis Sativa leaf). Microgram J., 1 Jan 2007, 5 (1–4), 20–25. 41 kB.

Reed, EC; Kiddon, GS. The characterization of three FLY compounds (2C-B-FLY, 3C-B-FLY, and Bromo-DragonFLY). Microgram J., 1 Jan 2007, 5 (1–4), 26–33. 112 kB.

Dal Cason, TA. Synthesis and identification of N,N-dimethylcathinone hydrochloride. Microgram J., 1 Jan 2007, 5 (1–4), 3–12. 93 kB.

Ropero-Miller, JD; Stout, PR; Bynum, ND; Casale, JF. Comparison of the novel direct analysis in real time time-of-flight mass spectrometry (AccuTOF-DART™) and signature analysis for the identification of constituents of refined illicit cocaine. Microgram J., 1 Jan 2007, 5 (1–4), 34–40. 501 kB.

Fasanello, JA; Placke, AD. The isolation, identification, and quantitation of dimethyltryptamine (DMT) in Mimosa Hostilis. Microgram J., 1 Jan 2007, 5 (1–4), 41–52. 168 kB.

Anon. Microgram Journal, January–December 2006, U.S. Drug Enforcement Administration, 1 Jan 2006.

Tsujikawa, K; Kanamori, T; Kuwayama, K; Miyaguchi, H; Iwata, YT; Inoue, H. Analytical profiles for 3,4,5-, 2,4,5-, and 2,4,6-trimethoxyamphetamine. Microgram J., 1 Jan 2006, 4 (1–4), 12–23. 162 kB.

Sarwar, M. A new, highly specific color test for ketamine. Microgram J., 1 Jan 2006, 4 (1–4), 24–28. 93 kB.

Franckowski, RE; Thompson, RA. Eszopiclone (Lunesta™): An analytical profile. Microgram J., 1 Jan 2006, 4 (1–4), 29–36. 162 kB.

Blackledge, RD; Phelan, CP. Identification of bufotenine in Yopo seeds via GC/IRD. Microgram J., 1 Jan 2006, 4 (1–4), 3–11. 334 kB.

Casale, JF; Piñero, EL; Corbeil, EM. Isolation of cis-cinnamoylcocaine from crude illicit cocaine via alumina column chromatography. Microgram J., 1 Jan 2006, 4 (1–4), 37–41. 95 kB.

Casale, JF; Hays, PA; Spratley, TK; Smith, PR. The characterization of 4-methoxy-N-ethylamphetamine hydrochloride. Microgram J., 1 Jan 2006, 4 (1–4), 42–46. 103 kB.

Piñero, EL; Casale, JF. Quantitation of cocaine by gas chromatography-flame ionization detection utilizing isopropylcocaine as a structurally related internal standard. Microgram J., 1 Jan 2006, 4 (1–4), 47–53. 108 kB.

Wisniewski, ES; Hays, PA. Dehydrochlormethyltestosterone: An analytical profile. Microgram J., 1 Jan 2006, 4 (1–4), 54–65. 231 kB.

Edwards, NR. Qualitative and quantitative analysis of Ionamin 30 capsules (containing a time-release formulation of phentermine). Microgram J., 1 Jan 2006, 4 (1–4), 66–69. 115 kB.

Valentino, AMM; Fuentecilla, K. Levamisole: An analytical profile. Microgram J., 1 Jul 2005, 3 (3–4), 134–137. 463 kB.

Lurie, IS; Cox, KA. Rapid chiral separation of dextro- and levo- methorphan using capillary electrophoresis with dynamically coated capillaries. Microgram J., 1 Jul 2005, 3 (3–4), 138–141. 111 kB.

Kitlinski, LM; Harman, AL; Brousseau, MM; Skinner, HF. Reduction of phenylephrine with hydriodic acid/red phosphorus or iodine/red phosphorus: 3-Hydroxy-N-methylphenethylamine. Microgram J., 1 Jul 2005, 3 (3–4), 142–153. 529 kB.

Rodriguez, WR; Allred, RA. Synthesis of trans-4-methylaminorex from norephedrine and potassium cyanate. Microgram J., 1 Jul 2005, 3 (3–4), 154–165. 559 kB.

Koper, C; Ali-Tolppa, E; Bozenko, JS; Dufey, V; Puetz, M; Weyermann, C; Zrcek, F. Identification of a new amphetamine type stimulant: 3,4-Methylenedioxy-(2-hydroxyethyl)amphetamine (MDHOET). Microgram J., 1 Jul 2005, 3 (3–4), 166–174. 406 kB.

Rodriguez-Cruz, SE. Analysis and characterization of psilocybin and psilocin using liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS) with collision-induced-dissociation (CID) and source-induced-dissociation (SID). Microgram J., 1 Jul 2005, 3 (3–4), 175–182. 560 kB.

Hanson, AJ. Specificity of the Duquenois-Levine and cobalt thiocyanate tests substituting methylene chloride or butyl chloride for chloroform. Microgram J., 1 Jul 2005, 3 (3–4), 183–185. 91 kB.

Blackledge, RD. The identification of 1-dehydromethandrostenolone. Microgram J., 1 Jul 2005, 3 (3–4), 186–189. 437 kB.

Anon. Microgram Journal, July–December 2005, U.S. Drug Enforcement Administration, 1 Jul 2005.

Rodriguez-Cruz, SE. Analysis and characterization of designer tryptamines using electrospray ionization mass spectrometry (ESI-MS). Microgram J., 1 Jul 2005, 3 (3–4), 107–129. 1577 kB.

Casale, JF. Assessment of the volatility (smokeability) of cocaine base containing 50 percent mannitol: Is it a smokeable form of “crack” cocaine? Microgram J., 1 Jul 2005, 3 (3–4), 130–133. 231 kB.

Anon. Microgram Journal, January–June 2005, U.S. Drug Enforcement Administration, 1 Jan 2005.

Bianchi, RP; Shah, MN; Rogers, DH; Mrazik, TJ. Laboratory analysis of the conversion of pseudoephedrine to methamphetamine from over-the-counter products. Microgram J., 1 Jan 2005, 3 (1–2), 11–15. 32 kB.

Allred, RA. Spectral characterization of 2,4-dimethoxy-3-methylphenethylamine and comparison to 2,5-dimethoxy-4-methylphenethylamine (“2C-D”). Microgram J., 1 Jan 2005, 3 (1–2), 16–26. 107 kB.

Morris, JA. Analytical profile of modafinil. Microgram J., 1 Jan 2005, 3 (1–2), 27–30. 310 kB.

Phelan, CP. Quantitation and enantiomeric determination of propoxyphene using capillary zone electrophoresis. Microgram J., 1 Jan 2005, 3 (1–2), 31–38. 132 kB.

Smith, PR; Frohwein, AK; Hays, PA; Lurie, IS. Identification and quantitation of hydromorphone hydrochloride in Palladone® (extended time-release) capsules. Microgram J., 1 Jan 2005, 3 (1–2), 39–45. 186 kB.

DeFrancesco, JV. gamma-Hydroxybutyrate, silver salt (AgGHB): Identification of gamma-hydroxybutyrate (GHB) via conversion to the silver salt. Microgram J., 1 Jan 2005, 3 (1–2), 46–53. 195 kB.

Spratley, TK; Hays, PA; Geer, LC; Cooper, SD; McKibben, TD. Analytical profiles for five “designer” tryptamines. Microgram J., 1 Jan 2005, 3 (1–2), 54–68. 473 kB.

DiPari, SC; Bordelon, JA; Skinner, HF. Desloratadine: The reaction byproduct of the reduction of cold tablets containing Loratadine with hydriodic acid/red phosphorus. Microgram J., 1 Jan 2005, 3 (1–2), 69–77. 234 kB.

Krawczeniuk, AS. Identification of phenethylamines and methylenedioxyamphetamines using liquid chromatography atmospheric pressure electrospray ionization mass spectrometry. Microgram J., 1 Jan 2005, 3 (1–2), 78–100. 979 kB.

Anon. Microgram Journal, January–December 2004, U.S. Drug Enforcement Administration, 1 Jan 2004.

Peters, DE. Diltiazem HCl: An analytical profile. Microgram J., 1 Jan 2004, 2 (1–4), 11–16. 157 kB.

Odeneal, NG; Casale, JF; Wojno, HL. Hydroxyzine: An analytical profile. Microgram J., 1 Jan 2004, 2 (1–4), 17–21. 164 kB.

Maurer, HH. Mass spectra of select benzyl- and phenyl- piperazine designer drugs. Microgram J., 1 Jan 2004, 2 (1–4), 22–26. 326 kB.

Chong, YK; Kaprawi, MM; Kee. The quantitation of nimetazepam in Erimin-5 tablets and powders by reverse-phase HPLC. Microgram J., 1 Jan 2004, 2 (1–4), 27–33. 325 kB.

Parsons, R. Letter to the Editor regarding “A rapid extraction and GC/MS methodology for the identification of psilocyn in mushroom/chocolate concoctions” Microgram J., 1 Jan 2004, 2 (1–4), 3. 10 kB.

Ramsey, RT; Woods, P. Improvised explosive device disguised as a smoking pipe. Microgram J., 1 Jan 2004, 2 (1–4), 34–35. 178 kB.

Mohrhaus, AS; Gratz, SR. Identification and determination of carisoprodol in tablets by liquid chromatography/mass spectrometry. Microgram J., 1 Jan 2004, 2 (1–4), 36–41. 53 kB.

Waumans, D; Bruneel, N; Tytgat, J. Anise oil as a precursor for 2-alkoxy-5-methoxybenzaldehydes. Microgram J., 1 Jan 2004, 2 (1–4), 4–10. 114 kB.

Zimmerman, MM. The identification of 5-methoxy-alpha-methyltryptamine (5-MeO-AMT). Microgram J., 1 Jul 2003, 1 (3–4), 158–162. 269 kB.

Chan, KB; Chong, YK; Nazar, M. The identification of N,N-dimethylamphetamine (DMA) in an exhibit in Malaysia. Microgram J., 1 Jul 2003, 1 (3–4), 163–168. 247 kB.

Makino, Y; Kurobane, S; Miyasaka, K. Profiling of ecstasy tablets seized in Japan. Microgram J., 1 Jul 2003, 1 (3–4), 169–176. 614 kB.

Sarwar, M; McDonald, JL. A rapid extraction and GC/MS methodology for the identification of psilocyn in mushroom/chocolate concoctions. Microgram J., 1 Jul 2003, 1 (3–4), 177–183. 211 kB.

Waumans, D; Bruneel, N; Hermans, B; Tytgat, J. A rapid and simple GC/MS screening method for 4-methoxyphenol in illicitly prepared 4-methoxyamphetamine (PMA). Microgram J., 1 Jul 2003, 1 (3–4), 184–189. 231 kB.

Geer, LC; Hays, PA. Letrozole (Femara®). Microgram J., 1 Jul 2003, 1 (3–4), 190–195. 377 kB.

Coyle, HM; Palmbach, T; Juliano, N; Ladd, C; Lee, HC. An overview of DNA methods for the identification and individualization of marijuana. Microgram J., 1 Jul 2003, 1 (3–4), 196–207. 614 kB.

Bono, JP. Report of the Scientific Working Group for the Analysis of Seized Drugs (SWGDRUG) conference (Montreal). Microgram J., 1 Jul 2003, 1 (3–4), 208–236. 222 kB.

Anon. Microgram Journal, July–December 2003, U.S. Drug Enforcement Administration, 1 Jul 2003.

Ausili, P. Letter to the Editor regarding “Instrumental separation of 3,4-methylenedioxyamphetamine (MDA) from 1-(3,4-methylenedioxyphenyl)-2-propanol, a co-eluting compound” Microgram J., 1 Jul 2003, 1 (3–4), 157. 82 kB.

Blackledge, RD; Taylor, CM. Psychotria viridis—A botanical source of dimethyltryptamine (DMT). Microgram J., 1 Jan 2003, 1 (1–2), 18–22. 429 kB.

Azoury, M; Zelkowicz, A; Goren, Z; Almog, J. Evaluation of ninhydrin analogues and other electron-deficient compounds as spray reagents for drugs on thin layer chromatograms. Microgram J., 1 Jan 2003, 1 (1–2), 23–31. 318 kB.

Anon. Microgram Journal, January–June 2003, U.S. Drug Enforcement Administration, 1 Jan 2003.

Vohlken, BA; Layton, SM. Instrumental separation of 3,4-methylenedioxyamphetamine (MDA) from 1-(3,4- methylenedioxyphenyl)-2-propanol, a co-eluting compound. Microgram J., 1 Jan 2003, 1 (1–2), 32–36. 208 kB.

Newell, CJ. Potency of cannabis seized in Central Florida during June 2002. Microgram J., 1 Jan 2003, 1 (1–2), 37–39. 180 kB.

Deakin, AL. A study of acids used for the acidified cobalt thiocyanate test for cocaine base. Microgram J., 1 Jan 2003, 1 (1–2), 40–43. 373 kB.

Klein, RFX; Hays, PA. Detection and analysis of drugs of forensic interest, 1992–2001; A literature review. Microgram J., 1 Jan 2003, 1 (1–2), 55–153. 487 kB.

Garcia, AD; Catterton, AJ. 1,4-Butanediol (BD)—A forensic profile. Microgram J., 1 Jan 2003, 1 (1–2), 44–54. 611 kB.

Wesley, JF. Osmolality—A novel and sensitive tool for detection of tampering of beverages adulterated with ethanol, γ-butyrolactone, and 1,4-butanediol, and for detection of dilution-tampered Demerol syringes. Microgram J., 1 Jan 2003, 1 (1–2), 8–17. 241 kB.

Ross, EA; Reisfield, GM; Watson, MC; Chronister, CW; Goldberger, BA. Psychoactive “bath salts” intoxication with methylenedioxypyrovalerone. Sep 2012. 248 kB. doi:10.1016/j.amjmed.2012.02.019

Morris, H. Blood Spore: Of Murder and Mushrooms. Harper’s Magazine, 1 Jul 2013, 41–56. 13834 kB.

Ger, A; Ger, D. Triple Goddess of the Night. British Neuroscience Association Bulletin, 1 Mar 2011, 63, 28–30. 234 kB. Dmitri Ger is credited with the discovery of Jelena, also known as 2C-IP.

Weil, AT. The use of nutmeg as a psychotropic agent. Bull. Narc., United Nations Office on Drugs and Crime, 1 Jan 1966.

Shulgin, AT; Shulgin, A. A Magical Blend—The Shulgins at Home. Magical Blend, 1992. 729317 kB. Audio recording. iTunes won’t play it. Imagine.

Demonic. Eugenoloids: BZOMA; 4-Benzyloxy-3-methoxyamphetamine. 242 kB.

Demonic. Eugenoloids: POMA; 4-Propoxy-3-methoxyamphetamine. 105 kB.

Demonic. Eugenoloids: IPOMA; 4-Isopropoxy-3-methoxyamphetamine. 233 kB.

Demonic. Eugenoloids: C-POMA; 2-Chloro-4-propoxy-5-methoxyamphetamine. 192 kB.

Shulgin, AT. Lab notes 1. Sasha’s laboratory notebooks, Erowid, 1 Jan 1980. Transcribed into “print” for easier reading and searching.

Shulgin, AT. Lab notes 6. Sasha’s laboratory notebooks, Erowid, 1 Jan 1980. Transcribed into “print” for easier reading and searching.

Shulgin, AT. Lab notes 3. Sasha’s laboratory notebooks, Erowid, 1 Jan 1980. Transcribed into “print” for easier reading and searching.

Shulgin, AT. Lab notes 2. Sasha’s laboratory notebooks, Erowid, 1 Jan 1980. Transcribed into “print” for easier reading and searching.

Morris, H; Wallach, J. Sea DMT: God Molecule or Barnacle Repellent? Vice, 26 Mar 2013.

Shulgin, AT. Drogenpolitik. Zur schleichenden Entmündigung des Bürgers , Löhrbach Pieper’s Medienexperimente Solothurn Nachtschatten-Verl., 1 Jan 1994. German pamphlet edition of PiHKAL chapter 42, Lecture at the University.

Griffin, OH. Is the government keeping the peace or acting like our parents? Rationales for the legal prohibitions of GHB and MDMA. J. Drug Issues, 1 Jul 2012, 42 (3), 247–262. 703 kB. doi:10.1177/0022042612456014

Sayin, . A comparative review of the neuropsychopharmacology of hallucinogen-induced altered states of consciousness: The uniqueness of some hallucinogens. NeuroQuantology, 1 Jun 2012, 10 (2), 316–340. 1348 kB.

Labate, BC. Paradoxes of Ayahuasca expansion: The UDV-DEA agreement and the limits of freedom of religion. Drugs Educ. Prev. Policy, 1 Feb 2012, 19 (1), 19–26. 112 kB. doi:10.3109/09687637.2011.606397

Gibbons, S. ‘Legal Highs’—Novel and emerging psychoactive drugs: a chemical overview for the toxicologist. Clin. Toxicol., 1 Jan 2012, 50 (1), 15–24. 976 kB. doi:10.3109/15563650.2011.645952

Sumnall, HR; Measham, F; Brandt, SD; Cole, JC. Salvia divinorum use and phenomenology: results from an online survey. J. Psychopharmacol., 1 Nov 2011, 25 (11), 1496–1507. 186 kB. doi:10.1177/0269881110385596

McGrane, O; Simmons, J; Jacobsen, E; Skinner, C. Alarming trends in a novel class of designer drugs. J. Clinic. Toxicol., 1 Nov 2011, 1 (2). 775 kB. doi:10.4172/2161-0494.1000108

Iversen, LL. Consideration of desoxypipradrol (2-DPMP) and related pipradrol compounds, Advisory Council on the Misuse of Drugs, 13 Sep 2011.

Derungs, A; Schietzel, S; Meyer, MR; Maurer, HH; Krähenbühl, S; Liechti, ME. Sympathomimetic toxicity in a case of analytically confirmed recreational use of naphyrone (naphthylpyrovalerone). Clin. Toxicol., 1 Aug 2011, 49 (7), 691–693. 90 kB. doi:10.3109/15563650.2011.592838

Spiller, HA; Ryan, ML; Weston, RG; Jansen, J. Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clin. Toxicol., 1 Jul 2011, 49 (6), 499–505. 130 kB. doi:10.3109/15563650.2011.590812

Gatch, MB; Forster, MJ; Janowsky, A; Eshleman, AJ. Abuse liability profile of three substituted tryptamines. J. Pharmacol. Exp. Ther., 1 Jul 2011, 338 (1), 280–289. 1188 kB. doi:10.1124/jpet.111.179705

Montagne, M. Drugs and the media: An introduction. Subst. Use Misuse, 1 May 2011, 46 (7), 849–851. 134 kB. doi:10.3109/10826084.2011.570609

Baumann, MH; Clark, RD; Woolverton, WL; Wee, S; Blough, BE; Rothman, RB. In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat. J. Pharmacol. Exp. Ther., 1 Apr 2011, 337 (1), 218–225. 380 kB. doi:10.1124/jpet.110.176271

Bovens, M; Schläpfer, M. A survey of recent seizures and an attempt to a more effective handling from a Swiss perspective. Toxichem Krimtech, 1 Apr 2011, 78 (special issue), 167–175. 708 kB.

Brochu, S; Duff, C; Asbridge, M; Erickson, PG. “There’s what’s on paper and then there’s what happens, out on the sidewalk”: Cannabis users knowledge and opinions of Canadian drug laws. J. Drug Issues, 1 Jan 2011, 41 (1), 95–115. 195 kB. doi:10.1177/002204261104100105

Baggott, MJ; Siegrist, JD; Galloway, GP; Robertson, LC; Coyle, JR; Mendelson, JE. Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): A randomized controlled trial in humans. PLOS ONE, 2 Dec 2010, 5 (12). 1435 kB. doi:10.1371/journal.pone.0014074

Shen, H; Jiang, X; Winter, JC; Yu, A. Psychedelic 5-methoxy-N,N-dimethyltryptamine: Metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Curr. Drug Metab., 1 Oct 2010, 11 (8), 659–666. 589 kB. doi:10.2174/138920010794233495

Chemel, BR. Exploring the molecular determinants of binding selectivity and efficacy for D1 dopamine receptor agonists. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 May 2010. 1919 kB.

Byrska, B; Zuba, D; Stanaszek, R. Determination of piperazine derivatives in “legal highs” Probl. Forensic Sci., 2010, 81, 101–113. 852 kB.

Sessa, B. Is it time to revisit the role of psychedelic drugs in enhancing human creativity? J. Psychopharmacol., 1 Nov 2008, 22 (8), 821–827. 158 kB. doi:10.1177/0269881108091597

Johnson, MW; Richards, WA; Griffiths, RR. Human hallucinogen research: guidelines for safety. J. Psychopharmacol., 1 Aug 2008, 22 (6), 603–620. 271 kB. doi:10.1177/0269881108093587

Partilla, JS; Dempsey, AG; Nagpal, AS; Blough, BE; Baumann, MH; Rothman, RB. Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J. Pharmacol. Exp. Ther., 1 Oct 2006, 319 (1), 237–246. 367 kB. doi:10.1124/jpet.106.103622

Walsh, R; Grob, CS. Early psychedelic investigators reflect on the psychological and social implications of their research. J. Humanist. Psychol., 1 Oct 2006, 46 (4), 432–448. 83 kB. doi:10.1177/0022167806286745

Laban, U. Synthesis of 4-aminomethylchromans: Novel dopamine D2-selective agonists. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Dec 2004. 9226 kB.

Rothman, RB; Vu, N; Partilla, JS; Roth, BL; Hufeisen, SJ; Compton-Toth, BA; Birkes, J; Young, R; Glennon, RA. In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J. Pharmacol. Exp. Ther., 1 Oct 2003, 307 (1), 138–145. 516 kB. doi:10.1124/jpet.103.053975

Kurrasch-Orbaugh, DM. Elucidation of the serotonin 5-HT2A receptor-coupled phospholipase A2 signaling pathway. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 May 2002. 7865 kB.

Foley, KF. Aminopropiophenones at the norepinephrine transporter: Structure-activity relationships and behavioral effects of methcathinone analogs. Ph. D. Thesis, Brody School of Medicine, Greenville, NC, USA, 1 May 2002. 8573 kB.

Lewis, RJ; Reed, D; Service, AG; Langford, AM. The identification of 2-chloro-4,5-methylenedioxymethylamphetamine in an illicit drug seizure. J. Forensic Sci., 1 Sep 2000, 45 (5), 1119–1125. 708 kB. doi:10.1520/JFS14838J

Grubbs, RA. Synthesis of novel dopaminergic ligands: A bioisosteric approach. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Aug 2000. 3813 kB.

Stolaroff, MJ. Are psychedelics useful in the practice of Buddhism? J. Humanist. Psychol., 1 Jan 1999, 39 (1), 60–80. 141 kB. doi:10.1177/0022167899391009

Qandil, AM. Selective dopamine D1 receptor ligands: Synthesis of naphthisoquinolines and benzisoquinolines. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Dec 1998. 3736 kB.

Parker, MA. Studies of perceptiotropic phenethylamines: Determinants of affinity for the 5-HT2A receptor. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 May 1998. 2719 kB.

Walsh, R. Psychedelics and psychological well-being. J. Humanist. Psychol., 1 Jul 1982, 22 (3), 22–32. 1072 kB. doi:10.1177/0022167882223004

Hofmann, A; Troxler, F. Esters of indoles. U.S. Patent 3,075,992, 29 Jan 1963. 633 kB.

Szára, S. The comparison of the psychotic effect of tryptamine derivatives with the effects of mescaline and LSD-25 in self-experiments. In Psychotropic Drugs [proceedings]; Garattini, S; Ghetti, V, Eds., Elsevier, 1957; pp 460–467. 480 kB.

Gaujac, A; Martinez, ST; Gomes, AA; Andrade, SJ; Pinto, AC; David, JM; Navickiene, S; Andrade, JB. Application of analytical methods for the structural characterization and purity assessment of N,N-dimethyltryptamine, a potent psychedelic agent isolated from Mimosa tenuiflora inner barks. Microchem. J., Jul 2013. 685 kB. doi:10.1016/j.microc.2012.03.033

Khreit, OIG; Grant, MH; Zhang, T; Henderson, C; Watson, DG; Sutcliffe, OB. Elucidation of the Phase I and Phase II metabolic pathways of (±)-4′-methylmethcathinone (4-MMC) and (±)-4′-(trifluoromethyl)methcathinone (4-TFMMC) in rat liver hepatocytes using LC–MS and LC–MS2. J. Pharm. Biomed. Anal., 18 Jan 2013, 72, 177–185. 800 kB. doi:10.1016/j.jpba.2012.08.015

Cozzi, NV; Brandt, SD; Daley, PF; Partilla, JS; Rothman, RB; Tulzer, A; Sitte, HH; Baumann, MH. Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs. Eur. J. Pharmacol., 15 Jan 2013, 699 (1–3), 180–187. 590 kB. doi:10.1016/j.ejphar.2012.11.008

Brierley, DI; Davidson, C. Developments in harmine pharmacology — Implications for ayahuasca use and drug-dependence treatment. Prog. Neuro-Psychopharmacol. Biol. Psych., 3 Dec 2012, 39 (2), 263–272. 353 kB. doi:10.1016/j.pnpbp.2012.06.001

Corkery, JM; Elliott, S; Schifano, F; Corazza, O; Ghodse, AH. 2-DPMP (desoxypipradrol, 2-benzhydrylpiperidine, 2-phenylmethylpiperidine) and D2PM (diphenyl-2-pyrrolidin-2-yl-methanol, diphenylprolinol): A preliminary review. Prog. Neuro-Psychopharmacol. Biol. Psych., 3 Dec 2012, 39 (2), 253–258. 347 kB. doi:10.1016/j.pnpbp.2012.05.021

Dawson, P; Moffatt, JD. Cardiovascular toxicity of novel psychoactive drugs: Lessons from the past. Prog. Neuro-Psychopharmacol. Biol. Psych., 3 Dec 2012, 39 (2), 244–252. 358 kB. doi:10.1016/j.pnpbp.2012.05.003

Seely, KA; Lapoint, J; Moran, JH; Fattore, L. Spice drugs are more than harmless herbal blends: A review of the pharmacology and toxicology of synthetic cannabinoids. Prog. Neuro-Psychopharmacol. Biol. Psych., 3 Dec 2012, 39 (2), 234–243. 780 kB. doi:10.1016/j.pnpbp.2012.04.017

Dal Cason, TA; Corbett, CA; Poole, PK; Haseth, JA; Gouldthorpe, DK. An unusual clandestine laboratory synthesis of 3,4-methylenedioxyamphetamine (MDA). Forensic Sci. Int., 30 Nov 2012, 223 (1–3), 279–291. 898 kB. doi:10.1016/j.forsciint.2012.10.002

Abiedalla, YFH; Abdel-Hay, KM; DeRuiter, J; Clark, CR. Synthesis and GC-MS analysis of a series of homologs and regioisomers of 3,4-methylenedioxypyrovalerone (MDPV). Forensic Sci. Int., 30 Nov 2012, 223 (1–3), 189–197. 657 kB. doi:10.1016/j.forsciint.2012.08.040

Westphal, F; Junge, T. Ring positional differentiation of isomeric N-alkylated fluorocathinones by gas chromatography/tandem mass spectrometry. Forensic Sci. Int., 30 Nov 2012, 223 (1–3), 97–105. 470 kB. doi:10.1016/j.forsciint.2012.08.011

Davis, S; Blakey, K; Rands-Trevor, K. GC-MS and GC-IRD analysis of 2-, 3- and 4-methylmethamphetamine and 2-, 3- and 4-methylamphetamine. Forensic Sci. Int., 10 Jul 2012, 220 (1–3), 67–73. 1158 kB. doi:10.1016/j.forsciint.2012.01.028

Bruno, R; Matthews, AJ; Dunn, M; Alati, R; McIlwraith, F; Hickey, S; Burns, L; Sindicich, N. Emerging psychoactive substance use among regular ecstasy users in Australia. Drug Alcohol Depend., 1 Jul 2012, 124 (1–2), 19–25. 384 kB. doi:10.1016/j.drugalcdep.2011.11.020

Gambaro, V; Arnoldi, S; Colombo, ML; Dell’Acqua, L; Guerrini, K; Roda, G. Determination of the active principles of Catha Edulis: Quali-quantitative analysis of cathinone, cathine, and phenylpropanolamine. Forensic Sci. Int., 10 Apr 2012, 217 (1–3), 87–92. 479 kB. doi:10.1016/j.forsciint.2011.09.028

Nakanishi, K; Miki, A; Zaitsu, K; Kamata, H; Shima, N; Kamata, T; Katagi, M; Tatsuno, M; Tsuchihashi, H; Suzuki, K. Cross-reactivities of various phenethylamine-type designer drugs to immunoassays for amphetamines, with special attention to the evaluation of the one-step urine drug test Instant-View™, and the Emit® assays for use in drug enforcement. Forensic Sci. Int., 10 Apr 2012, 217 (1–3), 174–181. 397 kB. doi:10.1016/j.forsciint.2011.11.003

Westphal, F; Junge, T; Girreser, U; Greibl, W; Doering, C. Mass, NMR and IR spectroscopic characterization of pentedrone and pentylone and identification of their isocathinone by-products. Forensic Sci. Int., 10 Apr 2012, 217 (1–3), 157–167. 853 kB. doi:10.1016/j.forsciint.2011.10.045

Błachut, D; Wojtasiewicz, K; Krawczyk, K; Maurin, J; Szawkało, J; Czarnocki, Z. Identification and synthesis of by-products found in 4-methylthioamphetamine (4-MTA) produced by the Leuckart method. Forensic Sci. Int., 10 Mar 2012, 216 (1–3), 108–120. 643 kB. doi:10.1016/j.forsciint.2011.09.005

Addy, PH. Acute and post-acute behavioral and psychological effects of salvinorin A in humans. Psychopharmacology, 1 Mar 2012, 220 (1), 195–204. 193 kB. doi:10.1007/s00213-011-2470-6

Zuba, D. Identification of cathinones and other active components of ‘legal highs’ by mass spectrometric methods. Trends Anal. Chem., 1 Feb 2012, 32, 15–30. 576 kB. doi:10.1016/j.trac.2011.09.009

Trevorrow, P. Response to the letter: Comments on BZP and New Zealand’s alternative approach to prohibition. Drug Test. Anal., 1 Jan 2012, 4 (1), 58. 43 kB. doi:10.1002/dta.354

Morgan, CJA; Curran, HV. Ketamine use: a review. Addiction, 1 Jan 2012, 107 (1), 27–38. 158 kB. doi:10.1111/j.1360-0443.2011.03576.x

Kavanagh, PV; Angelov, D; O’Brien, J; Fox, J; O’Donnell, C; Christie, R; Power, JD; McDermott, SD. The syntheses and characterization 3β-(4-fluorobenzoyloxy)tropane (fluorotropacocaine) and its 3α isomer. Drug Test. Anal., 1 Jan 2012, 4 (1), 33–38. 730 kB. doi:10.1002/dta.362

Schep, LJ; Slaughter, RJ; Temple, WA; Gee, P. Comments on BZP and New Zealand’s alternative approach to prohibition. Drug Test. Anal., 1 Jan 2012, 4 (1), 57. 47 kB. doi:10.1002/dta.356

Striebel, JM; Pierre, JM. Acute psychotic sequelae of “bath salts” Schizophr. Res., 1 Dec 2011, 133 (1–3), 259–260. 112 kB. doi:10.1016/j.schres.2011.09.001

Kondo, M; Sawa, A. Anti-/propsychotic drug signalling via heteromeric GPCRs—a balancing act? Cell, 23 Nov 2011, 147 (5), 964–965. 190 kB. doi:10.1016/j.cell.2011.11.012

Fribourg, M; Moreno, JL; Holloway, T; Provasi, D; Baki, L; Mahajan, R; Park, G; Adney, SK; Hatcher, C; Eltit, JM; Ruta, JD; Albizu, L; Li, Z; Umali, A; Shim, J; Fabiato, A; . Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell, 23 Nov 2011, 147 (5), 1011–1023. 1470 kB. doi:10.1016/j.cell.2011.09.055

McDermott, SD; Power, JD; Kavanagh, PV; O’Brien, J. The analysis of substituted cathinones. Part 2: An investigation into the phenylacetone based isomers of 4-methylmethcathinone and N-ethylcathinone. Forensic Sci. Int., 10 Oct 2011, 212 (1–3), 13–21. 1129 kB. doi:10.1016/j.forsciint.2011.06.030

Mohamed, WMY; Hamida, SB; Cassel, J; Vasconcelos, AP; Jones, BC. MDMA: Interactions with other psychoactive drugs. Pharmacol. Biochem. Behav., 1 Oct 2011, 99 (4), 759–774. 396 kB. doi:10.1016/j.pbb.2011.06.032

Hout, MC; Brennan, R. ‘Heads held high’: An exploratory study of legal highs in pre-legislation Ireland. J. Ethn. Subst. Abuse, 2 Sep 2011, 10 (3), 256–272. 97 kB. doi:10.1080/15332640.2011.600210

Moonzwe, LS; Schensul, JJ; Kostick, KM. The role of MDMA (Ecstasy) in coping with negative life situations among urban young adults. J. Psychoactive Drugs, 29 Aug 2011, 43 (3), 199–210. 137 kB. doi:10.1080/02791072.2011.605671

Móró, L; Simon, K; Bárd, I; Rácz, J. Voice of the psychonauts: Coping, life purpose, and spirituality in psychedelic drug users. J. Psychoactive Drugs, 29 Aug 2011, 43 (3), 188–198. 129 kB. doi:10.1080/02791072.2011.605661

Bonner, ET; Friedman, HL. A conceptual clarification of the experience of awe: An interpretative phenomenological analysis. The Humanistic Psychologist, 5 Aug 2011, 39 (3), 222–235. 93 kB. doi:10.1080/08873267.2011.593372

Smith, RC. The world of the Haight-Ashbury speed freak. J. Psychoactive Drugs, 25 Jul 2011, 43 (2), 165–171. 94 kB. doi:10.1080/02791072.2011.587714

Kriikku, P; Wilhelm, L; Schwarz, O; Rintatalo, J. New designer drug of abuse: 3,4-Methylenedioxypyrovalerone (MDPV). Findings from apprehended drivers in Finland. Forensic Sci. Int., 15 Jul 2011, 210 (1–3), 195–200. 618 kB. doi:10.1016/j.forsciint.2011.03.015

Sauer, C; Hoffmann, K; Schimmel, U; Peters, FT. Acute poisoning involving the pyrrolidinophenone-type designer drug 4′-methyl-alpha-pyrrolidinohexanophenone (MPHP). Forensic Sci. Int., 20 May 2011, 208 (1–3), e20–e25. 455 kB. doi:10.1016/j.forsciint.2011.02.026

Walsh, C. Drugs, the Internet and change. J. Psychoactive Drugs, 8 Apr 2011, 43 (1), 55–63. 658 kB. doi:10.1080/02791072.2011.566501

Amsterdam, J; Opperhuizen, A; Brink, W. Harm potential of magic mushroom use: A review. Regul. Toxicol. Pharm., 1 Apr 2011, 59 (3), 423–429. 219 kB. doi:10.1016/j.yrtph.2011.01.006

Zarantonello, P; Bettini, E; Paio, A; Simoncelli, C; Terreni, S; Cardullo, F. Novel analogues of ketamine and phencyclidine as NMDA receptor antagonists. Bioorg. Med. Chem. Lett., 1 Apr 2011, 21 (7), 2059–2063. 594 kB. doi:10.1016/j.bmcl.2011.02.009

Sharp, T; Cowen, PJ. 5-HT and depression: is the glass half-full? Curr. Opin. Pharmacol., 1 Feb 2011, 11 (1), 45–51. 196 kB. doi:10.1016/j.coph.2011.02.003

McNamara, YM; Cloonan, SM; Knox, AJS; Keating, JJ; Butler, SG; Peters, GH; Meegan, MJ; Williams, DC. Synthesis and serotonin transporter activity of 1,3-bis(aryl)-2-nitro-1-propenes as a new class of anticancer agents. Bioorg. Med. Chem., 1 Feb 2011, 19 (3), 1328–1348. 3938 kB. doi:10.1016/j.bmc.2010.11.054

Namera, A; Nakamoto, A; Saito, T; Nagao, M. Colorimetric detection and chromatographic analyses of designer drugs in biological materials: a comprehensive review. Forensic Toxicol., 1 Jan 2011, 29 (1), 1–24. 552 kB. doi:10.1007/s11419-010-0107-9

Vicente, R. Recent advances in indole syntheses: New routes for a classic target. Org. Biomol. Chem., 2011, 9, 6469–6480. 504 kB. doi:10.1039/c1ob05750b

Brandt, SD; Moore, SA; Freeman, S; Kanu, AB. Characterization of the synthesis of N,N-dimethyltryptamine by reductive amination using gas chromatography ion trap mass spectrometry. Drug Test. Anal., 1 Jul 2010, 2 (7), 330–338. 192 kB. doi:10.1002/dta.142

Maher, HM; Awad, T; DeRuiter, J; Clark, CR. GC–IRD methods for the identification of some tertiary amines related to MDMA. Forensic Sci. Int., 15 Jun 2010, 199 (1–3), 18–28. 877 kB. doi:10.1016/j.forsciint.2010.02.022

Moura, S; Carvalho, FG; Oliveira, CDR; Pinto, E; Yonamine, M. qNMR: An applicable method for the determination of dimethyltryptamine in ayahuasca, a psychoactive plant preparation. Phytochem. Lett., 11 Jun 2010, 3 (2), 79–83. 227 kB. doi:10.1016/j.phytol.2009.12.004

Cloonan, SM; Keating, JJ; Corrigan, D; O’Brien, JE; Kavanagh, PV; Williams, DC; Meegan, MJ. Synthesis and in vitro toxicity of 4-MTA, its characteristic clandestine synthesis byproducts and related sulfur substituted α-alkylthioamphetamines. Bioorg. Med. Chem., 1 Jun 2010, 18 (11), 4009–4031. 1174 kB. doi:10.1016/j.bmc.2010.04.022

Morris, K. UK places generic ban on mephedrone drug family. Lancet, 17 Apr 2010, 375 (9723), 1333–1334. 52 kB. doi:10.1016/S0140-6736(10)60559-4

Westphal, F; Rösner, P; Junge, T. Differentiation of regioisomeric ring-substituted fluorophenethylamines with product ion spectrometry. Forensic Sci. Int., 30 Jan 2010, 194 (1–3), 53–59. 521 kB. doi:10.1016/j.forsciint.2009.10.007

Cloonan, SM; Keating, JJ; Butler, SG; Knox, AJS; Jørgensen, AM; Peters, GH; Rai, D; Corrigan, D; Lloyd, DG; Williams, DC; Meegan, MJ. Synthesis and serotonin transporter activity of sulphur-substituted α-alkyl phenethylamines as a new class of anticancer agents. Eur. J. Med. Chem., 1 Dec 2009, 44 (12), 4862–4888. 1199 kB. doi:10.1016/j.ejmech.2009.07.027

Westphal, F; Junge, T; Rösner, P; Sönnichsen, F; Schuster, F. Mass and NMR spectroscopic characterization of 3,4-methylenedioxypyrovalerone: A designer drug with α-pyrrolidinophenone structure. Forensic Sci. Int., 10 Sep 2009, 190 (1–3), 1–8. 657 kB. doi:10.1016/j.forsciint.2009.05.001

Pires, APS; Oliveira, CDR; Moura, S; Dörr, FA; Silva, WAE; Yonamine, M. Gas chromatographic analysis of dimethyltryptamine and β-carboline alkaloids in ayahuasca, an Amazonian psychoactive plant beverage. Phytochem. Anal., 1 Mar 2009, 20 (2), 149–153. 131 kB. doi:10.1002/pca.1110

Takahashi, M; Nagashima, M; Suzuki, J; Seto, T; Yasuda, I; Yoshida, T. Creation and application of psychoactive designer drugs data library using liquid chromatography with photodiode array spectrophotometry detector and gas chromatography–mass spectrometry. Talanta, 15 Feb 2009, 77 (4), 1245–1272. 1175 kB. doi:10.1016/j.talanta.2008.07.062

Martins, CPB; Awan, MA; Freeman, S; Herraiz, T; Alder, JF; Brandt, SD. Fingerprint analysis of thermolytic decarboxylation of tryptophan to tryptamine catalyzed by natural oils. J. Chromatogr. A, 7 Nov 2008, 1210 (1), 115–120. 450 kB. doi:10.1016/j.chroma.2008.09.036

Green, AR. Gaddum and LSD: the birth and growth of experimental and clinical neuropharmacology research on 5-HT in the UK. Br. J. Pharmacol., 1 Aug 2008, 1554 (8), 1583–1599. 418 kB. doi:10.1038/bjp.2008.207

Lewin, AH; Navarro, HA; Mascarella, SW. Structure-activity correlations for β-phenethylamines at human trace amine receptor 1. Bioorg. Med. Chem., 1 Aug 2008, 16 (15),. 366 kB. doi:10.1016/j.bmc.2008.06.009

Brandt, SD; Martins, CPB; Freeman, S; Dempster, N; Riby, PG; Gartz, J; Alder, JF. Halogenated solvent interactions with N,N-dimethyltryptamine: Formation of quaternary ammonium salts and their artificially induced rearrangements during analysis. Forensic Sci. Int., 4 Jul 2008, 178 (2–3), 162–170. 785 kB. doi:10.1016/j.forsciint.2008.03.013

Chen, B; Liu, J; Chen, W; Chen, H; Lin, C. A general approach to the screening and confirmation of tryptamines and phenethylamines by mass spectral fragmentation. Talanta, 15 Jan 2008, 74 (4), 512–517. 486 kB. doi:10.1016/j.talanta.2007.06.012

Montagne, M. Drugs on the Internet. I: Introduction and web sites on psychedelic drugs. Subst. Use Misuse, 1 Jan 2008, 43 (1), 17–25. 142 kB. doi:10.1080/10826080701690698

Nelson, LS; Erdman, AR; Booze, LL; Cobaugh, DJ; Chyka, PA; Woolf, AD; Scharman, EJ; Wax, PM; Manoguerra, AS; Christianson, G; Caravati, EM; Troutman, WG. Selective serotonin reuptake inhibitor poisoning: An evidence-based consensus guideline for out-of-hospital management. Clin. Toxicol., 1 Jan 2007, 45 (4), 315–332. 188 kB. doi:10.1080/15563650701285289

Sauer, C; Peters, FT; Staack, RF; Fritschi, G; Maurer, HH. New designer drug N-(1-phenylcyclohexyl)-3-ethoxypropanamine (PCEPA): Studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass Spectrom., 1 Aug 2006, 41 (8), 1014–1029. 503 kB. doi:10.1002/jms.1058

Brandt, SD; Mansell, D; Freeman, S; Fleet, IA; Alder, JF. Analytical characterisation of the routes by thermolytic decarboxylation from tryptophan to tryptamine using ketone catalysts, resulting in tetrahydro-β-carboline formation. J. Pharm. Biomed. Anal., 7 Jun 2006, 41 (3), 872–882. 610 kB. doi:10.1016/j.jpba.2006.02.007

Meatherall, R; Sharma, P. Foxy, a designer tryptamine hallucinogen. J. Anal. Toxicol., 1 Jul 2003, 27 (5), 313–317. 988 kB. doi:10.1093/jat/27.5.313

Smythies, J. The adrenochrome hypothesis of schizophrenia revisited. Neurotox. Res., 1 Jan 2002, 4 (2), 147–150. 68 kB. doi:10.1080/10298420290015827

Reviriego, F; Navarro, P; Domènech, A; García-España, E. Effective complexation of psychotropic phenethylammonium salts from a disodium dipyrazolate salt of macrocyclic structure. J. Chem. Soc. Perkin Trans. 2, 2002, 1634–1638. 115 kB. doi:10.1039/b200607c

King, LA; Meer, AJPV. New synthetic drugs in the European Union. Sci. Justice, 1 Jul 2001, 41 (3), 200–202. 445 kB. doi:10.1016/S1355-0306(01)71891-6

Muchowski, JM. Synthesis of indole-4-carboxaldehydes and 4-acetylindole from N-alkyl-5-aminoisoquinolinium salts. J. Heterocycl. Chem., 1 Sep 2000, 37 (5), 1293–1297. 414 kB. doi:10.1002/jhet.5570370545

Khalil, EM; Angelis, JD; Cole, PA. Indoleamine analogs as probes of the substrate selectivity and catalytic mechanism of serotonin N-acetyltransferase. J. Biol. Chem., 13 Nov 1998, 273 (46), 30321–30327. 247 kB. doi:10.1074/jbc.273.46.30321

Thunhorst, M; Holzgrabe, U. Utilizing NMR spectroscopy for assessing drug enantiomeric composition. Magn. Reson. Chem., 1 Mar 1998, 36 (3), 211–216. 237 kB. doi:10.1002/(SICI)1097-458X(199803)363211AID-OMR2463.0.CO;2-Y

Iorio, MA; Tomassini, L; Mattson, MV; George, C; Jacobson, AE. Synthesis, stereochemistry, and biological activity of the 1-(1-phenyl-2-methylcyclohexyl)piperidines and the 1-(1-phenyl-4-methylcyclohexyl)piperidines. Absolute configuration of the potent trans-(-)-1-(1-phenyl-2-methylcyclohexyl)piperidine. J. Med. Chem., 1 Aug 1991, 34 (8), 2615–2623. 1199 kB. doi:10.1021/jm00112a041

Daldrup, T; Heller, C; Matthiesen, U; Honus, S; Bresges, A; Haarhoff, K. Etryptamin, eine neue designer-droge mit fataler Wirkung. Z. Rechtsmed., 1 Sep 1986, 97 (1), 61–68. 496 kB. doi:10.1007/BF00200960

Perrone, R; Bettoni, G; Tortorella, V. Synthesis and absolute configurations of hexahydronaphthoxazines as rigid congeners of phenmetrazine. Arch. Pharm., 1983, 316 (7), 617–624. 448 kB. doi:10.1002/ardp.19833160707

Grotjahn, DB. Synthesis and characterization of 5H-1,3-dioxolo[4,5-f]indoleethylamines. J. Heterocycl. Chem., 1 Jul 1982, 20 (4), 1031–1036. 517 kB. doi:10.1002/jhet.5570200438

Repke, DB; Ferguson, WJ. Psilocin analogs. III. Synthesis of 5-methoxy- and 5-hydroxy-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indoles. J. Heterocycl. Chem., 1 Jul 1982, 19 (4), 845–848. 288 kB. doi:10.1002/jhet.5570190428

Migliaccio, GP; Shieh, TN; Byrn, SR; Hathaway, BA; Nichols, DE. Comparison of solution conformational preferences for the hallucinogens bufotenin and psilocin using 360-MHz proton NMR spectroscopy. J. Med. Chem., 1 Feb 1981, 24 (2), 206–209. 564 kB. doi:10.1021/jm00134a016

Repke, DB; Ferguson, WJ; Bates, DK. Synthesis of secondary methylalkylamines. Tetrahedron Lett., 1979, 20 (43), 4183–4184. 149 kB. doi:10.1016/S0040-4039(01)86538-2

Ghosal, S; Srivastava, RS. β-Phenethylamine, tetrahydroisoquinoline and indole alkaloids of Desmodium tiliaefolium. Phytochemistry, 1 Jan 1973, 12 (1), 193–197. 552 kB. doi:10.1016/S0031-9422(00)84646-4

Fregnan, GB; Glässer, AH. Structure-activity relationship of various acyl derivatives of 6-methyl-8β-aminomethyl-10α-ergoline (dihydrolysergamine). Cell. Mol. Life Sci., 1 Feb 1968, 24 (2), 150–151. 247 kB. doi:10.1007/BF02146953

Steiner, WG; Pscheidt, GR; Costa, E; Himwich, HE. α-Ethyltryptamine (etryptamine): An electroencephalographic, behavioral and neurochemical analysis. Psychopharmacology, 1 Sep 1963, 4 (5), 354–366. 780 kB. doi:10.1007/BF00405246

Fennoy, LV. Substituted phenylalanines and phenylethylamines. J. Org. Chem., 1 Nov 1961, 26 (11), 4696–4698. 279 kB. doi:10.1021/jo01069a516

Elz, S; Kläß, T; Heim, R; Warnke, U; Pertz, HH. Development of highly potent partial agonists and chiral antagonists as tools for the study of 5-HT2A-receptor mediated functions. N-S. Arch. Pharmacol., 2002, 365 (Suppl. 1), R29. 630 kB.

Pertz, HH; Heim, R; Elz, S. N-Benzylated phenylethanamines are highly potent partial agonists at 5-HT2A receptors. Arch. Pharm. Pharm. Med. Chem., Oct 2000, 333 (Suppl. 2), 30. 583 kB. Poster abstract

Elz, S; Heim, R; Heil, WL; Pertz, HH. Partial agonists for vascular 5-HT2A-receptors: Selectivity vis-à-vis to 5-HT1B, 5-HT3 and 5-HT4 receptors. Arch. Pharm. Pharm. Med. Chem., Oct 1999, 331 (Suppl. 2), 10. 608 kB. Poster abstract

Heim, R; Pertz, HH; Elz, S. Preparation and in-vitro pharmacology of novel secondary amine-type 5-HT2A-receptor agonists: From submillimolar to subnanomolar activity. Arch. Pharm. Pharm. Med. Chem., Mar 1999, 331 (Suppl. 1), 34. 493 kB. Poster abstract

Pertz, HH; Rheineck, A; Elz, S. N-Benzylated derivatives of the hallucinogenic drugs mescaline and escaline as partial agonists at rat vascular 5-HT2A receptors. N-S. Arch. Pharmacol., 1999, 359 (Suppl. 3), R29. 104 kB.

Heim, R; Pertz, H; Walther, I; Elz, S. Congeners of 3-(2-benzylaminoethyl)-2,4-quinazolinedione: Partial agonists for rat vascular 5-HT2A receptors. N-S. Arch. Pharmacol., 1998, 358 (Suppl. 1), R105. 575 kB.

Fenderson5555. Two syntheses of bromo-dragonFLY. 15 Dec 2012. 9769 kB.

Anon. Report on the risk assessment of 4-methylamphetamine (4-MA), European Monitoring Centre for Drugs and Drug Addiction, Jan 2014.

Wood, DM; Dargan, PI. Mephedrone (4-methylmethcathinone): What is new in our understanding of its use and toxicity. Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 3 Dec 2012. 251 kB. doi:10.1016/j.pnpbp.2012.04.020

Corkery, JM; Durkin, E; Elliott, S; Scchifano, F; Ghodse, AH. The recreational tryptamine 5-MeO-DALT (N,N-diallyl-5-methoxytryptamine): A brief review. Prog. Neuro-Psychopharmacol. Biol. Psych., 1 Dec 2012, 39 (1), 259—262. 307 kB. doi:10.1016/j.pnpbp.2012.05.022

Spetea, M; Berzetei-Gurske, IP; Guerrieri, E; Schmidhammer, H. Discovery and pharmacological evaluation of a diphenethylamine derivative (HS665), a highly potent and selective K opioid receptor agonist. J. Med. Chem., 26 Nov 2012, 55 (22), 10302–10306. 409 kB. doi:10.1021/jm301258w

McCorvy, JD; Watts, VJ; Nichols, DE. Comparison of the D1 dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson’s disease. Psychopharmacology, 1 Jul 2012, 222 (1), 81–87. 242 kB. doi:10.1007/s00213-011-2625-5

Carroll, FI; Lewin, AH; Mascarella, SW; Seltzman, HH; Reddy, PA. Designer drugs: a medicinal chemistry perspective. Ann. N.Y. Acad. Sci., 1 Feb 2012, 1248, 18–38. 1552 kB. doi:10.1111/j.1749-6632.2011.06199.x

Casale, JF; Hays, PA. The characterization of 2-(5-methoxy-1-benzofuran-3-yl)-N,N-dimethylethanamine (5-MeO-BFE) and differentiation from its N-ethyl analog. Microgram J., 2012, 9 (1), 39–45. 6734 kB.

Toole, KE; Fu, S; Shimmon, RG; Kraymen, M; Taflaga, S. Color tests for the preliminary identification of methcathinone and analogues of methcathinone. Microgram J., 2012, 9 (1), 27–32. 496 kB.

Casale, JF; Hays, PA. The characterization of 4- and 5-iodo-2-aminoindan. Microgram J., 2012, 9 (1), 18–26. 1758 kB.

Casale, JF. Letter to the editor regarding: Abbreviations for 5- and 6-(2-aminopropyl)-2,3-dihydrobenzofuran vs. 5- and 6-(2-aminopropyl)benzofuran: A clarification of “APB” and “APDB” Microgram J., 2012, 9 (1), 46. 220 kB.

Armenian, P; Mamantov, TM; Tsutaoka, BT; Gerona, RRL; Silman, EF; Wu, AHB; Olson, KR. Multiple MDMA (ecstasy) overdoses at a rave event: A case series. J. Intensive Care, 2012. 130 kB. doi:10.1177/0885066612445982

Dargan, PI; Sedefov, R; Gallegos, A; Wood, DM. The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone). Drug Test. Anal., 1 Jul 2011, 3 (7–8), 454–463. 149 kB. doi:10.1002/dta.312

King, LA; Kicman, AT. A brief history of ‘new psychoactive substances’ Drug Test. Anal., 1 Jul 2011, 3 (7–8), 401–403. 62 kB. doi:10.1002/dta.319

Elliott, S. Current awareness of piperazines: pharmacology and toxicology. Drug Test. Anal., 1 Jul 2011, 3 (7–8), 430–438. 148 kB. doi:10.1002/dta.307

Sumnall, HR; Evans-Brown, M; McVeign, J. Social, policy, and public health perspectives on new psychoactive substances. Drug Test. Anal., 1 Jul 2011, 3 (7–8), 515–523. 140 kB. doi:10.1002/dta.310

Archer, RP; Treble, R; Williams, K. Reference materials for new psychoactive substances. Drug Test. Anal., 1 Jul 2011, 3 (7–8), 505–514. 310 kB. doi:10.1002/dta.317

Anon. Report on the risk assessment of mephedrone, European Monitoring Centre for Drugs and Drug Addiction, May 2011.

Błachut, D; Danikiewicz, W; Wojtasiewicz, K; Olejnik, M; Kalinowska, I; Szawkało, J; Czarnocki, Z. The synthesis, mass spectrometric properties and identification of some N,N-di-(β-arylisopropyl)formamides related to the synthesis of ring-modified amphetamines. Forensic Sci. Int., 20 Mar 2011, 206 (1), 197–206. 760 kB. doi:10.1016/j.forsciint.2010.08.007

Casale, JF; Hays, PA. Characterization of the “methylenedioxy-2-aminoindans” Microgram J., 2011, 8 (2), 43–52. 1303 kB.

Casale, JF; Hays, PA. Methiopropamine: An analytical profile. Microgram J., 2011, 8 (2), 53–57. 881 kB.

Casale, JF; Hays, PA. Ethylphenidate: An analytical profile. Microgram J., 2011, 8 (2), 58–61. 906 kB.

Yohannan, MA; Berrier, A. Detection of phenethylamine, amphetamine, and tryptamine imine by-products from an acetone extraction. Microgram J., 2011, 8 (1), 29–35. 1376 kB.

Kirby, DA. The characterization of N-methylphthalimide (NMP). Microgram J., 2011, 8 (2), 36–38. 886 kB.

Casale, JF; Hays, PA. The characterization of 5- and 6-(2-aminopropyl)-2,3-dihydrobenzofuran. Microgram J., 2011, 8 (2), 62–74. 1031 kB.

Carroll, FI; Cueva, JP; Thomas, JB; Mascarella, SW; Runyon, SP; Navarro, HA. 1-Substituted 4-(3-hydroxyphenyl)piperazines are pure opioid receptor antagonists. ACS Med. Chem. Lett., 14 Oct 2010, 1 (7), 365–369. 594 kB. doi:10.1021/ml100126b

Martins, CPB; Freeman, S; Alder, JF; Passie, T; Brandt, SD. Profiling psychoactive tryptamine-drug synthesis by focusing on detection using mass spectrometry. Trends Anal. Chem., 1 Apr 2010, 29 (4), 285–296. 425 kB. doi:10.1016/j.trac.2010.01.009

Yohannan, JC; Bozenko, JS. The characterization of 3,4-methylenedioxypyrovalerone. Microgram J., 1 Mar 2010, 7 (1), 12–15. 690 kB.

McIlhenny, EH; Pipkin, KE; Standish, LJ; Wechkin, HA; Strassman, R; Barker, SA. Direct analysis of psychoactive tryptamine and harmala alkaloids in the Amazonian botanical medicine ayahuasca by liquid chromatography–electrospray ionization-tandem mass spectrometry. J. Chromatogr. A, 18 Dec 2009, 1216 (51), 8960–8968. 450 kB. doi:10.1016/j.chroma.2009.10.088

Anon. Report on the risk assessment of BZP, European Monitoring Centre for Drugs and Drug Addiction, Feb 2009.

Gillman, PK. Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): A review. Headache, 1 Jan 2009, 49 (1), 1–9. 83 kB. doi:10.1111/j.1526-4610.2009.01575.x

Fantegrossi, WE; Murnane, KS; Reissig, CJ. The behavioral pharmacology of hallucinogens. Biochem. Pharmacol., 1 Jan 2008, 75 (1), 17–33. 359 kB. doi:10.1016/j.bcp.2007.07.018

Takahashi, M; Nagashima, M; Suzuki, J; Seto, T; Yasuda, I; Yoshida, T. Analysis of phenethylamines and tryptamines in designer drugs using gas chromatography-mass spectrometry. J. Health Sci., 2008, 54 (1), 89–96. 1882 kB. doi:10.1248/jhs.54.89

Schultz, DM. Synthesis of serotonin agonists as 5-HT2A and 5-HT2C receptor molecular probes. UW-LaCrosseJUR, 2006, 9, 1–6. 117 kB.

Parrish, JC; Braden, MR; Gundy, E; Nichols, DE. Differential phospholipase C activation by phenylalkylamine serotonin 5-HT2A receptor agonists. J. Neurochem., 1 Dec 2005, 95 (6), 1575–1584. 301 kB. doi:10.1111/j.1471-4159.2005.03477.x

Sulzer, D; Sonders, MS; Poulsen, NW; Galli, A. Mechanisms of neurotransmitter release by amphetamines: A review. Prog. Neurobiol., 1 Apr 2005, 75 (6), 406–433. 469 kB. doi:10.1016/j.pneurobio.2005.04.003

Brandt, SD; Freeman, S; McGagh, P; Abdul-Halim, N; Alder, JF. An analytical perspective on favoured synthetic routes to the psychoactive tryptamines. J. Pharm. Biomed. Anal., 19 Nov 2004, 36 (4), 675–691. 398 kB. doi:10.1016/j.jpba.2004.08.022

Anon. Report on the risk assessment of TMA-2, European Monitoring Centre for Drugs and Drug Addiction, May 2004.

Anon. Report on the risk assessment of 2C-I, 2C-T-2 and 2C-T-7, European Monitoring Centre for Drugs and Drug Addiction, May 2004.

Anon. Report on the risk assessment of PMMA, European Monitoring Centre for Drugs and Drug Addiction, Mar 2003. Pages cropped (as was intended but never done, apparently)

May, EJ. Synthesis of mixed heterocyclic phenylethylamines as serotonin receptor probes. UW-LaCrosseJUR, 2002, 5, 391–398. 311 kB.

Prescher, JA. Design and synthesis of substituted furobenzopyrans as new serotonergic molecular probes. UW-LaCrosseJUR, 2001, 4, 143–152. 753 kB.

Glennon, RA; Lee, M; Rangisetty, JB; Dukat, M; Roth, BL; Savage, JE; McBridge, A; Rauser, L; Hufeisen, SJ; Lee, DKH. 2-Substituted tryptamines: Agents with selectivity for 5-HT6 serotonin receptors. J. Med. Chem., 9 Mar 2000, 43 (5), 1011–1018. 137 kB. doi:10.1021/jm990550b

Prescher, JA. Design and synthesis of substituted dihydrofuranochromans as new serotonergic molecular probes. UW-LaCrosseJUR, 2000, 3, 181–193. 838 kB.

Schulze-Alexandru, M; Kovar, K; Vedani, A. Quasi-atomistic receptor surrogates for the 5-HT2A receptor: A 3D-QSAR study on hallucinogenic substances. Quant. Struct.-Act. Relat., 1 Dec 1999, 18 (6), 548–560. 312 kB. doi:10.1002/(SICI)1521-3838(199912)18:6<548::AID-QSAR548>3.0.CO;2-B

Anon. Report on the risk assessment of 4-MTA, European Monitoring Centre for Drugs and Drug Addiction, Oct 1999.

Anon. Report on the risk assessment of MBDB, European Monitoring Centre for Drugs and Drug Addiction, Jun 1999.

Whiteside, MS. Synthesis of hexahydrobenzodipyrans as ring-expanded analogues of potent serotonin 5-HT2A/2C receptor probes. UW-LaCrosseJUR, 1999, 2, 61–68. 272 kB.

Nuñez-Vergara, LJ; Matus, C; Alvarez-Lueje, AF; Cassels, BK; Squella, JA. Nitro radical anion formation from nitro-substituted amphetamine derivatives. Electroanalysis, 1 May 1994, 6 (5–6), 509–513. 477 kB. doi:10.1002/elan.1140060525

Nichols, DE; Marona-Lewicka, D; Huang, X; Johnson, MP. Novel serotonergic agents. Drug Des. Discovery, 1993, 9 (3–4), 299–312. 4732 kB.

Mckenna, DJ; Towers, GHN; Abbott, FS. Monoamine oxidase inhibitors in South American hallucinogenic plants part 2: Constituents of orally-active Myristicaceous hallucinogens. J. Ethnopharmacol., 1 Nov 1984, 12 (2), 179–211. 2504 kB. doi:10.1016/0378-8741(84)90048-5

Gupta, SP; Singh, P; Bindal, MC. QSAR studies on hallucinogens. Chem. Rev., 1 Dec 1983, 83 (6), 633–649. 2763 kB. doi:10.1021/cr00058a003

Majchrzak, MW; Kotełko, A; Guryn, R; Lambert, JB; Szadowska, A; Kowalczyk, K. Synthesis and action on the central nervous system of mescaline analogues containing piperazine or homopiperazine rings. J. Pharm. Sci., 1 Mar 1983, 72 (3), 304–306. 404 kB. doi:10.1002/jps.2600720324

Glennon, RA; Liebowitz, SM; Anderson, GM. Serotonin receptor affinities of psychoactive phenalkylamine analogues. J. Med. Chem., 1 Mar 1980, 23 (3), 294–299. 844 kB. doi:10.1021/jm00177a017

Ögren, S; Ross, SB. Substituted amphetamine derivatives. II. Behavioural effects in mice related to monoaminergic neurones. Acta Pharmacol. Toxicol., 1 Oct 1977, 41 (4), 353–368. 1335 kB. doi:10.1111/j.1600-0773.1977.tb02674.x

Smythies, JR. The mescaline phenomena. Br. J. Philos. Sci., 1 Feb 1953, 3 (12), 339–347. 72 kB. doi:10.1093/bjps/III.12.339

Pigott, A; Frescas, SP; McCorvy, JD; Huang, X; Roth, BL; Nichols, DE. trans-2-(2,5-Dimethoxy-4-iodophenyl)cyclopropylamine and trans-2-(2,5-dimethoxy-4-bromophenyl)cyclopropylamine as potent agonists for the 5-HT2 receptor family. Beilstein J. Org. Chem, 8 Oct 2012, 8, 1705–1709. 298 kB. doi:10.3762/bjoc.8.194

Jensen, N. Tryptamines as ligands and modulators of the serotonin 5-HT2A receptor and the isolation of aeruginascin from the hallucinogenic mushroom Inocybe aeruginascens. Ph. D. Thesis, Georg-August-Universität zu Göttingen, Göttingen, Germany, 4 Nov 2004. 2268 kB. Referent: Prof. Dr. H. Laatsch; Korreferent: Prof. D. E. Nichols.

Shulgin, AT. Composés pour améliorer la capacité de travail intellectuel des mammifères et leur procédé d’obtention. French Patent 2205330, 31 May 1974. 862 kB. In French.

Zuba, D; Sekuła, K; Buczek, A. 25C-NBOMe – New potent hallucinogenic substance identified on the drug market. Forensic Sci. Int., Apr 2013. 638 kB. doi:10.1016/j.forsciint.2012.08.027

Clark, AH; McCorvy, JD; Conley, JM; Williams, WK; Bekkam, M; Watts, VJ; Nichols, DE. Identification of a 2-phenyl-substituted octahydrobenzo[f]quinoline as a dopamine D3 receptor-selective full agonist ligand. Bioorg. Med. Chem., 1 Nov 2012, 20 (21), 6366–6374. 586 kB. doi:10.1016/j.bmc.2012.08.058

Zuba, D; Byrska, B. Alpha- and beta-asarone in herbal medicinal products. A case study. Forensic Sci. Int., Nov 2012. 229 kB. doi:10.1016/j.forsciint.2012.08.015

Zuba, D; Sekuła, K; Buczek, A. Identification and characterization of 2,5-dimethoxy-4-nitro-β-phenethylamine (2C-N)–A new member of 2C-series of designer drug. Forensic Sci. Int., 10 Oct 2012, 222 (1–3), 298–305. 588 kB. doi:10.1016/j.forsciint.2012.07.006

Tsujikawa, K; Mikuma, T; Kuwayama, K; Miyaguchi, H; Kanamori, T; Iwata, YT; Inoue, H. Degradation pathways of 4-methylmethcathinone in alkaline solution and stability of methcathinone analogs in various pH solutions. Forensic Sci. Int., 10 Jul 2012, 220 (1–3), 103–110. 671 kB. doi:10.1016/j.forsciint.2012.02.005

Vevelstad, M; Øiestad, EL; Middelkoop, G; Hasvold, I; Lilleng, P; Delaveris, GJM; Eggen, T; Mørland, J; Arnestad, M. The PMMA epidemic in Norway: Comparison of fatal and non-fatal intoxications. Forensic Sci. Int., 10 Jun 2012, 219 (1–3), 151–157. 332 kB. doi:10.1016/j.forsciint.2011.12.014

Davis, S; Rands-Trevor, K; Boyd, S; Edirisinghe, M. The characterisation of two halogenated cathinone analogues: 3,5-Difluoromethcathinone and 3,5-dichloromethcathinone. Forensic Sci. Int., 10 Apr 2012, 217 (1–3), 139–145. 983 kB. doi:10.1016/j.forsciint.2011.10.042

Warrick, BJ; Wilson, J; Hedge, M; Freeman, S; Leonard, K; Aaron, C. Lethal serotonin syndrome after methylone and butylone ingestion. J. Med. Toxicol., 1 Mar 2012, 8 (1), 65–68. 150 kB. doi:10.1007/s13181-011-0199-6

Pilgrim, JL; Gerostamoulos, D; Woodford, N; Drummer, OH. Serotonin toxicity involving MDMA (ecstasy) and moclobemide. Forensic Sci. Int., 10 Feb 2012, 215 (1–3), 184–188. 189 kB. doi:10.1016/j.forsciint.2011.04.008

Cueva, JP; Chemel, BR; Juncosa, JI; Lill, MA; Watts, VJ; Nichols, DE. Analogues of doxanthrine reveal differences between the dopamine D1 receptor binding properties of chromanoisoquinolines and hexahydrobenzo[a]phenanthridines. Eur. J. Med. Chem., 1 Feb 2012, 48, 97–107. 545 kB. doi:10.1016/j.ejmech.2011.11.039

Arunotayanun, W; Gibbons, S. Natural product ‘legal highs’ Nat. Prod. Rep., 2012, 29 (11), 1304–1316. 543 kB. doi:10.1039/C2NP20068F

Brunt, TM; Poortman, A; Niesink, RJM; Brink, W. Instability of the ecstasy market and a new kid on the block: mephedrone. J. Psychopharmacol., 1 Nov 2011, 25 (11), 1543–1547. 238 kB. doi:10.1177/0269881110378370

Kelly, JP. Cathinone derivatives: A review of their chemistry, pharmacology and toxicology. Drug Test. Anal., 1 Jul 2011, 3 (7–8), 439–453. 210 kB. doi:10.1002/dta.313

Nichols, DE. Legal highs: the dark side of medicinal chemistry. Nature, 6 Jan 2011, 469 (7328), 7. 75 kB. doi:10.1038/469007a

Magyar, K. The pharmacology of selegiline. Int. Rev. Neurobiol., 2011, 100, 65–84. 168 kB. doi:10.1016/B978-0-12-386467-3.00004-2

Capela, JP; Carmo, H; Remião, F; Bastos, ML; Meisel, A; Carvalho, FG. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: An overview. Mol. Neurobiol., 1 Jun 2009, 39 (3), 210–271. 1946 kB. doi:10.1007/s12035-009-8064-1

Langlitz, N. Pharmacogivilance and post-black market surveillance. Soc. Stud. Sci., 1 Jun 2009, 39 (3), 395–420. 265 kB. doi:10.1177/0306312708101977

May, JA; Sharif, NA; Chen, H; Liao, JC; Kelly, CR; Glennon, RA; Young, R; Li, J; Rice, KC; France, CP. Pharmacological properties and discriminative stimulus effects of a novel and selective 5-HT2 receptor agonist AL-38022A [(S)-2-(8,9-dihydro-7H-pyrano[2,3-g]indazol-1-yl)-1-methylethylamine]. Pharmacol. Biochem. Behav., 1 Jan 2009, 91 (3), 307–314. 476 kB. doi:10.1016/j.pbb.2008.07.015

May, JA; Dantanarayana, AP; Zinke, PW; McLaughlin, MA; Sharif, NA. 1-((S)-2-Aminopropyl)-1H-indazol-6-ol: A potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J. Med. Chem., 12 Jan 2006, 49 (1), 318–328. 124 kB. doi:10.1021/jm050663x

Measham, F. The decline of ecstasy, the rise of ‘binge’ drinking and the persistence of pleasure. Probat. J., 1 Dec 2004, 51 (4), 309–326. 238 kB. doi:10.1177/0264550504048220

Altun, A; Golcuk, K; Kumru, M; Jalbout, AF. Electron-conformation study for the structure-hallucinogenic activity relationships of phenylalkylamines. Bioorg. Med. Chem., 1 Dec 2003, 11 (24), 3861–3868. 577 kB. doi:10.1016/S0968-0896(03)00437-1

Kostrzewa, RM. Selective neurotoxins, chemical tools to probe the mind: The first thirty years and beyond. Neurotox. Res., 1 Mar 1999, 1 (1), 3–25. 3620 kB. doi:10.1007/BF03033336

McKenna, DJ; Repke, DB; Lo, L; Peroutka, SJ. Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. Neuropharmacology, 1 Mar 1990, 29 (3), 191–198. 679 kB. doi:10.1016/0028-3908(90)90001-8

Bach, NJ; Hall, DA; Kornfeld, EC. Descarboxylysergic acid (9,10-didehydro-6-methylergoline). J. Med. Chem., 1 Mar 1974, 17 (3), 312–314. 430 kB. doi:10.1021/jm00249a011

Ho, B; Tansey, LW; Balster, RL; An, R; McIsaac, WM; Harris, RT. Amphetamine analogs. II. Methylated phenethylamines. J. Med. Chem., 1 Jan 1970, 13 (1), 134–135. 278 kB. doi:10.1021/jm00295a034

Gorodetzky, CW; Isbell, H. A comparison of 2,3-dihydro-lysergic acid diethylamide with LSD-25. Psychopharmacology, 1 May 1964, 6 (3), 229–233. 317 kB. doi:10.1007/BF00404013

Kalir, A; Szara, S. Synthesis and pharmacological activity of fluorinated tryptamine derivatives. J. Med. Chem., 1 Nov 1963, 6 (6), 716–719. 533 kB. doi:10.1021/jm00342a019

Harman, WW. Some aspects of the psychedelic-drug controversy. J. Humanist. Psychol., 1963, 3 (2), 93–107. 4281 kB. doi:10.1177/002216786300300209

Daly, J; Axelrod, J; Witkop, B. Methylation and demethylation in relation to the in vitro metabolism of mescaline. Ann. N.Y. Acad. Sci., 1 Jan 1962, 96, 37–43. 397 kB. doi:10.1111/j.1749-6632.1962.tb50099.x

Szara, S; Hearst, E. The 6-hydroxylation of tryptamine derivatives: A way of producing psychoactive metabolites. Ann. N.Y. Acad. Sci., 1 Jan 1962, 96, 134–141. 429 kB. doi:10.1111/j.1749-6632.1962.tb50108.x

Friedhoff, AJ; Goldstein, M. New developments in metabolism of mescaline and related amines. Ann. N.Y. Acad. Sci., 1 Jan 1962, 96, 5–13. 506 kB. doi:10.1111/j.1749-6632.1962.tb50097.x

Szara, S; Axelrod, J. Hydroxylation and N-demethylation of N,N-dimethyltryptamine. Experientia, 1 Jun 1959, 15 (6), 216–217. 304 kB. doi:10.1007/BF02158111

Ginzel, KH; Mayer-Gross, W. Prevention of psychological effects of d-lysergic acid diethylamide (LSD 25) by its 2-brom derivative (BOL 148). Nature, 28 Jul 1956, 178 (4526), 210. 129 kB. doi:10.1038/178210a0

Fenderson5555. DOC, DOB, DOI and DOET: Strategic considerations. 7 Sep 2013. Wanted! Please contact me if you find this video.

Fenderson5555. The trimethoxylated amphetamines (TMA-x). 9 Dec 2012. 7716 kB.

Fenderson5555. Shulgin’s syntheses of 2,5-DMA, DOB and DOEF. 5 Dec 2011. 3657 kB.

Fenderson5555. Total synthesis of lysergic acid via Pd-catalysed domino cyclizations. 4 Dec 2011. 6394 kB.

Fenderson5555. A more modern lysergic acid synthesis. 28 Jun 2011. 3348 kB.

Fenderson5555. Total synthesis of lysergic acid. 25 Jun 2011. 4413 kB.

Fenderson5555. DMT from tryptophan? 23 Mar 2011. Wanted! Please contact me if you find this video.

Fenderson5555. Two syntheses of mescaline. 21 Mar 2011. 2247 kB.

Fenderson5555. Mechanisms and named reactions in 2C-P synthesis. 7 Jan 2011. Wanted! Please contact me if you find this video.

Fenderson5555. Mechanisms in MDMA synthesis. 5 Jan 2011. 4446 kB.

Fenderson5555. Mechanisms in DMT synthesis. 3 Jan 2011. 2609 kB.

Boal, M. The agony and ecstasy of Alexander Shulgin. Playboy, 1 Mar 2004, 51 (3), 80. 21460 kB. A redacted excerpt, appropriate for all readers.

Shulgin, A. Letter to the DEA re scheduling of MDMA. 29 Aug 1984. 170 kB.

Daley, PF; Morris, H. Pages from the lab notebook of Alexander Shulgin: A glance through the history of psychedelic chemistry. Vice, 1 Oct 2012.

Morris, H; Smith, A. The last interview with Alexander Shulgin… which, technically, was not an interview at all. Vice, 2 May 2010. A pdf version.

Elie, L; Baron, M; Croxton, R; Elie, M. Microcrystalline identification of selected designer drugs. Forensic Sci. Int., 10 Jan 2012, 214 (1–3),. 1364 kB. doi:10.1016/j.forsciint.2011.08.005

Clark, AH; McCorvy, JD; Watts, VJ; Nichols, DE. Assessment of dopamine D1 receptor affinity and efficacy of three tetracyclic conformationally-restricted analogs of SKF38393. Bioorg. Med. Chem., 15 Sep 2011, 19 (18), 5420–5431. 830 kB. doi:10.1016/j.bmc.2011.07.057

Kerwin, J. Doors of deception—The diaspora of designer drugs. Drug Test. Anal., 1 Sep 2011, 3 (9), 527–531. 135 kB. doi:10.1002/dta.302

Sainsbury, PD; Kicman, AT; Archer, RP; King, LA; Braithwaite, RA. Aminoindanes—the next wave of ‘legal highs’? Drug Test. Anal., 1 Aug 2011, 3 (7–8), 479–482. 79 kB. doi:10.1002/dta.318

Angelov, D; O’Brien, J; Kavanagh, PV. The syntheses of 1-(2-thienyl)-2-(methylamino) propane (methiopropamine) and its 3-thienyl isomer for use as reference standards. Drug Test. Anal., 2011. 104 kB. doi:10.1002/dta.298

Bonner, LA; Chemel, BR; Watts, VJ; Nichols, DE. Facile synthesis of octahydrobenzo[h]isoquinolines: Novel and highly potent D1 dopamine agonists. Bioorg. Med. Chem., 15 Sep 2010, 18 (18), 6763–6770. 475 kB. doi:10.1016/j.bmc.2010.07.052

Zaitsu, K; Katagi, M; Kamata, H; Nakanishi, K; Shima, N; Kamata, T; Nishioka, H; Miki, A; Tatsuno, M; Tsuchichashi, H. Simultaneous analysis of six novel hallucinogenic (tetrahydrobenzodifuranyl)aminoalkanes (FLYs) and (benzodifuranyl)aminoalkanes (DragonFLYs) by GC-MS, LC-MS, and LC-MS-MS. Forensic Toxicol., 1 Jan 2010, 24 (1), 9–18. 570 kB. doi:10.1007/s11419-009-0083-0

Su, T; Hayashi, T; Vaupel, DB. When the endogenous hallucinogenic trace amine N,N-dimethyltryptamine meets the sigma-1 receptor. Sci. Signal., 10 Mar 2009, 2 (61), 1–4. 392 kB. doi:10.1126/scisignal.261pe12

Nyandege, A; Kolanos, R; Roth, BL; Glennon, RA. Further studies on the binding of N1-substituted tryptamines at h5-HT6 receptors. Bioorg. Med. Chem. Lett., 15 Mar 2007, 17 (6),. 151 kB. doi:10.1016/j.bmcl.2006.12.089

Young, R. TDIQ (5,6,7,8–tetrahydro-1,3-dioxolo[4,5-g]isoquinoline): Discovery, pharmacological effects, and therapeutic potential. CNS Drug Rev., 2007, 13 (4), 405–422. 184 kB. doi:10.1111/j.1527-3458.2007.00022.x

Burchett, SA; Hicks, TP. The mysterious trace amines: Protean neuromodulators of synaptic transmission in mammalian brain. Prog. Neurobiol., 1 Aug 2006, 79 (5–6), 223–246. 477 kB. doi:10.1016/j.pneurobio.2006.07.003

Griffiths, RR; Richards, WA; McCann, U; Jesse, R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 1 Aug 2006, 187 (3), 268–283. 342 kB. doi:10.1007/s00213-006-0457-5

Mitchell, ES; Hoplight, BJ; Lear, SP; Neumaier, JF. BGC20-761, a novel tryptamine analog, enhances memory consolidation and reverses scopolamine-induced memory deficit in social and visuospatial memory tasks through a 5-HT6 receptor-mediated mechanism. Neuropharmacology, 1 Mar 2006, 50 (4), 412–420. 195 kB. doi:10.1016/j.neuropharm.2005.10.002

Meltzer, PC; Butler, D; Deschamps, JR; Madras, BK. 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: A promising class of monoamine uptake inhibitors. J. Med. Chem., 23 Feb 2006, 49 (4), 1420–1432. 179 kB. doi:10.1021/jm050797a

Bossong, MG; Dijk, JP; Niesink, RJM. Methylone and mCPP, two new drugs of abuse? Addict. Biol., 1 Dec 2005, 10 (4), 321–323. 69 kB. doi:10.1080/13556210500350794

El-Seedi, HR; Smet, PAGMD; Beck, O; Possnert, G; Bruhn, JG. Prehistoric peyote use: Alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas. J. Ethnopharmacol., 3 Oct 2005, 101 (1–3), 238–242. 200 kB. doi:10.1016/j.jep.2005.04.022

Boyer, EW; Shannon, M. The serotonin syndrome. N. Engl. J. Med., 17 Mar 2005, 352 (11), 1112–1120. 895 kB. doi:10.1056/NEJMra041867

Boer, D; Bosman, I. A new trend in drugs-of-abuse; the 2C-series of phenethylamine designer drugs. Pharm. World Sci., 1 Apr 2004, 26 (2), 110–113. 61 kB. doi:10.1023/B:PHAR.0000018600.03664.36

Glennon, RA; Grella, B; Tyacke, RJ; Lau, A; Westaway, J; Hudson, AL. Binding of β-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg. Med. Chem. Lett., 23 Feb 2004, 14 (4), 999–1002. 131 kB. doi:10.1016/j.bmcl.2003.11.078

Hong, S; Young, R; Glennon, RA. Discriminative stimulus properties of α-ethyltryptamine optical isomers. Pharmacol. Biochem. Behav., 1 Oct 2001, 70 (2–3),. 131 kB. doi:10.1016/S0091-3057(01)00605-0

King, LA; Meer, AJP; Huizer, H. 1-Phenylethylamines: a new series of illicit drugs? Forensic Sci. Int., 9 Feb 1996, 77 (3), 141–149. 491 kB. doi:10.1016/0379-0738(95)01852-2

Glennon, RA; Hong, S; Bondarev, M; Law, H; Dukat, M; Rakhit, S; Power, P; Fan, E; Kinneau, D; Kamboj, R; Teitler, M; Herrick-Davis, K; Smith, C. Binding of O-alkyl derivatives of serotonin at human 5-HT1Dβ receptors. J. Med. Chem., 5 Jan 1996, 39 (1), 314–322. 193 kB. doi:10.1021/jm950498t

Glennon, RA; Hong, S; Dukat, M; Teitler, M; Davis, K. 5-(Nonyloxy)tryptamine: A novel high-affinity 5-HTID β serotonin receptor agonist. J. Med. Chem., 1 Sep 1994, 37 (18), 2828–2830. 320 kB. doi:10.1021/jm00044a001

Gartz, J. Extraction and analysis of indole derivatives from fungal biomass. J. Basic. Microbiol., 1994, 34 (1), 17–22. 614 kB. doi:10.1002/jobm.3620340104

Glennon, RA; Raghupathi, R; Bartyzel, P; Teitler, M; Leonhardt, S. Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity. J. Med. Chem., 1 Feb 1992, 35 (4), 734–740. 1054 kB. doi:10.1021/jm00082a014

Zhao, Z; Castagnoli, N; Ricaurte, GA; Steele, T; Martello, M. Synthesis and neurotoxicological evaluation of putative metabolites of the serotonergic neurotoxin 2-(methylamino)-1-[3,4-(methylenedioxy)phenyl]propane [(methylenedioxy)methamphetamine]. Chem. Res. Toxicol., 1 Jan 1992, 5 (1), 89–94. 836 kB. doi:10.1021/tx00025a015

Naiman, N; Lyon, RA; Bullock, AE; Rydelek, LT; Teitler, M; Glennon, RA. 2-(Alkylamino)tetralin derivatives: interaction with 5-HT1A serotonin binding sites. J. Med. Chem., 1 Jan 1989, 32 (1), 253–256. 597 kB. doi:10.1021/jm00121a045

Gartz, J. Biotransformation of tryptamine derivatives in mycelia cultures of Psilocybe. J. Basic. Microbiol., 1989, 29 (6), 347–352. 357 kB. doi:10.1002/jobm.3620290608

Gornez-Jeria, JS; Morales-Lagos, D; Cassels, BK; Saavedra-Aguilar, JC. Electronic structure and serotonin receptor binding affinity of 7-substituted tryptamines QSAR of 7-substituted tryptamines. Quant. Struct.-Act. Relat., 1986, 5 (4), 153–157. 577 kB. doi:10.1002/qsar.19860050404

Sinhababu, AK; Ghosh, AK; Borchardt, RT. Molecular mechanism of action of 5,6-dihydroxytryptamine. Synthesis and biological evaluation of 4-methyl-, 7-methyl- and 4,7-dimethyl-5,6-dihydroxytryptamines. J. Med. Chem., 1 Sep 1985, 28 (9), 1273–1279. 1001 kB. doi:10.1021/jm00147a027

Reitz, AB; Avery, MA; Rosenkranz, RP; Verlander, MS; Melmon, KL; Hoffman, BB; Akita, Y; Castagnoli, N; Goodman, M. Conjugates of catecholamines. 6. Synthesis and β-adrenergic activity of N-(hydroxyalkyl)catecholamine derivatives. J. Med. Chem., 1 May 1985, 28 (5), 642–647. 865 kB. doi:10.1021/jm50001a018

Reitz, AB; Sonveaux, E; Rosenkranz, RP; Verlander, MS; Melmon, KL; Hoffman, BB; Akita, Y; Castagnoli, N; Goodman, M. Conjugates of catecholamines. 5. Synthesis and β-adrenergic activity of N-(aminoalkyl)norepinephrine derivatives. J. Med. Chem., 1 May 1985, 28 (5), 634–642. 1211 kB. doi:10.1021/jm50001a017

Cheng, AC; Castagnoli, N. Synthesis and physicochemical and neurotoxicity studies of 1-(4-substituted-2,5-dihydroxyphenyl)-2-aminoethane analogs of 6-hydroxydopamine. J. Med. Chem., 1 Apr 1984, 27 (4), 513–520. 1214 kB. doi:10.1021/jm00370a014

Delliou, D. 4-Bromo-2,5-dimethoxyamphetamine: Psychoactivity, toxic effects and analytical methods. Forensic Sci. Int., 1 May 1983, 21 (3), 259–267. 1358 kB. doi:10.1016/0379-0738(83)90131-7

Jacob, P; Kline, TB; Castagnoli, N. Chemical and biological studies of 1-(2,5-dihydroxy-4-methylphenyl)-2-aminopropane, an analog of 6-hydroxydopamine. J. Med. Chem., 1 Jun 1979, 22 (6), 662–671. 1389 kB. doi:10.1021/jm00192a011

Zweig, JS; Castagnoli, N. In vitro O-demethylation of the psychotomimetic amine, 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane. J. Med. Chem., 1 Mar 1977, 20 (3), 414–421. 1182 kB. doi:10.1021/jm00213a020

Zweig, JS; Castagnoli, N. Chemical conversion of the psychotomimetic amine 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane to 5-hydroxy-2,6-dimethylindole. J. Med. Chem., 1 Jul 1974, 17 (7), 747–749. 438 kB. doi:10.1021/jm00253a019

Cushman, M; Castagnoli, N. Synthesis of pharmacologically active nitrogen analogs of the tetrahydrocannabinols. J. Org. Chem., 1 May 1974, 39 (11), 1546–1550. 707 kB. doi:10.1021/jo00924a021

Cushman, M; Castagnoli, N. Novel approach to the synthesis of nitrogen analogs of the tetrahydrocannabinols. J. Org. Chem., 1 Feb 1973, 38 (3), 440–448. 1320 kB. doi:10.1021/jo00943a007

McLain, L. A study of peyote. Clin. Toxicol., 1 Mar 1968, 1 (1), 81–85. 368 kB. doi:10.1039/15563656808990560

Kalir, A; Szara, S. Synthesis and pharmacological activity of alkylated tryptamines. J. Med. Chem., 1 May 1966, 9 (3), 341–344. 482 kB. doi:10.1021/jm00321a017

Carlsson, A; Corrodi, H; Magnusson, T. Basische Derivate des 4,5,6-Trimethoxyindols und des 3,4,5-Trimethoxyphenols. Helv. Chim. Acta, 1963, 46 (4), 1231–1235. 334 kB. doi:10.1002/hlca.19630460418

Zirkle, CL; Kaiser, C; Tedeschi, DH; Tedeschi, RE; Burger, A. 2-Substituted cyclopropylamines. II. Effect of structure upon monoamine oxidase-inhibitory activity as measured in vivo by potentiation of tryptamine convulsions. J. Med. Chem., 1 Nov 1962, 5 (6), 1265–1284. 1069 kB. doi:10.1021/jm01241a018

Troxler, F; Seemann, F; Hofmann, A. Abwandlungsprodukte von Psilocybin und Psilocin. 2. Mitteilung über synthetische Indolverbindungen. Helv. Chim. Acta, 1959, 42 (6), 2073–2103. 1589 kB. doi:10.1002/hlca.19590420638

Hofmann, A; Heim, R; Brack, A; Kobel, H; Frey, A; Ott, H; Petrzilka, T; Troxler, F. Psilocybin und Psilocin, zwei psychotrope Wirkstoffe aus mexikanischen Rauschpilzen. Helv. Chim. Acta, 1959, 42 (5), 1557–1572. 1132 kB. doi:10.1002/hlca.19590420518

Kornfeld, EC; Fornefeld, EJ; Kline, GB; Mann, MJ; Jones, RG; Woodward, RB. The total synthesis of lysergic acid and engrovine. J. Am. Chem. Soc., 1 Oct 1954, 76 (20), 5256–5257. 258 kB. doi:10.1021/ja01649a100

Shulgin, AT. 4-Alkyl-2,5-dimethoxy-alpha-methylphenethylamine and pharmacologically-acceptable salts. Canadian Patent CA 861564, 19 Jan 1971. 1135 kB.

Shulgin, AT. 1,2,3,4-Tetrahydro-5H-[1]benzypyrano[3,4-d]pyridines. Canadian Patent CA 857328, 1 Dec 1970. 1621 kB.

Shulgin, AT. 1-(2,5-Dimethoxy-4-alkylphenyl)-2-nitropropenes. Canadian Patent CA 828202, 25 Nov 1969. 612 kB.

Shulgin, AT. Amido- and imidophenyl methylcarbamate. Canadian Patent CA 759036, 16 May 1967. 1122 kB.

Shulgin, AT. Parasitizid. German Patent AT236699, 10 Nov 1964. 342 kB.

Shulgin, AT. Alpha amino substituted methylene malononitriles. U.S. Patent 3,057,864, 9 Oct 1962. 255 kB.

Shulgin, AT. Lernkapazitätssteigernde Verbindungen und Verfahren zu ihrer Herstellung (Learning capacity-enhancing compounds and methods for their production). German Patent 2 355 350, 16 May 1974. 1169 kB.

Shulgin, AT. N-Methylcarbaminsäure-(4-benzylidenamino)-phenylester. German Patent 1 300 546, 7 Aug 1969. 314 kB.

Shulgin, AT. Pesticides and parasiticides and method for their production. Great Britain Patent 935,160, 28 Aug 1963. 818 kB.

Shulgin, AT. Celebrating Gordon Wasson. In The Sacred Mushroom Seeker; Riedlinger, TJ, Ed., Dioscorides Press, 1 Jan 1990; .

Caudevilla-Gálligo, F; Riba, J; Ventura, M; González, D; Farré, M; Barbanoj, MJ; Bouso, JC. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects. J. Psychopharmacol., 1 Jul 2012, 26 (7), 1026–1035. 586 kB. doi:10.1177/0269881111431752

Juncosa, JI; Hansen, M; Bonner, LA; Cueva, JP; Maglathlin, R; McCorvy, JD; Marona-Lewicka, D; Lill, MA; Nichols, DE. Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands. ACS Chem. Neurosci., 2012. 3828 kB. doi:10.1021/cn3000668

Masson, J; Emerit, MB; Hamon, M; Darmon, M. Serotonergic signaling: multiple effectors and pleiotropic effects. WIREs Membr. Transp. Signal, 2012. 7113 kB. doi:10.1002/wmts.50

Paoli, GD; Brandt, SD; Pounder, DJ. Analytical characterization and rapid determination of 2-(diphenylmethyl)pyrrolidine in blood and application to an internet product. J. Chromatogr. B, 1 Dec 2011, 879 (31), 3771–3774. 353 kB. doi:10.1016/j.jchromb.2011.10.014

Kjellgren, A; Soussan, C. Heaven and Hell—A phenomenological study of recreational use of 4-HO-MET in Sweden. J. Psychoactive Drugs, 1 Jul 2011, 43 (3), 211–219. 231 kB. doi:10.1080/02791072.2011.605699

Carstairs, SD; Cantrell, FL. The spice of life: An analysis of nutmeg exposures in California. Clin. Toxicol., 1 Mar 2011, 49 (3), 177–180. 168 kB. doi:10.3109/15563650.2011.561210

Maurer, HH. Chemistry, pharmacology, and metabolism of emerging drugs of abuse. Ther. Drug Monit., 1 Oct 2010, 32 (5), 544–549. 142 kB. doi:10.1097/FTD.0b013e3181eea318

Brandt, SD; Martins, CPB. Analytical methods for psychoactive N,N-dialkylated tryptamines. Trends Anal. Chem., 1 Sep 2010, 29 (8), 858–869. 446 kB. doi:10.1016/j.trac.2010.04.008

Benzenhöfer, U; Passie, T. Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin. Addiction, 1 Aug 2010, 105 (8), 1355–1361. 794 kB. doi:10.1111/j.1360-0443.2010.02948.x

Meyer, MR; Wilhelm, J; Peters, FT; Maurer, HH. β-Keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal. Bioanal. Chem., 1 Jun 2010, 397 (3), 1225–1233. 412 kB. doi:10.1007/s00216-010-3636-5

Broadley, KJ. The vascular effects of trace amines and amphetamines. Pharmacol. Ther., 1 Mar 2010, 125 (3), 363–375. 1074 kB. doi:10.1016/j.pharmthera.2009.11.005

Martins, CPB; Freeman, S; Alder, JF; Brandt, SD. Characterisation of a proposed internet synthesis of N,N-dimethyltryptamine using liquid chromatography/electrospray ionisation tandem mass spectrometry. J. Chromatogr. A, 14 Aug 2009, 1216 (33), 6119–6123. 315 kB. doi:10.1016/j.chroma.2009.06.060

Guy, M; Freeman, S; Alder, JF; Brandt, SD. The Henry reaction: spectroscopic studies of nitrile and hydroxylamine by-products formed during synthesis of psychoactive phenylalkylamines. Cent. Eur. J. Chem., 1 Dec 2008, 6 (4), 526–534. 982 kB. doi:10.2478/s11532-008-0054-z

Bruhn, JG; EI-Seedi, HR; Stephanson, N; Beck, O; Shulgin, AT. Ecstasy analogues found in cacti. J. Psychoactive Drugs, 1 Jun 2008, 40 (2), 219–222. 884 kB. doi:10.1080/02791072.2008.10400635

Nicolaou, KC; Krasovskiy, A; Trépanier, V; Chen, DY. An expedient strategy for the synthesis of tryptamines and other heterocycles. Angew. Chem., 19 May 2008, 120 (22), 4285–4288. 365 kB. doi:10.1002/ange.200800404

Sessa, B; Nutt, DJ. MDMA, politics and medical research: Have we thrown the baby out with the bathwater? J. Psychopharmacol., 1 Nov 2007, 21 (8), 787–791. 178 kB. doi:10.1177/0269881107084738

Rothman, RB; Blough, BE; Baumann, MH. Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions. AAPS J., 2007, 9 (1), E1–E10. 999 kB. doi:10.1208/aapsj0901001

Benzenhöfer, U; Passie, T. Zur Frühgeschichte von “Ecstasy” Nervenarzt, 2006, 77 (1), 95–96, 98–99. 533 kB. doi:10.1007/s00115-005-2001-y

Staack, RF; Maurer, HH. Metabolism of designer drugs of abuse. Curr. Drug Metab., 1 Jun 2005, 6 (3), 259–274. 104 kB. doi:10.2174/1389200054021825

Anon. Abstracts of the 2005 North American Congress of Clinical Toxicology Annual Meeting. Clin. Toxicol., 1 Jan 2005, 43 (6), 631–777. 940 kB. doi:10.1080/15563650500269633

Passie, T; Hartmann, U; Schneider, U; Emrich, HM; Krüger, THC. Ecstasy (MDMA) mimics the post-orgasmic state: Impairment of sexual drive and function during acute MDMA-effects may be due to increased prolactin secretion. Med. Hypotheses, 2005, 64 (5), 899–903. 110 kB. doi:10.1016/j.mehy.2004.11.044

Brandt, SD; Freeman, S; Fleet, IA; McGagh, P; Alder, JF. Analytical chemistry of synthetic routes to psychoactive tryptamines. Part II. Characterisation of the Speeter and Anthony synthetic route to N,N-dialkylated tryptamines using GC-EI-ITMS, ESI-TQ-MS-MS and NMR. Analyst, 2005, 130 (3), 330–344. 403 kB. doi:10.1039/b413014f

Brandt, SD; Freeman, S; Fleet, IA; McGagh, P; Alder, JF. Analytical chemistry of synthetic routes to psychoactive tryptamines. Part I. Characterisation of the Speeter and Anthony synthetic route to 5-methoxy-N,N-diisopropyltryptamine using ESI-MS-MS and ESI-TOF-MS. Analyst, 2004, 129 (11), 1047–1057. 420 kB. doi:10.1039/b407239c

Sarker, SD. Book review: The Simple Plant Isoquinolines. Phytochemistry, 1 Jul 2003, 63 (5), 631–632. 81 kB. doi:10.1016/S0031-9422(03)00186-9

Schmidt, WJ; Mayerhofer, A; Meyer, A; Kovar, K. Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect? Neurosci. Lett., 27 Sep 2002, 330 (3), 251–254. 280 kB. doi:10.1016/S0304-3940(02)00823-6

Borsutzky, M; Passie, T; Paetzold, W; Emrich, HM; Schneider, U. Hawaiianische Holzrose: (Psycho-)Pharmakologische Wirkungen der Samen der Argyreia nervosa. Nervenarzt, 2002, 73 (9), 892–896. 148 kB. doi:10.1007/s00115-002-1374-4

Buffum, JC; Shulgin, AT. Overdose of 2.3 grams of intravenous methamphetamine: Case, analysis and patient perspective. J. Psychoactive Drugs, 1 Oct 2001, 33 (4), 409–412. 704 kB. doi:10.1080/02791072.2001.10399926

Pentney, AR. An exploration of the history and controversies surrounding MDMA and MDA. J. Psychoactive Drugs, 1 Jul 2001, 33 (3), 213–221. 871 kB. doi:10.1080/02791072.2001.10400568

Collins, M. Some new psychoactive substances: Precursor chemical and synthesis-driver end-products. Drug Test. Anal., 1 Jul 2001, 3 (7–8), 404–416. 178 kB. doi:10.1002/dta.315

Schoenwald, RD; Gadiraju, RR; Barfknecht, CF. Serotonin antagonists for use as antiglaucoma agents and their ocular penetration. Eur. J. Pharm. Biopharm., 1 Jun 1997, 43 (3), 273–281. 688 kB. doi:10.1016/S0939-6411(97)00055-6

Lyttle, T; Goldstein, D; Gartz, J. Bufo toads and bufotenine: Fact and fiction surrounding an alleged psychedelic. J. Psychoactive Drugs, 1 Sep 1996, 28 (3), 267–290. 24650 kB. doi:10.1080/02791072.1996.10472488

Glennon, RA. MDMA-like stimulus effects of α-ethyltryptamine and the α-ethyl homolog of DOM. Pharmacol. Biochem. Behav., 1 Oct 1993, 46 (2), 459–462. 396 kB. doi:10.1016/0091-3057(93)90379-8

Steele, TD; Katz, JL; Ricaurte, GA. Evaluation of the neurotoxicity of N-methyl-1-(4-methoxyphenyl)-2-aminopropane (para-methoxymethamphetamine, PMMA). Brain Res., 4 Sep 1992, 589 (2), 349–352. 554 kB. doi:10.1016/0006-8993(92)91298-S

Callaway, E. Psychopharmacology‘s need for linking variables. Biol. Psychiat., 1 Jan 1992, 31 (1), 1–3. 297 kB. doi:10.1016/0006-3223(92)90002-H

Higgs, RA; Glennon, RA. Stimulus properties of ring-methyl amphetamine analogs. Pharmacol. Biochem. Behav., 1 Dec 1990, 37 (4), 835–837. 238 kB. doi:10.1016/0091-3057(90)90571-X

Lenz, B. Book review: The Controlled Substances Act: A Resource Manual of the Current Status of the Federal Drug Laws. Int. J. Addict., 1990, 25 (12), 1489–1493. 289 kB. doi:10.3109/10826089009056234

Jansen, KLR; Prast, CJ. Ethnopharmacology of kratom and the Mitragyna alkaloids. J. Ethnopharmacol., 1 May 1988, 23 (1), 115–119. 366 kB. doi:10.1016/0378-8741(88)90121-3

Glennon, RA; Yousif, M; Patrick, G. Stimulus properties of 1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDA) analogs. Pharmacol. Biochem. Behav., 1 Mar 1988, 29 (3), 443–449. 551 kB. doi:10.1016/0091-3057(88)90001-9

Rasmussen, K; Glennon, RA; Aghajanian, GK. Phenethylamine hallucinogens in the locus coeruleus: potency of action correlates with rank order of 5-HT2 binding affinity. Eur. J. Pharmacol., 2 Dec 1986, 132 (1), 79–82. 267 kB. doi:10.1016/0014-2999(86)90014-2

Glennon, RA; Young, R. MDA: An agent that produces stimulus effects similar to those of 3,4-DMA, LSD and cocaine. Eur. J. Pharmacol., 23 Mar 1984, 99 (2–3), 249–250. 139 kB. doi:10.1016/0014-2999(84)90250-4

Baker, GB; Coutts, RT. Techniques and Instrumentation in Analytical Chemistry 4: Evaluation of Analytical Methods in Biological Systems. Part A. Analysis of Biogenic Amines, Elsevier, 1982.

Glennon, RA; Rosecrans, JA. Indolealkylamine and phenalkylamine hallucinogens: A brief overview. Neurosci. Biobehav. Rev., 1982, 6 (4). 489–497. 895 kB. doi:10.1016/0149-7634(82)90030-6

Guion, RR. Possible interactions between alkoxy amphetamines and brain serotonin receptors. J. Theor. Biol., 7 Jul 1981, 91 (1), 237–239. 141 kB. doi:10.1016/0022-5193(81)90384-2

Rusterholz, DB; Dryer, SE; Long, JP; Barfknecht, CF; Mott, J. Sedative and analgesic actions of methoxylated 2-aminotetralins; involvement of α1- and α2-adrenoreceptors. Eur. J. Pharmacol., 25 Jul 1980, 65 (2–3), 201–211. 870 kB. doi:10.1016/0014-2999(80)90393-3

Kohli, JD; Goldberg, LI; Nichols, DE. Dopamine vascular actions of N-substituted derivatives of 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene (ADTN). Eur. J. Pharmacol., Jun 1979, 56 (1–2), 39–44. 454 kB. doi:10.1016/0014-2999(79)90430-8

Nichols, DE; Mason, DL; Jacobsen, LB. Allylbenzene analogs of Δ9-tetrahydrocannabinol as tumor growth inhibitors. Life Sci., 1 Nov 1977, 21 (9), 1245–1247. 150 kB. doi:10.1016/0024-3205(77)90004-2

Vogel, WH; Evans, BD. Structure-activity-relationships of certain hallucinogenic substances based on brain levels. Life Sci., 15 May 1977, 20 (10), 1629–1635. 419 kB. doi:10.1016/0024-3205(77)90335-6

Ilhan, M; Nichols, DE; Long, JP; Cannon, JG. Apomorphine-like effect of an aminotetralin on the linguomandibular reflex of the cat. Eur. J. Pharmacol., 1 Aug 1975, 33 (1), 61–64. 308 kB. doi:10.1016/0014-2999(75)90138-7

Kapadia, GJ; Chowdhury, BK; Rao, GS; Pradhan, SN. Synthesis and psychotropic activity of 2-hydroxy-4,5-dimethoxyphenethanolamine, a potential endogenous psychotogen, and its methylenedioxy analog. J. Pharm. Sci., 1 Aug 1974, 63 (8), 1339–1341. 337 kB. doi:10.1002/jps.2600630849

Thiessen, PN; Cook, DA. The properties of 3,4-methylenedioxyamphetamine (MDA). I. A review of the literature. Clin. Toxicol., 1973, 6 (1), 45–52. 367 kB. doi:10.3109/15563657308991042

Barfknecht, CF; Smith, RV; Nichols, DE; Leseney, JL; Long, JP; Engelbrecht, JA. Chemistry and pharmacological evaluation of 1-phenyl-2-propanols and 1-phenyl-2-propanones. J. Pharm. Sci., 1 May 1971, 60 (5), 799–801. 352 kB. doi:10.1002/jps.2600600533

Anon. New ways with hallucinogens. Lancet, 8 Mar 1969, 293 (7593), 510. 181 kB. doi:10.1016/S0140-6736(69)91603-1

Hoffer, A; Osmond, H. The Hallucinogens, Academic Press, New York, 1967.

Alles, GA; Feigen, GA. Comparative physiological actions of phenyl-, thienyl- and furylisopropylamines. J. Pharmacol. Exp. Ther., 1 Jul 1941, 72 (3), 265–275. 1459 kB.

Nichols, DE; Glennon, RA. Medicinal Chemistry and Structure-Activity Relationships of Hallucinogens. In Hallucinogens: Neurochemical, Behavioural and Clinical Perspectives; Jacobs, BL, Ed., Raven Press, New York, 1 Jan 1984; pp 95–142. 84438 kB.

Hansen, M. Design and synthesis of selective serotonin receptor agonists for positron emission tomography imaging of the brain. Ph. D. Thesis, University of Copenhagen, 16 Dec 2012. 7921 kB.

Meyers-Riggs, B. 4-Hydroxy tryptamines. countyourculture: rational exploration of the underground, 7 Jul 2012.

Shulgin, AT. 1-(Di(lower alkoxy)-4-alkylphenyl)-2-nitropropenes. U.S. Patent 3,541,158, 17 Nov 1970. 367 kB.

Shulgin, AT. 1,2,3,4-Tetrahydro -5H[1]benzopyrano[3,4-d]pyridines and 1,2,3,4,13,14-tetrahydro -5H[1]benzopyrano[3,4-d]pyridines. U.S. Patent 3,522,260, 28 Jul 1970. 814 kB.

Shulgin, AT. 8-Alkyl-(and 8-cycloalkyl/lower-alkyl-)-10-hydroxy-5-oxo-1,2,3,4-tetrahydro -5H[1]benzopyrano[3,4-d]pyridines. U.S. Patent 3,429,889, 25 Feb 1969. 838 kB.

Shulgin, AT. Aminophenyl carbamates. Canadian Patent 734496, 17 May 1966. 1425 kB.

Shulgin, AT. 2,3,4,5,6-Pentachloro-benzylidenemalononitrile. U.S. Patent 3,250,798, 10 May 1966. 174 kB.

Shulgin, AT. Process for preparing tetrahalomuconic acids. U.S. Patent 3,153,669, 20 Oct 1964. 175 kB.

Shulgin, AT. Dimalononitriles. U.S. Patent 3,149,150, 15 Sep 1964. 170 kB.

Shulgin, AT. Heterocyclic dimalononitriles. U.S. Patent 3,134,780, 26 May 1964. 146 kB.

Shulgin, AT. Aminophenyl carbamates. U.S. Patent 3,084,098, 2 Apr 1964. 1013 kB.

Shulgin, AT. Schiff base carbamates. U.S. Patent 2,997,498, 22 Aug 1961. 181 kB.

Shulgin, AT. Schiff base carbamates. Canadian Patent 714575, 22 Aug 1961. 1240 kB.

Anon. Personal communication of unpublished research. 20 Aug 2013.

Anon. Personal communication of unpublished research. 1 Jun 2012.

Coppola, M; Mondola, R. Synthetic cathinones: Chemistry, pharmacology and toxicology of designer drugs of abuse marketed as “bath salts” or “plant food” Toxicol. Lett., 1 Jun 2012, 211 (2), 144–249. 305 kB. doi:10.1016/j.toxlet.2012.03.009

Halberstadt, AL; Nichols, DE; Geyer, MA. Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor. Psychopharmacology, 1 Jun 2012, 221 (4), 709–218. 296 kB. doi:10.1007/s00213-011-2616-6

Kavanagh, PV; O’Brien, J; Fox, J; O’Donnell, C; Christie, R; Power, JD; McDermott, SD. The analysis of substituted cathinones. Part 3. Synthesis and characterisation of 2,3-methylenedioxy substituted cathinones. Forensic Sci. Int., 10 Mar 2012, 216 (1–2), 19–28. 1580 kB. doi:10.1016/j.forsciint.2011.08.011

Coppola, M; Mondola, R. 3,4-Methylenedioxypyrovalerone (MDPV): Chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol. Lett., 5 Jan 2012, 208 (1), 12–25. 138 kB. doi:10.1016/j.toxlet.2011.10.002

Barker, SA; McIlhenny, EH; Strassman, R. A critical review of reports of endogenous psychedelic N,N-dimethyltryptamines in humans: 1955–2010. Drug Test. Anal., 2012. 270 kB. doi:10.1002/dta.422

Prosser, JM; Nelson, LS. The toxicology of bath salts: a review of synthetic cathinones. J. Med. Toxicol., 1 Nov 2011, 8 (1), 33–22. 267 kB. doi:10.1007/s13181-011-0193-z

Hill, SL; Thomas, SHL. Clinical toxicology of newer recreational drugs. Clin. Toxicol., 1 Oct 2011, 49 (8), 705–219. 336 kB. doi:10.3109/15563650.2011.615318

Klein, MT; Dukat, M; Glennon, RA; Teitler, M. Toward selective drug development for the human 5-hydroxytryptamine 1E receptor: A comparison of 5-hydroxytryptamine 1E and 1F receptor structure-affinity relationships. J. Pharmacol. Exp. Ther., 1 Jun 2011, 337 (3), 860–267. 1671 kB. doi:10.1124/jpet.111.179606

Kikura-Hanajiri, R; Uchiyama, N; Goda, Y. Survey of current trends in the abuse of psychotropic substances and plants in Japan. Leg. Med., 1 May 2011, 13 (3), 109–215. 639 kB. doi:10.1016/j.legalmed.2011.02.003

Neudörffer, A; Mueller, M; Martinez, C; Mechan, A; McCann, U; Ricaurte, GA; Largeron, M. Synthesis and neurotoxicity profile of 2,4,5-trihydroxymethamphetamine and its 6-(N-acetylcystein-S-yl) conjugate. Chem. Res. Toxicol., 2011, 24 (6), 968–278. 4808 kB. doi:10.1021/tx2001459

IÍsberg, V; Balle, T; Sander, T; Jørgensen, FS; Gloriam, DE. G protein- and agonist-bound serotonin 5-HT2A receptor model activated by steered molecular dynamics simulations. J. Chem. Inf. Model., 2011, 51 (2), 315–225. 1092 kB. doi:10.1021/ci100402f

Wasik, AM; Gandy, MN; McIldowie, M; Holder, MJ; Chamba, A; Challa, A; Lewis, KD; Young, SP; Scheel-Toellner, D; Dyer, MJ; Barnes, NM; Piggott, MJ; Gordon, J. Enhancing the anti-lymphoma potential of 3,4-methylenedioxymethamphetamine (‘ecstasy’) through iterative chemical redesign: mechanisms and pathways to cell death. Invest. New Drugs, 2011. 575 kB. doi:10.1007/s10637-011-9730-5

Torres-Altoro, MI; Kuntz, CP; Nichols, DE; Barker, EL. Structural analysis of the extracellular entrance to the serotonin transporter permeation pathway. J. Biol. Chem., 14 May 2010, 285 (20), 15369–25379. 2466 kB. doi:10.1074/jbc.M109.088138

Schindler, EAD. Behavioral and biochemical distinctions in the pharmacology of two common hallucinogens. Ph. D. Thesis, Drexel University, Philadelphia, PA, USA, 1 Apr 2010. 5870 kB.

Felim, A; Herrera, G; Neudörffer, A; Blanco, M; O’Connor, J; Largeron, M. Synthesis and in vitro cytotoxicity profile of the R-enantiomer of 3,4-dihydroxymethamphetamine (R-(-)-HHMA): Comparison with related catecholamines. Chem. Res. Toxicol., 2010, 23 (1), 211–219. 349 kB. doi:10.1021/tx9003374

Gandy, MN; Mclldowie, M; Lewis, K; Wasik, AM; Salomonczyk, D; Wagg, K; Millar, ZA; Tindiglia, D; Huot, P; Johnston, T; Thiele, S; Nguyen, B; Barnes, NM; Brotchie, JM; Martin-Iverson, MT. Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt’s lymphoma cytotoxicity. Med. Chem. Comm., 2010, 1 (4), 287–293. 177 kB. doi:10.1039/c0md00108b

Corbin, MD. Spirituality in the laboratory: Negotiating the politics of knowledge in the psychedelic sciences. Ph. D. Thesis, University of Maryland, College Park, MD, USA, 2010. 875 kB.

Stevens, SA. Extraction and photodegradation of plant species Salvia divinorum. M. Sc. Thesis, University of California, Davis, CA, USA, 2010. 1318 kB.

Ang, RLL. Molecular basis of the action of hallucinogens. Ph. D. Thesis, New York University, New York, NY, USA, 2010. 2402 kB.

Mumane, KS. Neuropharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) and its stereoisomers. Ph. D. Thesis, Emory University, Atlanta, GA, USA, 2010. 4307 kB.

Carroll, FI; Blough, BE; Mascarella, SW; Navarro, HA; Eaton, JB; Lukas, RJ; Damaj, MI. Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J. Med. Chem., 2010, 53 (5), 2204–2214. 948 kB. doi:10.1021/jm9017465

Stafford, GI; Jäger, AK; Staden, J. African psychoactive plants. In African Natural Plant Products: New Discoveries and Challenges in Chemistry and Quality; ACS Symposium Series; Juliani, HR; Simon, JE; Ho, C, Eds., American Chemical Society, Washington, DC, 20 Dec 2009; Vol. 1021, pp 323–246. 515 kB. doi:10.1021/bk-2009-1021.ch018

Koroch, AR; Juliani, HR; Kulakowski, D; Arthur, H; Asante-Dartey, J; Simon, JE. Voacanga africana: Chemistry, quality and pharmacological activity. In African Natural Plant Products: New Discoveries and Challenges in Chemistry and Quality; ACS Symposium Series; , American Chemical Society, Washington, DC, 20 Dec 2009; Vol. 1021, pp 363–280. 559 kB. doi:10.1021/bk-2009-1021.ch020

Huntington, BC. Synthesis and intermediate/by-product analysis of bromo-dragonfly, a dihydrobenzofuran analogue of phenethylamine hallucinogens. M. Sc. Thesis, University of California Davis, Sacramento, CA, USA, 2009. 927 kB.

Carroll, FI; Blough, BE; Abraham, P; Mills, AC; Holleman, JA; Wolckenhauer, SA; Decker, AM; Landavazo, A; McElroy, KT; Navarro, HA; Gatch, MB; Forster, MJ. Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J. Med. Chem., 2009, 52 (21), 6768–2781. 1104 kB. doi:10.1021/jm901189z

Thigpen, AL; Awad, T; DeRuiter, J; Clark, CR. GC-MS studies on the regioisomeric methoxy-methyl-phenethylamines related to MDEA, MDMMA, and MBDB. J. Chromatogr. Sci., 1 Nov 2008, 46 (10), 900–206. 448 kB. doi:10.1093/chromsci/46.10.900

Siff, SI. Glossy visions: Coverage of LSD in popular magazines, 1954-1968. Ph. D. Thesis, Ohio University, Athens, OH, USA, 1 Nov 2008. 3656 kB.

Runyon, SP; Mosier, PD; Roth, BL; Glennon, RA; Westkaemper, RB. Potential modes of interaction of 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives with the 5-HT2A receptor: A ligand structure-affinity relationship, receptor mutagenesis and receptor modeling investigation. J. Med. Chem., 2008, 51 (21), 6808–2828. 2229 kB. doi:10.1021/jm800771x

Szára, S. DMT at fifty. Neuropsychopharmacol. Hung., 1 Dec 2007, 9 (4), 201–205. 446 kB.

Huang, Y; Williams, WA. Enhanced selective serotonin re-uptake inhibitors as antidepressants: 2004–2006. Expert Opin. Ther. Patents, 1 Aug 2007, 17 (8), 889–207. 426 kB. doi:10.1517/13543776.17.8.889

Thigpen, AL; DeRuiter, J; Clark, CR. GC-MS studies on the regioisomeric 2,3- and 3,4-methylenedioxyphenethylamines related to MDEA, MDMMA, and MBDB. J. Chromatogr. Sci., 1 May 2007, 45 (5), 229–235. 332 kB. doi:10.1093/chromsci/45.5.229

Garcia, EE. Unraveling the role of G-proteins in hallucinogenic drug action. Ph. D. Thesis, Vanderbilt University, Nashville, TN, USA, 1 May 2007. 3538 kB.

Sanclemente, ADLT. Hallucinogen drugs: Epidemiological estimates for the risk of a dependence syndrome emerging soon after onset of use. M. Sc. Thesis, Michigan State University, East Lansing, MI, USA, 2007. 1851 kB.

Langlitz, ND. Neuropsychedelia. The revival of hallucinogen research since the decade of the brain. Ph. D. Thesis, University of California, San Francisco, CA, USA, 2007. 5818 kB.

Reissig, CJ. The 5-HT1A receptor and hallucinogens. Ph. D. Thesis, State University of New York, Buffalo, NY, USA, 7 Sep 2006. 943 kB.

Nichols, DE. Commentary on: Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance by Griffiths et al. Psychopharmacology, 1 Aug 2006, 187 (3), 284–286. 71 kB. doi:10.1007/s00213-006-0458-4

Gouzoulis-Mayfrank, E; Daumann, J. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? Addiction, 1 Mar 2006, 101 (3), 348–261. 139 kB. doi:10.1111/j.1360-0443.2006.01314.x

Milhazes, N; Cunha-Oliveira, T; Martins, P; Garrido, J; Oliveira, C; Rego, AC; Borges, F. Synthesis and cytotoxic profile of 3,4-methylenedioxymethamphetamine (“Ecstasy”) and its metabolites on undifferentiated PC12 cells: A putative structure-toxicity relationship. Chem. Res. Toxicol., 2006, 19 (10), 1294–2304. 204 kB. doi:10.1021/tx060123i

Vepsäläinen, JJ; Auriola, S; Tukiainen, M; Ropponen, N; Callaway, JC. Isolation and characterization of yuremamine, a new phytoindole. Planta Med., 1 Oct 2005, 71 (11), 1053–2057.. 138 kB. doi:10.1055/s-2005-873131

Regina, MJ. Biochemical changes associated with serotonergic hallucinogens. Ph. D. Thesis, State University of New York, Buffalo, NY, USA, 1 Jun 2005. 3431 kB.

Wee, S; Anderson, KG; Rothman, RB; Bough, BE; Woolverton, WL. Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J. Pharmacol. Exp. Ther., 1 May 2005, 313 (2), 848–254. 171 kB. doi:10.1124/jpet.104.080101

Curtis, BD. The forensic toxicology of 2,5-dimethoxy-4-N-propylthiophenethylamine (2C-T-7). Ph. D. Thesis, University of Oklahoma, Oklahoma City, OK, USA, 2005. 726 kB.

Freudenmann, RW; Spitzer, M. Neuropsychopharmacology and toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA). CNS Drug Rev., 1 Jun 2004, 10 (2), 89–216. 187 kB. doi:10.1111/j.1527-3458.2004.tb00007.x

Dorsey, JM; Miranda, MG; Cozzi, NV; Pinney, KG. Synthesis and biological evaluation of 2-(4-fluorophenoxy)-2-phenyl-ethyl piperazines as serotonin-selective reuptake inhibitors with a potentially improved adverse reaction profile. Bioorg. Med. Chem., 15 Mar 2004, 12 (6), 1483–2491. 247 kB. doi:10.1016/j.bmc.2003.12.021

Foley, KF; Cozzi, NV. Novel aminopropiophenones as potential antidepressants. Drug Develop. Res., 1 Dec 2003, 60 (4), 252–260. 1588 kB. doi:10.1002/ddr.10297

May, JA; Chen, H; Rusinko, A; Lynch, VM; Sharif, NA; McLaughlin, MA. A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-Aminopropyl)-8,9-dihydropyrano[3,2-e]indole. J. Med. Chem., 2003, 46 (19), 4188–2195. 126 kB. doi:10.1021/jm030205t

Cordell, GA. The Simple Plant Isoquinolines (book review). J. Nat. Prod., 2003, 66 (6), 902. 24 kB. doi:10.1021/np0307035

Eckler, JR. Stimulus control by hallucinogens: SSRI interactions. Ph. D. Thesis, State University of New York, Buffalo, NY, USA, 20 Dec 2002. 2879 kB.

Foley, KF; Dort, MEV; Sievert, MK; Ruoho, AE; Cozzi, NV. Stereospecific inhibition of monoamine uptake transporters by meta-hydroxyephedrine isomers. J. Neural Transm., 1 Oct 2002, 109 (10), 1229–2240. 86 kB. doi:10.1007/s00702-002-0695-6

Hewitt, KA. Psychedelics and psychosis: LSD and changing ideas of mental illness, 1943-1966. Ph. D. Thesis, University of Texas, Austin, TX, USA, 1 Aug 2002. 1026 kB.

Winstock, AR; Wolff, K; Ramsey, J. 4-MTA: a new synthetic drug on the dance scene. Drug Alcohol Depend., 1 Jul 2002, 67 (2), 111–215. 102 kB. doi:10.1016/S0376-8716(02)00018-2

Glennon, RA; Young, R; Rangisetty, JB. Further characterization of the stimulus properties of 5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline. Pharmacol. Biochem. Behav., 1 May 2002, 72 (1–2), 379–287. 129 kB. doi:10.1016/j.pbb.2006.04.006

Young, R; Glennon, RA. The stimulus effect of 5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline is similar to that of cocaine but different from that of amphetamine. Pharmacol. Biochem. Behav., 1 Jan 2002, 71 (1–2), 205–213. 94 kB. doi:10.1016/S0091-3057(01)00666-9

Runyon, SP; Peddi, S; Savage, JE; Roth, BL; Glennon, RA; Westkaemper, RB. Geometry-affinity relationships of the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene. J. Med. Chem., 2002, 45 (8), 1656–2664. 140 kB. doi:10.1021/jm010354g

Strassman, RJ. Human psychopharmacology of N,N,-dimethyltryptamine. Behav. Brain Res., 15 Dec 1995, 73 (1–2), 121–124. 396 kB. doi:10.1016/0166-4328(96)00081-2

Lancelot, JC; Robba, M; Bonnet, JJ; Vaugeois, JM; Costentin, J. Synthesis and preliminary study of the activity of thiophene analogues of pyrovalerone on the neuronal uptake of the monoamines. Eur. J. Med. Chem., 1 Apr 1992, 27 (3), 297–200. 305 kB. doi:10.1016/0223-5234(92)90015-S

Oberlender, R; Nichols, DE. (+)-N-Methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a discriminative stimulus in studies of 3,4-methylenedioxymethamphetamine-like behavioral activity. J. Pharmacol. Exp. Ther., 1 Dec 1990, 255 (3), 1098–1106. 1876 kB.

Glennon, RA; Seggel, MR. Interaction of phenylisopropylamines with central 5-HT2 receptors. Analysis by quantitative structure-activity relationships. In Probing Bioactive Mechanisms; ACS Symposium Series; Magee, PS; Henry, DR; Block, JH, Eds., American Chemical Society, Washington, DC, 14 Nov 1989; Vol. 413, pp 264–280. 4445 kB. doi:10.1021/bk-1989-0413.ch018

Oberlender, R; Nichols, DE. Drug discrimination studies with MDMA and amphetamine. Psychopharmacology, 1 May 1988, 95 (1), 71–26. 674 kB. doi:10.1007/BF00212770

Titeler, M; Lyon, RA; Glennon, RA. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology, 1 Feb 1988, 94 (2), 213–216. 431 kB. doi:10.1007/BF00176847

Freedman, DX. Hallucinogenic drug research – if so, so what?: Symposium summary and commentary. Pharmacol. Biochem. Behav., 1 Feb 1986, 24 (2), 407–215. 1024 kB. doi:10.1016/0091-3057(86)90371-0

Nichols, DE; Schooler, D; Yeung, MC; Oberlender, RA; Zabik, JE. Unreliability of the rat stomach fundus as a predictor of hallucinogenic activity in substituted phenethylamines. Life Sci., 24 Sep 1984, 35 (13), 1343–2348. 326 kB. doi:10.1016/0024-3205(84)90390-4

Ferrigni, NR; Nichols, DE; Mclaughlin, JL; Bye, RA. Cactus alkaloids. XLVIII. Nα,Nα-dimethylhistamine, a hypotensive component of Echinocereus triglochidiatus. J. Ethnopharmacol., 1 May 1982, 5 (3), 359–264. 494 kB. doi:10.1016/0378-8741(82)90017-4

Pummangura, S; Nichols, DE; McLaughlin, JL. Cactus alkaloids XXXIII: β-Phenethylamines from the Guatemalan cactus Pilosocereus maxonii. J. Pharm. Sci., 1 Oct 1977, 66 (10), 1485–2487. 441 kB. doi:10.1002/jps.2600661037

Deniker, P; Lôo, H; Cuche, H; Houx, JM. Utilisation abusive par les toxicomanes d’un psycho-stimulant, la pyrovalérone (French). Ann. Méd.-Psychol., 27 Oct 1975, 2 (4), 745–748. 5196 kB.

Gorceix, A; Jacquemin, C. Intérêt du pyrovalérone dans le traitement ambulatoire des états de fatigue (French). Ann. Méd.-Psychol., 1970, 1970 (2), 624–632. 8223 kB.

Mogar, RE. Current status and future trends in psychedelic (LSD) research. J. Humanist. Psychol., 1 Oct 1965, 5 (2), 147–266. 2661 kB. doi:10.1177/002216786500500204

Meyers-Riggs, B. Leminger’s scalines. countyourculture: rational exploration of the underground, 4 May 2012.

Baumann, MH; Ayestas, MA; Partilla, JS; Sink, JR; Shulgin, AT; Daley, PF; Brandt, SD; Rothman, RB; Ruoho, AE; Cozzi, NV. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology, 1 Apr 2012, 37, 1192–1203. 763 kB. doi:10.1038/npp.2011.304

Meyers-Riggs, B. N-Alkylated tryptamines. countyourculture: rational exploration of the underground, 10 Mar 2012.

Meyers-Riggs, B. Alpha substituted tryptamines. countyourculture: rational exploration of the underground, 1 Mar 2012.

Schindler, EAD; Dave, KD; Smolock, EM; Aloyo, VJ; Harvey, JA. Serotonergic and dopaminergic distinctions in the behavioral pharmacology of (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Pharmacol. Biochem. Behav., 1 Mar 2012, 101 (1), 69–76. 722 kB. doi:10.1016/j.pbb.2011.12.002

Angoa-Pérez, M; Kane, MJ; Francescutti, DM; Sykes, KE; Shah, MM; Mohammed, AM; Thomas, DM; Kuhn, DM. Mephedrone, an abused psychoactive component of ‘bath salts’ and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J. Neurochem., 1 Mar 2012, 120 (6), 1097–1107. 777 kB. doi:10.1111/j.1471-4159.2011.07632.x

Brandt, SD; Daley, PF; Cozzi, NV. Analytical characterization of three trifluoromethyl-substituted methcathinone isomers. Drug Test. Anal., 24 Feb 2012. 346 kB. doi:10.1002/dta.382

Meyers-Riggs, B. Biosynthesis of 4-substituted tryptamine derivatives. countyourculture: rational exploration of the underground, 17 Feb 2012.

Kremer, C; Paulke, A; Wunder, C; Toennes, SW. Variable adverse effects in subjects are ingestion of equal doses of Argyreia nervosa seeds. Forensic Sci. Int., 10 Jan 2012, 214 (1–3), e6–e8. 220 kB. doi:10.1016/j.forsciint.2011.06.025

Maheux, CR; Copeland, CR. Chemical analysis of two new designer drugs: Buphedrone and pentedrone. Drug Test. Anal., 1 Jan 2012, 4 (1), 17–23. 314 kB. doi:10.1002/dta.385

Nichols, DE. Structure-activity relationships of serotonin 5-HT2A agonists. WIREs Membr. Transp. Signal, 1 Jan 2012. 573 kB. doi:10.1002/wmts.42

Brandt, SD; Tearavarich, R; Dempster, N; Cozzi, NV; Daley, PF. Synthesis and characterization of 5-methoxy-2-methyl-N,N-dialkylated tryptamines. Drug Test. Anal., 1 Jan 2012, 4 (1), 24–32. 506 kB. doi:10.1002/dta.398

Trachsel, D. Fluorine in psychedelic phenethylamines. Drug Test. Anal., 13 Dec 2011. 1038 kB. doi:10.1002/dta.413

Meyers-Riggs, B. Grid biosynthesis of psilocybin. countyourculture: rational exploration of the underground, 5 Dec 2011.

Meyers-Riggs, B. Non-LSD ergoloids. countyourculture: rational exploration of the underground, 1 Dec 2011.

Anon. Personal communication of unpublished research. 1 Dec 2011.

McCorvy, JD; Harland, AA; Maglathlin, R; Nichols, DE. A 5-HT2C receptor antagonist potentiates a low dose amphetamine-induced conditioned place preference. Neurosci. Lett., 7 Nov 2011, 505 (1), 10–13. 194 kB. doi:10.1016/j.neulet.2011.07.036

Power, JD; McGlynn, P; Clarke, K; McDermott, S; Kavanagh, PV; O’Brien, J. The analysis of substituted cathinones. Part 1: Chemical analysis of 2-, 3-, and 4-methylmethcathinone. Forensic Sci. Int., 10 Oct 2011, 212 (1–3), 6–12. 1032 kB. doi:10.1016/j.forsciint.2011.04.020

Santali, EY; Cadogan, A; Daeid, NN; Savage, KA; Sutcliffe, OB. Synthesis, full chemical characterisation and development of validated methods for the quantification of (±)-4′-methylmethcathinone (mephedrone): a new “legal high” J. Pharm. Biomed. Anal., 10 Sep 2011, 56 (2), 246–255. 705 kB. doi:10.1016/j.jpba.2011.05.022

Halberstadt, AL; Geyer, MA. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 1 Sep 2011, 61 (3) 364–381. 817 kB. doi:10.1016/j.neuropharm.2011.01.017

Marona-Lewicka, D; Nichols, CD; Nichols, DE. An animal model of schizophrenia based on chronic LSD administration: Old idea, new results. Neuropharmacology, 1 Sep 2011, 61 (3), 503–512. 803 kB. doi:10.1016/j.neuropharm.2011.02.006

Brandt, SD; Freeman, S; Sumnall, HR; Measham, F; Cole, JC. Analysis of NRG ‘legal highs’ in the UK: Identification and formation of novel cathinones. Drug Test. Anal., 1 Sep 2011, 3 (9), 569–575. 176 kB. doi:10.1002/dta.204

Tearavarich, R; Hahnvajanawong, V; Dempster, N; Daley, PF; Cozzi, NV; Brandt, SD. Microwave-accelerated preparation and analytical characterization of 5-ethoxy-N,N-dialkyl-[α,α,β,β-H4]- and [α,α,β,β-D4]-tryptamines. Drug Test. Anal., 1 Sep 2011, 3 (9), 597–608. 253 kB. doi:10.1002/dta.223

Jankovics, P; Váradi, A; Tölgyesi, L; Lohner, S; Németh-Palotás, J; Kőszegi-Szalai, H. Identification and characterization of the new designer drug 4′-methylethcathinone (4-MEC) and elaboration of a novel liquid chromatography-tandem mass spectrometry (LC-MS/MS) screening method for seven different methcathinone analogs. Forensic Sci. Int., 15 Jul 2011, 210 (1–3), 213–220. 899 kB. doi:10.1016/j.forsciint.2011.03.019

Russell, MJ; Bogun, B. New “party pill” components in New Zealand: The synthesis and analysis of some β-ketone analogues of 3,4-methylenedioxymethamphetamine (MDMA) including βk-DMBDB (β-ketone-N,N-dimethyl-1-(1,3-benzodioxol-5-yl)-2-butanamine). Forensic Sci. Int., 15 Jul 2011, 210 (1–3), 174–181. 1161 kB. doi:10.1016/j.forsciint.2011.03.005

Puerta, E; Aguirre, N. Methylenedioxymethamphetamine (MDMA, ‘Ecstasy’): Neurodegeneration versus neuromodulation. Pharmaceuticals, 5 Jul 2011, 4 (7), 992–1018. 411 kB. doi:10.3390/ph4070992

Shulgin, AT; Manning, T; Daley, PF. The Shulgin Index, Vol. 1, #76. MBDB. Erowid, 1 Jun 2011.

Meyers-Riggs, B. The mirrored magic of MDMA. countyourculture: rational exploration of the underground, 23 May 2011.

Moreno, JL; Holloway, T; Albizu, L; Sealfon, SC; González-Maeso, J. Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Neurosci. Lett., 15 Apr 2011, 493 (3), 76–79. 196 kB. doi:10.1016/j.neulet.2011.01.046

Meyers-Riggs, B. Shulgin’s sulfur symphony—part II. countyourculture: rational exploration of the underground, 3 Apr 2011.

Meyers-Riggs, B. 2C-T-x substitution size and potency. countyourculture: rational exploration of the underground, 1 Apr 2011.

Shulgin, AT; Manning, T; Daley, PF. The Shulgin Index, Vol. 1. Psychedelic Phenethylamines and Related Compounds, Transform Press, Berkeley, CA, 1 Mar 2011.

Meyers-Riggs, B. Shulgin’s sulfur symphony—part I. countyourculture: rational exploration of the underground, 15 Jan 2011.

Silva, ME; Heim, R; Strasser, A; Elz, S; Dove, S. Theoretical studies on the interaction of partial agonists with the 5-HT2A receptor. J. Comput. Aided Mol. Des., 1 Jan 2011, 25 (1), 51–66. 834 kB. doi:10.1007/s10822-010-9400-2

Meyers-Riggs, B. AIRCR jumps the shark. countyourculture: rational exploration of the underground, 30 Dec 2010.

Maheux, CR; Copeland, CR; Pollard, MM. Characterization of three methcathinone analogs: 4-methylmethcathinone, methylone, and bk-MBDB. Microgram J., 1 Dec 2010, 7 (2), 43–49. 765 kB.

Ettrup, A; Hansen, M; Santini, MA; Paine, J; Gillings, N; Palner, M; Lehel, S; Herth, MM; Madsen, J; Kristensen, JL; Begtrup, M; Knudsen, GM. Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers. Eur. J. Nucl. Med. Mol. Imaging, 1 Apr 2011, 38 (4), 681–693. 752 kB. doi:10.1007/s00259-010-1686-8

Ettrup, A. Serotonin receptor studies in the pig brain: Pharmacological intervention and positron emission tomography tracer development. Ph. D. Thesis, University of Copenhagen, 15 Nov 2010. 4971 kB.

Meyers-Riggs, B. Phenethylamine and amphetamine. countyourculture: rational exploration of the underground, 2 Nov 2010.

Brandt, SD; Wootton, RCR; Paoli, GD; Freeman, S. The naphyrone story: The alpha or beta-naphthyl isomer? Drug Test. Anal., 20 Oct 2010, 2 (10), 496–502. 413 kB. doi:10.1002/dta.185

Meyers-Riggs, B. The alkylated 2Cs. countyourculture: rational exploration of the underground, 4 Oct 2010.

Meyers-Riggs, B. The halogenated 2Cs. countyourculture: rational exploration of the underground, 29 Sep 2010.

Ogunbodede, O; McCombs, D; Trout, K; Daley, PF; Terry, M. New mescaline concentrations from 14 taxa/cultivars of Echinopsis spp. (Cactaceae) (“San Pedro”) and their relevance to shamanic practice. J. Ethnopharmacol., 15 Sep 2010, 131 (2), 356–362. 324 kB. doi:10.1016/j.jep.2010.07.021

Vollenweider, FX; Kometer, M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat. Rev. Neurosci., 1 Sep 2010, 11 (9), 642–651. 588 kB. doi:10.1038/nrn2884

Fox, MA; French, HT; LaPorte, JL; Blackler, AR; Murphy, DL. The serotonin 5-HT2A receptor agonist TCB-2: A behavioral and neurophysiological analysis. Psychopharmacology, 1 Sep 2010, 212 (1), 13–23. 240 kB. doi:10.1007/s00213-009-1694-1

Brandt, SD; Sumnall, HR; Measham, F; Cole, JC. Analyses of second-generation ‘legal highs’ in the UK: Initial findings. Drug Test. Anal., 1 Aug 2010, 2 (8), 377–382. 317 kB. doi:10.1002/dta.155

Iversen, LL. Consideration of the naphthylpyrovalerone analogues and related compounds, Advisory Council on the Misuse of Drugs, 7 Jul 2010.

Iversen, LL. Consideration of the cathinones, Advisory Council on the Misuse of Drugs, 31 Mar 2010.

Samoylenko, V; Rahman, MM; Tekwani, BL; Tripathi, LM; Wang, Y; Khan, SI; Khan, IA; Miller, LS; Joshi, VC; Muhammad, I. Banisteriopsis caapi, a unique combination of MAO inhibitory and antioxidative constituents for the activities relevant to neurodegenerative disorders and Parkinson’s disease. J. Ethnopharmacol., 3 Feb 2010, 127 (2), 357–367. 357 kB. doi:10.1016/j.jep.2009.10.030

Ray, TS. Psychedelics and the human receptorome. PLOS ONE, 2 Feb 2010, 5 (2), e9019. 791 kB. doi:10.1371/journal.pone.0009019

Shulgin, AT; Shulgin, A. The Shulgin Legacy Project. Alexander Shulgin Research Institute, 1 Jan 2010.

Camilleri, A; Johnston, MR; Brennan, M; Davis, S; Caldicott, DGE. Chemical analysis of four capsules containing the controlled substance analogues 4-methylmethcathinone, 2-fluoromethamphetamine, α-phthalimidopropiophenone and N-ethylcathinone. Forensic Sci. Int., 1 Jan 2010, in press. 736 kB. doi:10.1016/j.forsciint.2009.12.048

Al-Hossaini, AM. GC-MS and GC-IRD studies on ethoxyphenethylamines related to MDEA, MDMMA and MBDB. Ph. D. Thesis, Auburn University, Auburn, AL, USA, 18 Dec 2009. 1195 kB.

Cozzi, NV; Gopalakrishnan, A; Anderson, LL; Feih, JT; Shulgin, AT; Daley, PF; Ruoho, AE. Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter. J. Neural. Transm., 1 Dec 2009, 116 (12), 1591–1599. 420 kB. doi:10.1007/s00702-009-0308-8

Błachut, D; Wojtasiewicz, K; Czarnocki, Z; Szukalski, B. The analytical profile of some 4-methylthioamphetamine (4-MTA) homologues. Forensic Sci. Int., 20 Nov 2009, 192 (1–3) 98–114. 683 kB. doi:10.1016/j.forsciint.2009.08.009

Bunch, KS. Psilocybin and spiritual experience. Psy. D. Thesis, Alliant International University, San Francisco, CA, USA, 1 Aug 2009. 5715 kB.

Westphal, F; Junge, T; Girreser, U; Stobbe, S; Pérez, SB. Structure elucidation of a new designer benzylpiperazine: 4-Bromo-2,5-dimethoxybenzylpiperazine. Forensic Sci. Int., 30 May 2009, 187 (1–3), 87–96. 859 kB. doi:10.1016/j.forsciint.2009.03.003

Vilches-Herrera, M; Miranda-Sepúlveda, J; Rebolledo-Fuentes, M; Fierro, A; Lühr, S; Iturriaga-Vasquez, P; Cassels, BK; Reyes-Parada, M. Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg. Med. Chem., 15 Mar 2009, 17 (6), 2452–2460. 509 kB. doi:10.1016/j.bmc.2009.01.074

Fontanilla, D; Johannessen, M; Hajipour, AR; Cozzi, NV; Jackson, MB; Ruoho, AE. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science, 13 Feb 2009, 323 (5916):,934–937. 529 kB. doi:10.1126/science.1166127

Matzdorf, T. 5-Carboxamidotryptamin-derivate als liganden für 5-HT7- und 5-HT2A-rezeptoren: synthese und in-vitro-pharmakologie. Ph. D. Thesis, Universität Regensburg, Berlin, Germany, 23 Jan 2009. 1011 kB.

Archer, RP. Fluoromethcathinone, a new substance of abuse. Forensic Sci. Int., 1 Jan 2009, 185 (1–3), 10–20. 1355 kB. doi:10.1016/j.forsciint.2008.11.013

Rucker, VC; Ackerman, LJ. Interviewing scientists: Alexander Shulgin as a case study. Sci. Educ., 1 Jan 2009, 18 (1), 67–71. 116 kB. doi:10.1007/s11191-007-9096-4

Brandt, SD; Tirunarayanapuram, SS; Freeman, S; Dempster, N; Barker, SA; Daley, PF; Cozzi, NV; Martins, CPB. Microwave-accelerated synthesis of psychoactive deuterated N,N-dialkylated-[α,α,β,β-d4]-tryptamines. J. Labelled Compd. Radiopharm., 1 Nov 2008, 51 (14), 423–429. 169 kB. doi:10.1002/jlcr.1557

Blaazer, AR; Smid, P; Kruse, CG. Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT2A receptors. ChemMedChem, 15 Sep 2008, 3 (9), 1299–1309. 461 kB. doi:10.1002/cmdc.200800133

Silva, ME. Theoretical study of the interaction of agonists with the 5-HT2A receptor. Ph. D. Thesis, Universität Regensburg, Regensburg, Germany, 26 Aug 2008. 5904 kB.

Callaghan, PD. Comparative neuropharmacology of the substituted amphetamines, p-methoxyamphatamine (PMA) & 3,4-methylenedioxymethamphetamine (MDMA). Ph. D. Thesis, University of Adelaide, Adelaide, Australia, 1 Aug 2008. 1551 kB.

Prainer, B. Tryptamin-derivate als 5-HT4-rezeptorliganden: synthese und in-vitro-pharmakologie dissertation. Ph. D. Thesis, Universität Regensburg, Regensburg, Germany, 21 Jul 2008. 2220 kB. In German.

Yu, A. Indolealkylamines: Biotransformations and potential drug-drug interactions. AAPS PharmSci, 1 Jun 2008, 10 (2), 242–253. 314 kB. doi:10.1208/s12248-008-9028-5

Trachsel, D; Nichols, DE; Kidd, S; Hadorn, M; Baumberger, F. 4-Aryl-substituted 2,5-dimethoxyphenethylamines: Synthesis and serotonin 5-HT2A receptor affinities. Chem. Biodiv., 28 May 2008, 6 (5), 692–704. 271 kB. doi:10.1002/cbdv.200800235

Worsham, JN. 5-HT3 receptor ligands and their effect on psychomotor stimulants. M. Sc. Thesis, Virginia Commonwealth University, Richmond, VA, USA, 1 May 2008. 956 kB.

Zaitsu, K; Katagi, M; Kamata, H; Kamata, T; Shima, N; Miki, A; Iwamura, T; Tsuchihashi, H. Discrimination and identification of the six aromatic positional isomers of trimethoxyamphetamine (TMA) by gas chromatography-mass spectrometry (GC-MS). J. Mass Spectrom., 1 Apr 2008, 43 (4), 528–534. 147 kB. doi:10.1002/jms.1347

Passie, T; Halpern, JH; Stichtenoth, DO; Emrich, HM; Hintzen, A. The pharmacology of lysergic acid diethylamide: A review. CNS Neurosci. Ther., 1 Jan 2008, 14 (4), 295–314. 690 kB. doi:10.1111/j.1755-5949.2008.00059.x

Nichols, DE; Frescas, SP; Chemel, BR; Rehder, KS; Zhong, D; Lewin, AH. High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): A high-affinity 5-HT2A receptor-selective agonist radioligand. Bioorg. Med. Chem., 1 Jan 2008, 16 (10), 6116–6123. 251 kB. doi:10.1016/j.bmc.2008.04.050

Schultz, DM; Prescher, JA; Kidd, S; Marona-Lewicka, D; Nichols, DE; Monte, A. ‘Hybrid’ benzofuran–benzopyran congeners as rigid analogs of hallucinogenic phenethylamines. Bioorg. Med. Chem., 1 Jan 2008, 16 (11), 6242–6251. 228 kB. doi:10.1016/j.bmc.2008.04.030

Parker, MA; Kurrasch, DM; Nichols, DE. The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg. Med. Chem., 1 Jan 2008, 16 (8), 4661–4669. 296 kB. doi:10.1016/j.bmc.2008.02.033

Nichols, DE; Nichols, CD. Serotonin receptors. Chem. Rev., 1 Jan 2008, 108 (5), 1614–1641. 2918 kB. doi:10.1021/cr078224o

Ewald, AH. The 2,5-Dimethoxyamphetamines—A new class of designer drugs. Ph. D. Thesis, Universität des Saarlandes, Saarbrücken, Germany, 1 Jan 2008. 195 kB.

Cozzi, NV; Shulgin, AT; Daley, PF; Gopalakrishnan, A; Anderson, LL; Feih, JT; Ruoho, AE. Psychoactive N,N-dialkyltryptamines modulate serotonin transport by at least two mechanisms. Soc. Neurosci. Abs., 1 Jan 2008, 536.17. 52 kB.

Costa, JL; Wang, AY; Micke, GA; Maldaner, AO; Romano, RL; Martins-Júnior, HA; Neto, ON; Magg, MF. Chemical identification of 2,5-dimethoxy-4-bromoamphetamine (DOB). Forensic Sci. Int., 20 Dec 2007, 173 (2–3), 130–136. 285 kB. doi:10.1016/j.forsciint.2007.02.018

Collins, M; Heagney, A; Cordaro, F; Odgers, D; Tarrant, G; Stewart, S. Methyl 3-[3′,4′-(methylenedioxy)phenyl]-2-methyl glycidate: an ecstasy precursor seized in Sydney, Australia. J. Forensic Sci., 1 Jul 2007, 52 (4), 898–903. 714 kB. doi:10.1111/j.1556-4029.2007.00480.x

Moya, PR; Berg, KA; Gutiérrez-Hernandez, MA; Sáez-Briones, P; Reyes-Parada, M; Cassels, BK; Clarke, WP. Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors. J. Pharmacol. Exp. Ther., 1 Jun 2007, 321 (3), 1054–1061. 188 kB. doi:10.1124/jpet.106.117507

Schumacher, M. Chirale arylmethoxytryptamine als 5-HT2B-Rezeptoragonisten: synthese, analytik und in-vitro-pharmakologie. Ph. D. Thesis, Universität Regensburg, Würzburg, Germany, 16 Mar 2007. 2194 kB. In German.

Cao, R; Peng, W; Wang, Z; Xu, A. β-Carboline alkaloids: Biochemical and pharmacological functions. Curr. Med. Chem., 1 Jan 2007, 14 (4), 479–500. 579 kB. doi:10.2174/092986707779940998

Marona-Lewicka, D; Nichols, DE. Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action. Pharmacol. Biochem. Behav., 1 Jan 2007, 87 (4), 453–461. 266 kB. doi:10.1016/j.pbb.2007.06.001

Selken, J; Nichols, DE. α1-Adrenergic receptors mediate the locomotor response to systemic administration of (±)-3,4-methylenedioxymethamphetamine (MDMA) in rats. Pharmacol. Biochem. Behav., 1 Jan 2007, 86 (4), 622–630. 1005 kB. doi:10.1016/j.pbb.2007.02.006

Urban, JD; Clarke, WP; Zastrow, M; Nichols, DE; Kobilka, B; Weinstein, H; Javitch, JA; Roth, BL; Christopoulos, A; Sexton, PM; Miller, KJ; . Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther., 1 Jan 2007, 320 (1), 1–13. 506 kB. doi:10.1124/jpet.106.104463

Braden, MR; Nichols, DE. Assessment of the roles of serines 5.43(239) and 5.46(242) for binding and potency of agonist ligands at the human serotonin 5-HT2A receptor. Mol. Pharmacol., 1 Jan 2007, 72 (5), 1200–1209. 487 kB. doi:10.1124/mol.107.039255

Barreto, RL; Nascimbem, LBLR; Correiaa, CRD. Synthesis of the 3-(3,4,5-trimethoxyphenyl)-pyrrolidine: a new conformationally constrained mescaline analogue. Synth. Commun., 1 Jan 2007, 37 (12), 2011–2018. 76 kB. doi:10.1080/00397910701356504

Trout, K. Some Simple Tryptamines, 2nd ed., Better Days Publishing, 1 Jan 2007.

Braden, MR. Towards a biophysical understanding of hallucinogen action. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 2007. 8442 kB.

Zaitsu, K; Katagi, M; Kamata, T; Kamata, H; Shima, N; Tsuchihashi, H; Hayashi, T; Kuroki, H; Matoba, R. Determination of a newly encountered designer drug “p-methoxyethylamphetamine” and its metabolites in human urine and blood. Forensic Sci. Int., 1 Jan 2007, 177 (1), 77–84. 226 kB. doi:10.1016/j.forsciint.2007.11.001

Westphal, F; Junge, T; Rösner, P; Fritschi, G; Kleinc, B; Girreser, U. Mass spectral and NMR spectral data of two new designer drugs with an α-aminophenone structure: 4′-Methyl-α-pyrrolidinohexanophenone and 4′-methyl-α-pyrrolidinobutyrophenone. Forensic Sci. Int., 1 Jan 2007, 169 (1), 32–42. 1465 kB. doi:10.1016/j.forsciint.2006.07.024

Capela, JP; Macedo, C; Branco, PS; Ferreira, LM; Lobo, AM; Fernandes, E; Remião, F; Bastos, ML; Dirnagl, U; Meisel, A; Carvalho, FG. Neurotoxicity mechanisms of thioether Ecstasy metabolites. Neuroscience, 1 Jan 2007, 146, 1743–1757. 995 kB. doi:10.1016/j.neuroscience.2007.03.028

Theobald, DS. The 2C-series—A new class of designer drugs. Ph. D. Thesis, Universität des Saarlandes, Saarbrücken, Germany, 18 Dec 2006. 1370 kB.

Rothman, RB; Blough, BE; Baumann, MH. Dual dopamine-5-HT releasers: potential treatment agents for cocaine addiction. Trends Pharmacol. Sci., 1 Dec 2006, 27 (12), 612–618. 519 kB. doi:10.1016/j.tips.2006.10.006

Callaway, JC; Grob, CS; McKenna, DJ; Nichols, DE; Shulgin, AT; Tupper, KW; Sklerov, JH; Levine, B; Moore, KA. A demand for clarity regarding a case report on the ingestion of 5-methoxy-N, N-Dimethyltryptamine (5-MeO-DMT) in an Ayahuasca preparation. J. Anal. Toxicol., 1 Jul 2006, 30 (6), 406–407. 53 kB. doi:10.1093/jat/30.6.406

Sard, HP; Shuster, L; Roth, B; Morency, C; Kumaran, G. Indole compounds useful as serotonin selective agents. U.S. Patent 2006/0100266, 11 May 2006. 1261 kB.

Trachsel, D; Hadorn, M; Baumberger, F. Synthesis of fluoro analogues of 3,4-(methylenedioxy)amphetamine (MDA) and Its derivatives. Chem. Biodiv., 23 Mar 2006, 3 (3), 326–336. 106 kB. doi:10.1002/cbdv.200690035

Tanaka, E; Kamata, T; Katagi, M; Tsuchihashi, H; Honda, K. A fatal poisoning with 5-methoxy-N,N-diisopropyltryptamine, Foxy. Forensic Sci. Int., 1 Jan 2006, 163 (1), 152–154. 105 kB. doi:10.1016/j.forsciint.2005.11.026

Shulgin, AT. Forward. In Chemical Warfare Secrets Almost Forgotten; Ketchum, JS, ChemBooks Inc, Santa Rosa, CA, 1 Jan 2006; . 40 kB.

McLean, TH; Chambers, JJ; Parrish, JC; Braden, MR; Marona-Lewicka, D; Kurrasch-Orbaugh, D; Nichols, DE. C-(4,5,6-trimethoxyindan-1-yl)methanamine: A mescaline analogue designed using a homology model of the 5-HT2A receptor (additions and corrections). J. Med. Chem., 1 Jan 2006, 49 (25), 7558–7558. 51 kB. doi:10.1021/jm0612259

Braden, MR; Parrish, JC; Naylor, JC; Nichols, DE. Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol. Pharmacol., 1 Jan 2006, 70 (6), 1956–1964. 361 kB. doi:10.1124/mol.106.028720

McLean, TH; Parrish, JC; Braden, MR; Marona-Lewicka, D; Gallardo-Godoy, A; Nichols, DE. 1-Aminomethylbenzocycloalkanes: Conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists. J. Med. Chem., 1 Jan 2006, 49 (19), 5794–5803. 522 kB. doi:10.1021/jm060656o

McLean, TH; Chambers, JJ; Parrish, JC; Braden, MR; Marona-Lewicka, D; Kurrasch-Orbaugh, D; Nichols, DE. C-(4,5,6-trimethoxyindan-1-yl)methanamine: A mescaline analogue designed using a homology model of the 5-HT2A receptor. J. Med. Chem., 1 Jan 2006, 49 (14), 4269–4274. 370 kB. doi:10.1021/jm060272y

Munro, TA. The chemistry of Salvia divinorum. Ph. D. Thesis, University of Melbourne, Australia, 1 Jan 2006. 6664 kB.

Schardl, CL; Panaccione, DG; Tudzynski, P. Ergot alkaloids—Biology and molecular biology. Alkaloids Chem. Biol., 1 Jan 2006, 63, 45–86. 559 kB. doi:10.1016/S1099-4831(06)63002-2

Parrish, JC. Toward a molecular understanding of hallucinogen action. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 2006. 5475 kB.

Tsujikawa, K; Mohri, H; Kuwayama, K; Miyaguchi, H; Iwata, YT; Gohda, A; Fukushima, S; Inoue, H; Kishi, T. Analysis of hallucinogenic constituents in Amanita mushrooms circulated in Japan. Forensic Sci. Int., 1 Jan 2006, 164 (2–3), 172–178. 634 kB. doi:10.1016/j.forsciint.2006.01.004

Shulgin, AT. 4-Hydroxy-5-methoxy-N,N-dimethyltryptamine, Psilocybe mushrooms, psilocin. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 7 Dec 2005.

Fantegrossi, WE; Harrington, AW; Eckler, JR; Arshad, S; Rabin, RA; Winter, JC; Coop, A; Rice, KC; Woods, JH. Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats. Psychopharmacology, 1 Sep 2005, 181 (3), 496–503. 182 kB. doi:10.1007/s00213-005-0009-4

Shulgin, AT. Psychedelic science—How to prepare. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 2 Jun 2005.

Świst, M; Wilamowski, J; Zuba, D; Kochana, J; Parczewski, A. Determination of synthesis route of 1-(3,4-methylenedioxyphenyl)-2-propanone (MDP-2-P) based on impurity profiles of MDMA. Forensic Sci. Int., 10 May 2005, 149 (2–3), 181–192. 594 kB. doi:10.1016/j.forsciint.2004.06.016

Shulgin, AT. DOB and other possible prodrugs. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 3 May 2005.

Shulgin, AT. Ice, crank, speed or methamphetamine. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 6 Apr 2005.

Shulgin, AT. Drug testing hair for MDMA (Ecstasy). Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 4 Mar 2005.

Baumann, MH; Clark, RD; Budzynski, AG; Partilla, JS; Blough, BE; Rothman, RB. N-Substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or ‘Ecstasy’). Neuropsychopharmacology, 1 Mar 2005, 30 (3), 550–560. 184 kB. doi:10.1038/sj.npp.1300585

Torre, R; Farré, M; Monks, TJ; Jones, D. Response to Sprague and Nichols: Contribution of metabolic activation to MDMA neurotoxicity. Trends Pharmacol. Sci., 1 Feb 2005, 26 (2), 60–61. 60 kB. doi:10.1016/j.tips.2004.12.004

Sprague, JE; Nichols, DE. Neurotoxicity of MDMA (ecstasy): beyond metabolism. Trends Pharmacol. Sci., 1 Feb 2005, 26 (2), 59–60. 60 kB. doi:10.1016/j.tips.2004.12.001

Shulgin, AT. Dr. Shulgin Featured in New York Times Magazine. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 29 Jan 2005.

Shulgin, AT. Juul‘s giant cactus (aka Jewel‘s giant). Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 4 Jan 2005.

Wilson, JM; McGeorge, F; Smolinske, S; Meatherall, R. A foxy intoxication. Forensic Sci. Int., 1 Jan 2005, 148 (1), 31–36. 160 kB. doi:10.1016/j.forsciint.2004.04.017

Sard, H; Kumaran, G; Morency, C; Roth, BL; Toth, BA; Hec, P; Shuster, L. SAR of psilocybin analogs: Discovery of a selective 5-HT2C agonist. Bioorg. Med. Chem. Lett., 1 Jan 2005, 15 (20), 4555–4599. 134 kB. doi:10.1016/j.bmcl.2005.06.104

Shulgin, AT; Shulgin, A. Frontiers of Pharmacology: Chemistry and Consciousness. In Higher Wisdom: Eminent Elders Explore the Continuing Impact of Psychedelics; Walsh, R; Grob, CS, Eds., SUNY Press, 1 Jan 2005; pp 69–90. 3679 kB.

Shulgin, AT. Abused substances. Tech. Rev., 1 Jan 2005, August, 80–81. 415 kB.

Gallardo-Godoy, A; Fierro, A; McLean, TH; Castillo, M; Cassels, BK; Reyes-Parada, M; Nichols, DE. Sulfur-substituted α-alkyl phenethylamines as selective and reversible MAOA inhibitors: Biological activities, CoMFA analysis, and active site modeling. J. Med. Chem., 1 Jan 2005, 48 (7), 2407–2419. 901 kB. doi:10.1021/jm0493109

Brandt, SD; Freeman, S; Fleet, IA; Alder, JF. Analytical chemistry of synthetic routes to psychoactive tryptamines. Part III. Characterisation of the Speeter and Anthony route to N,N-dialkylated tryptamines using CI-IT-MS-MS. Analyst, 1 Jan 2005, 130 (9), 1258–1262. 250 kB. doi:10.1039/b504001a

Tsumura, Y; Mitome, T; Kimoto, S. False positives and false negatives with a cocaine-specific field test and modification of test protocol to reduce false decision. Forensic Sci. Int., 1 Jan 2005, 155 (2), 158–164. 320 kB. doi:10.1016/j.forsciint.2004.11.011

Shulgin, AT. Drug testing for mushrooms. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 1 Dec 2004.

Torre, R; Farré, M. Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol. Sci., 1 Oct 2004, 25 (10), 505–508. 104 kB. doi:10.1016/j.tips.2004.08.001

Casale, JF; McKibben, TD; Bozenko, JS; Hays, PA. Characterization of the “Indanylamphetamines” Microgram J., 1 Jan 2005, 3 (1–2), 3–10. 208 kB.

Shulgin, AT. Repeal the criminal drug laws. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 1 Sep 2004.

Shulgin, AT. Illegal research. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 1 Aug 2004.

Shulgin, AT. Nomenclature. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 1 Jul 2004.

Shulgin, AT. Cathinone. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 3 Jun 2004.

McKenna, DJ. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacol. Ther., 1 May 2004, 102 (2), 111–129. 443 kB. doi:10.1016/j.pharmthera.2004.03.002

Maurer, HH; Kraemer, T; Springer, D; Staack, RF. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (Ecstasy), piperazine, and pyrrolidinophenone types. A synopsis. Ther. Drug Monit., 1 Apr 2004, 26 (2), 127–131. 121 kB.

Shulgin, AT. Yaba (methamphetamine). Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 9 Mar 2004.

Shulgin, AT. LSD and pregnancy. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 28 Jan 2004.

Hendrickson, JB; Wang, J. A new synthesis of lysergic acid. Org. Lett., 1 Jan 2004, 6 (1), 3–5. 52 kB. doi:10.1021/ol0354369

Rösner, P; Quednow, B; Girreser, U; Junge, T. Isomeric fluoro-methoxy-phenylalkylamines: A new series of controlled-substance analogues (designer drugs). Forensic Sci. Int., 1 Jan 2004, 148 (2–3), 143–156. 282 kB. doi:10.1016/j.forsciint.2004.05.003

Baumgarten, HG; Lachenmayer, L. Serotonin neurotoxins—past and present. Neurotox. Res., 1 Jan 2004, 6 (7–8), 589–614. 402 kB. doi:10.1007/BF03033455

Osorio-Olivares, M; Rezende, MC; Sepúlveda-Boza, S; Cassels, BK; Fierro, A. MAO inhibition by arylisopropylamines: the effect of oxygen substituents at the β-position. Bioorg. Med. Chem., 1 Jan 2004, 12 (15), 4055–4066. 412 kB. doi:10.1016/j.bmc.2004.05.033

Glennon, RA; Bondarev, ML; Khorana, N; Young, R. β-Oxygenated analogues of the 5-HT2A serotonin receptor agonist 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane. J. Med. Chem., 1 Jan 2004, 47 (24), 6034–6041. 146 kB. doi:10.1021/jm040082s

Halpern, JH. Hallucinogens and dissociative agents naturally growing in the United States. Pharmacol. Ther., 1 Jan 2004, 102 (2), 131–138. 202 kB. doi:10.1016/j.pharmthera.2004.03.003

Heim, R. Synthesis and pharmacology of potent 5-HT2A receptor agonists with N-2-methoxybenzyl partial structure. SC. D. Thesis, Freie Universität, Berlin, 1 Jan 2004. In German.

Roman, DL; Saldaña, SN; Nichols, DE; Carroll, FI; Barker, EL. Distinct molecular recognition of psychostimulants by human and Drosophila serotonin transporters. J. Pharmacol. Exp. Ther., 1 Jan 2004, 308 (2), 679–687. 519 kB. doi:10.1124/jpet.103.057836

Nichols, DE. Hallucinogens. Pharmacol. Ther., 1 Jan 2004, 101 (2),131–181. 855 kB. doi:10.1016/j.pharmthera.2003.11.002

Rodríguez, GJ; Roman, DL; White, KJ; Nichols, DE; Barker, EL. Distinct recognition of substrates by the human and Drosophila serotonin transporters. J. Pharmacol. Exp. Ther., 1 Jan 2004, 306 (1), 338–346. 452 kB. doi:10.1124/jpet.103.048751

Shulgin, AT. Mushrooms and aeruginascin. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 21 Oct 2003.

Shulgin, AT. On the question of marijuana safety. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 22 Sep 2003.

Trachsel, D. Synthesis of novel (phenylalkyl)amines for the investigation of structure-activity relationships. Part 3. 4-Ethynyl-2,5-dimethoxyphenethylamine (= 4-Ethynyl-2,5-dimethoxybenzeneethanamine; 2C-YN). Helv. Chim. Acta, 28 Aug 2003, 86 (8), 2754–2759. 84 kB. doi:10.1002/hlca.200390224

Trachsel, D. Synthesis of novel (phenylalkyl)amines for the investigation of structure-activity relationships. Part 2. 4-Thio-substituted [2-(2,5-dimethoxyphenyl)ethyl]amines (=2,5-dimethoxybenzeneethanamines). Helv. Chim. Acta, 5 Aug 2003, 86 (7), 2610–2619. 133 kB. doi:10.1002/hlca.200390210 In German.

Shulgin, AT. Salvia divinorum, law, and medicine. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 23 Jul 2003.

Shulgin, AT. DXM (dextromethorphan). Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 9 Jul 2003.

Shulgin, AT. MDMA and its methylenedioxy ring. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 3 Jun 2003.

Shulgin, AT. MDMA variations & freedom of inquiry. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 24 Apr 2003.

Shulgin, AT. MMDA (MMDA-4). Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 11 Apr 2003.

Shulgin, AT. TMA, PMA, PMMA, and MDMA effects. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 27 Mar 2003.

Wolfson, P; Jacob, P; Shulgin, AT. Edible herbal compositions for relieving nicotine craving. U S. Patent 6,534,527, 18 Mar 2003. 216 kB.

Shulgin, AT. The Secret Chief and MAPS. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 12 Mar 2003.

Shulgin, AT. Psilocybe mushroom extractions. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 5 Mar 2003.

Shulgin, AT. Oxycontin, oxycodone, heroin. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 20 Feb 2003.

Shulgin, AT. 2,5-Dimethoxy-4-bromophenethylamine (2C-B). Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 7 Feb 2003.

Shulgin, AT. Taking MDMA (Ecstasy) and other drugs when pregnant. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 28 Jan 2003.

Eckler, JR; Chang-Fong, J; Rabin, RA; Smith, C; Teitler, M; Glennon, RA; Winter, JC. Behavioral characterization of 2-O-desmethyl and 5-O-desmethyl metabolites of the phenylethylamine hallucinogen DOM. Pharmacol. Biochem. Behav., 1 Jan 2003, 75 (4), 845–852. 294 kB. doi:10.1016/S0091-3057(03)00159-X

Shulgin, AT. Basic Pharmacology and Effects. In Hallucinogens. A Forensic Drug Handbook; Laing, R; Siegel, JA, Eds., Academic Press, London, 1 Jan 2003; pp 67–137. 6330 kB.

Chambers, JJ; Parrish, JC; Jensen, NH; Kurrasch-Orbaugh, DM; Marona-Lewicka, D; Nichols, DE. Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT2A/2C receptor ligands. J. Med. Chem., 1 Jan 2003, 46 (16), 3526–3535. 423 kB. doi:10.1021/jm030064v

Glennon, RA. Higher-end serotonin receptors: 5-HT5, 5-HT6 and 5-HT7. J. Med. Chem., 1 Jan 2003, 46 (14), 2795–2812. 335 kB. doi:10.1021/jm030030n

Green, AR; Mechan, AO; Elliott, JM; O’Shea, E; Colado, MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”). Pharmacol. Rev., 1 Jan 2003, 55 (3), 463–508. 544 kB. doi:10.1124/pr.55.3.3

Shulgin, AT. Datura, thornapple, atropine & scopolamine. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 31 Dec 2002.

Shulgin, AT. 5-Me-DMT or 5,N,N-TMT (5,N,N-trimethyltryptamine). Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 18 Nov 2002.

Gross, ST. Psychotropic drugs in developmental mushrooms: A case study review. J. Forensic Sci., 1 Nov 2002, 47 (6), 1–5. 369 kB. doi:10.1520/JFS15564J

Shulgin, AT. Morning glory seeds. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 17 Oct 2002.

Marona-Lewicka, D; Kurrasch-Orbaugh, DM; Selken, JR; Cumbay, MG; Lisnicchia, JG; Nichols, DE. Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioural effects overlap its other properties in rats. Psychopharmacology, 1 Oct 2002, 164 (1), 93–107. 293 kB. doi:10.1007/s00213-002-1141-z

Shulgin, AT. DMT and tryptophan. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 19 Sep 2002.

Shulgin, AT. Ecstasy pill testing. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 12 Sep 2002.

Shulgin, AT. Poppers. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 2 Aug 2002.

Shulgin, AT. Salvinorin A and the Analogue Act. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 12 Jul 2002.

Trachsel, D. Synthesis of novel (phenylalkyl)amines for the investigation of structure-activity relationships. Part 1. Mescalin derivatives. Helv. Chim. Acta, 21 Jun 2002, 85 (9), 3019–3026. 98 kB. doi:10.1002/1522-2675(200209)85:9<3019::AID-HLCA3019>3.0.CO;2-4 In German.

Shulgin, AT. Future psychedelics. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 12 Jun 2002.

Acuña-Castillo, C; Villalobos, C; Moya, PR; Sáez, P; Cassels, BK; Huidobro-Toro, JP. Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT2A and 5-HT2C receptors. Br. J. Pharmacol., 1 Jun 2002, 136 (4), 510–519. 232 kB. doi:10.1038/sj.bjp.0704747

Shulgin, AT. Salvinorin A. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 22 May 2002.

Shulgin, AT. Making MDMA (II): “Ecstasy”, MDMA, & Safrole. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 1 May 2002.

Shulgin, AT. MDMA (Ecstasy) tolerance. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 10 Apr 2002.

Shulgin, AT. Trimethoxylated amphetamine derivatives. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 14 Mar 2002.

Shulgin, AT. 5-Methoxy-N-ethyl-N-isopropyltryptamine, 5-MeO-MIPT, 5-MeO-DIPT, 5-MeO-EIPT. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 27 Feb 2002.

Shulgin, AT. Ayahuasca and MAO inhibitors. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 12 Feb 2002.

Wurst, M; Kysilka, R; Flieger, M. Psychoactive tryptamines from Basidiomycetes. Folia Microbiol., 1 Feb 2002, 47 (1), 3–27. 3077 kB. doi:10.1007/BF02818560

Shulgin, AT. More on the disregard syndrome (Letters). The Scientist, 21 Jan 2002, 16 (2), 13–13. 3183 kB.

Shulgin, AT. Salvia divinorum and Salvinorin-A receptor sites. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 9 Jan 2002.

Chambers, JJ; Kurrasch-Orbaugh, DM; Nichols, DE. Translocation of the 5-alkoxy substituent of 2,5-dialkoxyarylalkylamines to the 6-position: Effects on 5-HT2A/2C receptor affinity. Bioorg. Med. Chem. Lett., 1 Jan 2002, 12 (15), 1997–1999. 100 kB. doi:10.1016/S0960-894X(02)00306-2

Falk, EM; Cook, VJ; Nichols, DE; Sprague, JE. An antisense oligonucleotide targeted at MAO-B attenuates rat striatal serotonergic neurotoxicity induced by MDMA. Pharmacol. Biochem. Behav., 1 Jan 2002, 72 (3), 617–622. 120 kB. doi:10.1016/S0091-3057(02)00728-1

Shulgin, AT; Perry, WE. The Simple Plant Isoquinolines, Transform Press, Berkeley, CA, 1 Jan 2002.

Whiteside, MS; Kurrasch-Orbaugh, D; Marona-Lewicka, D; Nichols, DE; Monte, A. Substituted hexahydrobenzodipyrans as 5-HT2A/2C receptor probes. Bioorg. Med. Chem., 1 Jan 2002, 10 (10), 3301–3306. 141 kB. doi:10.1016/S0968-0896(02)00209-2

Shulgin, AT. Retro Flections. In The Politics of PsychoPharmacology; Leary, T, Ronin Publishing, Berkeley, CA, 1 Jan 2002; pp 5–9.

Rezende, MC; Núñez, C; Sepúlveda-Boza, S; Cassels, BK; Hurtado-Guzmán, C. S-Oxidation products of alkylthioamphetamines. Synth. Commun., 1 Jan 2002, 32 (17), 2741–2750. 225 kB. doi:10.1081/SCC-120006041

Freeman, S; Alder, JF. Arylethylamine psychotropic recreational drugs: A chemical perspective. Eur. J. Med. Chem., 1 Jan 2002, 37 (7), 527–539. 256 kB. doi:10.1016/S0223-5234(02)01382-X

Yamada, F; Tamura, M; Hasegawa, A; Somei, M. Synthetic studies of psilocin analogs having either a formyl group or bromine atom at the 5- or 7-position. Chem. Pharm. Bull., 1 Jan 2002, 50 (1) 92–99. 107 kB. doi:10.1248/cpb.50.92

Nichols, DE; Frescas, SP; Marona-Lewicka, D; Kurrasch-Orbaugh, DM. Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD). J. Med. Chem., 1 Jan 2002, 45 (19), 4344–4349. 268 kB. doi:10.1021/jm020153s

Passie, T; Seifert, J; Schneider, U; Emrich, HM. The pharmacology of psilocybin. Addict. Biol., 1 Jan 2002, 7 (4), 357–364. 184 kB. doi:10.1080/135562102100000593

Chambers, JJ. Use of conformationally-restricted analogues and homology modeling to provide insight into the nature of the 5-HT2A receptor agonist binding site. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 2002. 8389 kB.

Shulgin, AT. Salvia divinorum cuttings. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 12 Dec 2001.

Shulgin, AT. Psychedelics and anaesthetics. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 29 Nov 2001.

Shulgin, AT. Peyote and MAO inhibitors. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 14 Nov 2001.

Shulgin, AT. MDMA (Ecstasy) and holes in the brain. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 30 Oct 2001.

Shulgin, AT. MDMA (Ecstasy) testing and Marquis reagent. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 5 Oct 2001.

Shulgin, AT. Acacias and natural amphetamine. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 21 Sep 2001.

Shulgin, AT. Roadblocks to entheogen research. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 12 Sep 2001.

Ott, J. Pharmanopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine. J. Psychoactive Drugs, 1 Sep 2001, 33 (3), 273–281. 1158 kB. doi:10.1080/02791072.2001.10400574

Shulgin, AT. MDMA isomers. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 27 Aug 2001.

Shulgin, AT. Favorite music. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 14 Aug 2001.

Shulgin, AT. Salvia divinorum seeds and growing. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 20 Jul 2001.

Shulgin, AT. Entheogens—significance and future. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 11 Jul 2001.

Shulgin, AT. 2C-T-7. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 28 Jun 2001.

Shulgin, AT. Entheogens and education. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 30 May 2001.

Shulgin, AT. Tryptamines in Phalaris & phenethylamines in cacti. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 15 May 2001.

Shulgin, AT. Thought policing MDMA users (AB 1416). Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 20 Apr 2001.

Shulgin, AT. THC and lichens. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 2 Apr 2001.

Shulgin, AT. Making MDA, MDEA, MDMA. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 15 Mar 2001.

Shulgin, AT. Parahexl. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 7 Mar 2001.

Shulgin, AT. LSD Flashbacks. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 1 Mar 2001.

Shulgin, AT. PMA. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 20 Feb 2001.

Shulgin, AT. MDMA (Ecstasy) v. Methamphetamine. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 15 Feb 2001.

Toad. 4-Acetoxy-DET primer. Erowid, 1 Jan 2001.

Laban, U; Kurrasch-Orbaugh, D; Marona-Lewicka, D; Nichols, DE. A novel fluorinated tryptamine with highly potent serotonin 5-HT1A receptor agonist properties. Bioorg. Med. Chem. Lett., 1 Jan 2001, 11 (6), 793–795. 102 kB. doi:10.1016/S0960-894X(01)00062-2

Kalant, H. The pharmacology and toxicology of “Ecstasy” (MDMA) and related drugs. CMAJ, 1 Jan 2001, 165 (7), 917–928. 253 kB.

Shulgin, AT. A scientist‘s view of miracles and magic. In Psychoactive Sacramentals: Essays on Entheogens and Religion; Roberts, TB, Ed., Council on Spiritual Practices, San Francisco, CA, 1 Jan 2001; pp 113–119.

Rangisetty, JB; Dukat, M; Dowd, CS; Herrick-Davis, K; DuPre, A; Gadepalli, S; Teitler, M; Kelley, CR; Sharif, NA; Glennon, RA. 1-[2-Methoxy-5-(3-phenylpropyl)]-2-aminopropane unexpectedly shows 5-HT2A serotonin receptor affinity and antagonist character. J. Med. Chem., 1 Jan 2001, 44 (20), 3283–3291. 115 kB. doi:10.1021/jm0100739

Dal Cason, TA. A re-examination of the mono-methoxy positional ring isomers of amphetamine, methamphetamine and phenyl-2-propanone. Forensic Sci. Int., 1 Jan 2001, 119 (3), 168–194. 678 kB. doi:10.1016/S0379-0738(00)00425-4

Chambers, JJ; Kurrasch-Orbaugh, DM; Parker, MA; Nichols, DE. Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT2A/2C receptor agonists. J. Med. Chem., 1 Jan 2001, 44 (6), 1003–1010. 337 kB. doi:10.1021/jm000491y

Acuña-Castillo, C; Scorza, C; Reyes-Parada, M; Cassels, BK; Huidobro-Toro, JP. ALEPH-2, a suspected anxiolytic and putative hallucinogenic phenylisopropylamine derivative, is a 5-HT2A and 5-HT2C receptor agonist. Life Sci., 17 Nov 2000, 67 (26), 3241–3247. 89 kB. doi:10.1016/S0024-3205(00)00906-1

Glennon, RA; Dukat, M; Grella, B; Hong, S; Costantino, L; Teitler, M; Smith, C; Egan, C; Davis, K; Mattson, MV. Binding of β-carbolines and related agents at serotonin (5-HT2 and 5-HT1A), dopamine (D2) and benzodiazepine receptors. Drug Alcohol Depend., 1 Aug 2000, 60 (2), 121–132. 276 kB. doi:10.1016/S0376-8716(99)00148-9

Gross, ST. Detecting psychoactive drugs in the developmental stages of mushrooms. J. Forensic Sci., 1 May 2000, 45 (3), 527–537. 6189 kB. doi:10.1520/JFS14725J

Shulgin, AT. Human toxicology of psychedelic drugs (Meeting abstract 24-TOXI). Amer. Chem. Soc. Abs., 26 Mar 2000, 219 (1), U477.

Winter, JC; Filipink, RA; Timineri, D; Helsley, SE; Rabin, RA. The paradox of 5-methoxy-N,N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors. Pharmacol. Biochem. Behav., 1 Jan 2000, 65 (1), 75–82. 157 kB. doi:10.1016/S0091-3057(99)00178-1

Blair, JB; Kurrasch-Orbaugh, D; Marona-Lewicka, D; Cumbay, MG; Watts, VJ; Barker, EL; Nichols, DE. Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J. Med. Chem., 1 Jan 2000, 43 (24), 4701–4710. 494 kB. doi:10.1021/jm000339w

McBride, MC. Bufotenine: Toward an understanding of possible psychoactive mechanisms. J. Psychoactive Drugs, 1 Jan 2000, 32 (3), 321–331. 1639 kB. doi:10.1080/02791072.2000.10400456

Shulgin, AT; Shulgin, A. Preface. In In Search of the Ultimate High; Saunders, N; Saunders, A; Pauli, M, Rider, London, 1 Jan 2000; pp 7–9. 232 kB.

Bentley, KW. β-Phenylethylamines and the isoquinoline alkaloids. Nat. Prod. Rep., 1 Jan 2000, 17 (3), 247–268. 686 kB. doi:10.1039/a900251k

Toad. 4-Acetoxy-DiPT primer. Erowid, 1 Nov 1999.

Gems, D. Alexander Shulgin and Ann Shulgin, PIHKAL, A chemical love story. Alexander Shulgin and Ann Shulgin, TIHKAL, The continuation (book reviews). Theor. Med. Bioeth., 1 Sep 1999, 20 (5), 477–479. 17 kB. doi:10.1023/A:1009922516904

Cozzi, NV; Sievert, MK; Shulgin, AT; Jacob, P; Ruoho, AE. Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Eur. J. Pharmacol., 1 Jan 1999, 381 (1), 63–69. 111 kB. doi:10.1016/S0014-2999(99)00538-5

Gerasimov, M; Marona-Lewicka, D; Kurrasch-Orbaugh, DM; Qandil, AM; Nichols, DE. Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain. J. Med. Chem., 1 Jan 1999, 42 (20), 4257–4263. 163 kB. doi:10.1021/jm990325u

Blair, JB; Marona-Lewicka, D; Kanthasamy, A; Lucaites, VL; Nelson, DL; Nichols, DE. Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine. J. Med. Chem., 1 Jan 1999, 42 (6), 1106–1111. 129 kB. doi:10.1021/jm980692q

Nichols, DE; Frescas, SP. Improvements to the Synthesis of Psilocybin and a Facile Method for Preparing the O-Acetyl Prodrug of Psilocin. Synthesis, 1 Jan 1999, 1999, 935–938. 1481 kB. doi:10.1055/s-1999-3490

Jacob, P; Yu, L; Shulgin, AT; Benowitz, NL. Minor tobacco alkaloids as biomarkers for tobacco use: Comparison of users of cigarettes, smokeless tobacco, cigars, and pipes. Am. J. Public Health, 1 Jan 1999, 89 (5), 731–736. 1737 kB. doi:10.2105/AJPH.89.5.731

Lieberman, JA; Mailman, RB; Duncan, G; Sikich, L; Chakos, M; Nichols, DE; Kraus, JE. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol. Psychiat., 1 Dec 1998, 44 (11), 1099–1117. 154 kB. doi:10.1016/S0006-3223(98)00187-5

Toad. DPT Primer. Erowid, 15 Nov 1998.

Nelson, DL; Lucaites, VL; Wainscott, DB; Glennon, RA. Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, 5-HT2B and 5-HT2C receptors. N-S. Arch. Pharmacol., 6 Sep 1998, 359 (1), 1–6. 66 kB. doi:10.1007/PL00005315

Shulgin, AT. Spoils of the Drug War. San Jose Mercury News, 10 Mar 1998. 342 kB.

Cozzi, NV; Frescas, SP; Marona-Lewicka, D; Huang, X; Nichols, DE. Indan analogs of fenfluramine and norfenfluramine have reduced neurotoxic potential. Pharmacol. Biochem. Behav., 1 Jan 1998, 59 (3), 709–715. 110 kB. doi:10.1016/S0091-3057(97)00557-1

Parker, MA; Marona-Lewicka, D; Lucaites, VL; Nelson, DL; Nichols, DE. A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor. J. Med. Chem., 1 Jan 1998, 41 (26), 5148–5149. 81 kB. doi:10.1021/jm9803525

Vangveravong, S; Kanthasamy, A; Lucaites, VL; Nelson, DL; Nichols, DE. Synthesis and serotonin receptor affinities of a series of trans-2-(indol-3-yl)cyclopropylamine derivatives. J. Med. Chem., 1 Jan 1998, 41 (25), 4995–5001. 140 kB. doi:10.1021/jm980318q

Monte, AP; Marona-Lewicka, D; Lewis, MM; Mailman, RB; Wainscott, DB; Nelson, DL; Nichols, DE. Substituted naphthofurans as hallucinogenic phenethylamine—ergoline hybrid molecules with unexpected muscarinic antagonist activity. J. Med. Chem., 1 Jan 1998, 41 (12), 2134–2145. 258 kB. doi:10.1021/jm980076u

Parker, MA; Marona-Lewicka, D; Kurrasch, D; Shulgin, AT; Nichols, DE. Synthesis and pharmacological evaluation of ring-methylated derivatives of 3,4-(methylenedioxy)amphetamine (MDA). J. Med. Chem., 1 Jan 1998, 41 (6), 1001–1005. 117 kB. doi:10.1021/jm9705925

Clement, BA; Goff, CM; Forbes, TDA. Toxic amines and alkaloids from Acacia rigidula. Phytochemistry, 1 Jan 1998, 49 (5), 1377–1380. 124 kB. doi:10.1016/S0031-9422(97)01022-4

Cozzi, NV; Shulgin, AT; Ruoho, AE. Methcathinone (MCAT) and 2-methylamino-1-(3,4-methylenedioxyphenyl)propan-1-one (MDMCAT) inhibit [3H]serotonin uptake into human platelets. Amer. Chem. Soc. Div. Med. Chem. Abs., 1 Jan 1998, 215, 152. 11 kB.

Lee, S. The total syntheses of ring-A substituted ergolines. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 1998. 4709 kB. Note: The structure for Ergoline seems to be 6-Methylergoline.

Cozzi, NV; Sievert, MK; Shulgin, AT; Jacob, P; Ruoho, AE. Methcathinone and 2-methylamino-1-(3,4-methylenedioxyphenyl)propan-1-one (methylone) selectively inhibit plasma membrane catecholamine reuptake transporters. Soc. Neurosci. Abs., 1 Jan 1998, 24, 341.8. 9 kB.

Ciprian-Ollivier, J; Cetkovich-Bakmas, MG. Altered consciousness states and endogenous psychoses: a common molecular pathway? Schizophr. Res., 19 Dec 1997, 28 (2–3), 257–265. 722 kB. doi:10.1039/S0920-9964(97)00116-3

Scorza, M; Carrau, C; Silveira, R; Zapata-Torres, G; Cassels, BK; Reyes-Parada, M. Monoamine oxidase inhibitory properties of some methoxylated and alkylthio amphetamine derivatives. Biochem. Pharmacol., 15 Dec 1997, 54 (12), 1361–1369. 697 kB. doi:10.1016/S0006-2952(97)00405-X

Dal Cason, TA; Young, R; Glennon, RA. Cathinone: An investigation of several N-alkyl and methylenedioxy-substituted analogs. Pharmacol. Biochem. Behav., 1 Jan 1997, 58 (4), 1109–1116. 97 kB. doi:10.1016/S0091-3057(97)00323-7

Shulgin, AT; Shulgin, A. TiHKAL: The Continuation, Transform Press, Berkeley, CA, 1 Jan 1997.

Monte, AP; Waldman, SR; Marona-Lewicka, D; Wainscott, DB; Nelson, DL; Sanders-Bush, E; Nichols, DE. Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives. J. Med. Chem., 1 Jan 1997, 40 (19), 2997–3008. 367 kB. doi:10.1021/jm970219x

Shulgin, AT; Shulgin, A. A new vocabulary. In Entheogens and the Future of Religion; Forte, R, Ed., Council on Spiritual Practices, San Francisco, CA, 1 Jan 1997; Vol. 5, pp 41–47.

Clement, BA; Goff, CM; Forbes, TDA. Toxic amines and alkaloids from Acacia berlandieri. Phytochemistry, 1 Jan 1997, 46 (2), 249–254. 435 kB. doi:10.1016/S0031-9422(97)00240-9

Achenbach, H; Benirschke, M; Torrenegra, R. Alkaloids and other compounds from seeds of Tabernaemontana cymosa. Phytochemistry, 1 Jan 1997, 45 (2), 325–335. 826 kB. doi:10.1016/S0031-9422(96)00645-0

Dal Cason, TA. The characterization of some 3,4-methylenedioxycathinone (MDCATH) homologs. Forensic Sci. Int., 1 Jan 1997, 87 (1), 9–53. 909 kB. doi:10.1016/S0379-0738(97)02133-6

Blair, JB. Synthesis and pharmacological evaluation of fluorinated hallucinogenic tryptamine analogs and thienopyrrole bioisosteres of N,N-dimethyltryptamine. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 1997. 3251 kB.

Jacob, P; Shulgin, AT. Preparation of novel N-substituted-2-amino-3′,4′-methylenedioxypropiophenones as anti-depressant and anti-parkinsonism agents. International patent WO 96/39133, 12 Dec 1996. 941 kB.

Reyes-Parada, M; Scorza, C; Romero, V; Silveira, R; Medina, JH; Andrus, D; Nichols, DE; Cassels, BK. (±)-1-(2,5-Dimethoxy-4-ethylthiophenyl)-2-aminopropane (ALEPH-2), a novel putative anxiolytic agent lacking affinity for benzodiazepine sites and serotonin-1A receptors. N-S. Arch. Pharmacol., 1 Nov 1996, 354 (5), 579–585. 1417 kB. doi:10.1007/BF00170831

Sprague, JE; Johnson, MP; Schmidt, CJ; Nichols, DE. Studies on the mechanism of p-chloroamphetamine neurotoxicity. Biochem. Pharmacol., 25 Oct 1996, 52 (8), 1271–1277. 859 kB. doi:10.1016/0006-2952(96)00482-0

Marona-Lewicka, D; Rhee, G; Sprague, JE; Nichols, DE. Reinforcing effects of certain serotonin-releasing amphetamine derivatives. Pharmacol. Biochem. Behav., 1 Jan 1996, 53 (1), 99–105. 1028 kB. doi:10.1016/0091-3057(95)00205-7

Waldman, SR; Monte, AP; Bracey, A; Nichols, DE. One-pot Claisen rearrangement/O-methylation/alkene isomerization in the synthesis of Ortho-methoxylated phenylisopropylamines. Tetrahedron Lett., 1 Jan 1996, 37 (44), 7880–7892. 246 kB. doi:10.1016/0040-4039(96)01807-2

Gerdes, JM; Keil, RN; Shulgin, AT; Mathis, CA. High pressure nucleophilic fluoride-ion substitution reactions: formation of fluoroalkylbenzenes. J. Fluorine Chem., 1 Jan 1996, 78 (2), 121–129. 900 kB. doi:10.1016/0022-1139(96)03417-3

Monte, AP; Marona-Lewicka, D; Parker, MA; Wainscott, DB; Nelson, DL; Nichols, DE. Dihydrobenzofuran analogues of hallucinogens. 3. 1 Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups. J. Med. Chem., 1 Jan 1996, 39 (15), 2953–2961. 290 kB. doi:10.1021/jm960199j

Nichols, DE; Monte, A; Huang, X; Marona-Lewicka, D. Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent. Behav. Brain Sci., 15 Dec 1995, 73 (1–2), 117–119. 267 kB. doi:10.1016/0166-4328(96)00080-0

Casale, JF; Hays, PA; Klein, RFX. Synthesis and characterization of the 2,3-methylenedioxyamphetamines. J. Forensic Sci., 1 May 1995, 40 (3), 391–400. 500 kB. doi:10.1520/JFS13793J

Oberlender, R; Ramachandran, PV; Johnson, MP; Huang, X; Nichols, DE. Effect of a chiral 4-alkyl substituent in hallucinogenic amphetamines. J. Med. Chem., 1 Jan 1995, 38 (18), 3593–3601. 1288 kB. doi:10.1021/jm00018a019

Galloway, G; Shulgin, AT; Kornfeld, H; Frederick, SL. Amphetamine, not MDMA, is associated with intracranial hemorrhage. J. Accid Emerg Med., 1 Jan 1995, 12 (3), 231–2. 428 kB. doi:10.1136/emj.12.3.231 The target of Sasha’s critique: Intracranial haemorrhage associated with ingestion of ‘Ecstasy’.

Monte, AP; Marona-Lewicka, D; Kanthasamy, A; Sanders-Bush, E; Nichols, DE. Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes. J. Med. Chem., 1 Jan 1995, 38 (6), 958–966. 1156 kB. doi:10.1021/jm00006a015

Glennon, RA; Young, R; Martin, BR; Dal Cason, TA. Methcathinone (“Cat”): An enantiomeric potency comparison. Pharmacol. Biochem. Behav., 1 Jan 1995, 50 (4) 601–606. 709 kB. doi:10.1016/0091-3057(94)00348-3

Marona-Lewicka, D; Rhee, G; Sprague, JE; Nichols, DE. Psychostimulant-like effects of p-fluoroamphetamine in the rat. Eur. J. Pharmacol., 1 Jan 1995, 287 (2), 105–113. 965 kB. doi:10.1016/0014-2999(95)00478-5

Watts, VJ; Mailman, RB; Lawler, CP; Neve, KA; Nichols, DE. LSD and structural analogs: Pharmacological evaluation at D1 dopamine receptors. Psychopharmacology, 1 Jan 1995, 118 (4), 401–409. 1367 kB. doi:10.1007/BF02245940

Torres, MA; Cassels, BK; Rezende, MC. The preparation of potentially psychoactive β-alkoxyphenethylamines. Synth. Commun., 1 Jan 1995, 25 (8), 1239–1247. 415 kB. doi:10.1080/00397919508012687

Vangveravong, S; Nichols, DE. Stereoselective synthesis of trans-2-(indol-3-yl)cyclopropylamines: Rigid tryptamine analogues. J. Org. Chem., 1 Jan 1995, 60 (11), 3409–3413. 654 kB. doi:10.1021/jo00116a028

Shulgin, AT. Entactogen research: An act of balance. In Worlds of Consciousness; Schlichting, M; Leuner, H, Eds., VWB, Berlin, 1 Jan 1995; pp 177–183.

Monte, AP; Marona-Lewicka, D; Cozzi, NV; Nelson, DL; Nichols, DE. Conformationally restricted tetrahydro-1-benzoxepin analogs of hallucinogenic phenethylamines. Med. Chem. Res., 1 Jan 1995, 5, 651–663. 2040 kB.

Glennon, RA; Dukat, M; El-Bermawy, M; Law, H; De Los Angeles, J; Teitler, M; King, A; Herrick-Davis, K. Influence of amine substituents on 5-HT2A versus 5-HT2C binding of phenylalkyl- and indolylalkylamines. J. Med. Chem., 1 Jun 1994, 37 (13), 1929–1935. 1058 kB. doi:10.1021/jm00039a004

Sprague, JE; Huang, X; Kanthasamy, A; Nichols, DE. Attenuation of 3,4-methylenedioxymethamphetamine (MDMA) induced neurotoxicity with the serotonin precursors tryptophan and 5-hydroxytryptophan. Life Sci., 1 Jan 1994, 55 (15), 1193–1198. 336 kB. doi:10.1016/0024-3205(94)00658-X

Huang, X; Marona-Lewicka, D; Pfaff, RC; Nichols, DE. Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives. Pharmacol. Biochem. Behav., 1 Jan 1994, 47 (3), 667–673. 650 kB. doi:10.1016/0091-3057(94)90172-4

Marona-Lewicka, D; Nichols, DE. Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan. Eur. J. Pharmacol., 1 Jan 1994, 258 (1–2), 1–13. 1252 kB. doi:10.1016/0014-2999(94)90051-5

Jara, AN; Torres, MA; Cassels, BK; Rezende, MC. Some fluoro and nitro analogues of hallucinogenic amphetamines. Synth. Commun., 1 Jan 1994, 24 (3), 417–426. 440 kB. doi:10.1080/00397919408011201 Rhodium.

Hegadoren, KM; Greenshaw, AJ; Baker, GB; Martin-lverson, MT; Lodge, BA; Soin, S. 4-Ethoxyamphetamine: effects on intracranial self-stimulation and in vitro uptake and release of 3H-dopamine and 3H-serotonin in the brains of rats. J. Psychiatry Neurosci., 1 Jan 1994, 19 (1), 57–62. 910 kB.

Jacob, P; Shulgin, AT. Structure-activity relationships of the classic hallucinogens and their analogs. In Hallucinogens: An update. NIDA Research Monograph 146; Lin, GC; Glennon, RA, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office, Washington, DC, 1 Jan 1994; pp 74–91. 51 kB.

Nichols, DE. Medicinal chemistry and structure-activity relationships. In Amphetamine and its Analogs; Cho, AK; Segal, DS, Eds., Academic Press, San Diego, CA, 1 Jan 1994; pp 3–41. 6868 kB.

Pfaff, RC; Huang, X; Marona-Lewicka, D; Oberlender, R; Nichols, DE. Lysergamides revisited. In Hallucinogens: An update. NIDA Research Monograph 146; Lin, GC; Glennon, RA, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office, Washington, DC, 1 Jan 1994; pp 52–73. 181 kB.

Cozzi, NV. Pharmacological studies of some psychoactive phenylalkylamines: entactogens, hallucinogens, and anorectics. Ph. D. Thesis, University Of Wisconsin-Madison, 1 Jan 1994. 10616 kB.

Nichols, DE; Frescas, SP; Marona-Lewicka, D; Huang, X; Roth, BL; Gudelsky, GA; Nash, JF. 1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: A potent serotonin 5-HT2A/2C agonist. J. Med. Chem., 1 Jan 1994, 37 (25), 4346–4351. 873 kB. doi:10.1021/jm00051a011

Krebs, KM; Geyer, MA. Behavioral characterization of alpha-ethyltryptamine, a tryptamine derivative with MDMA-like properties in rats. Psychopharmacology, 1 Dec 1993, 113 (2), 284–287. 472 kB. doi:10.1007/BF02245712

Monte, AP; Marona-Lewicka, D; Cozzi, NV; Nichols, DE. Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine. J. Med. Chem., 1 Jan 1993, 36 (23), 3700–3706. 1026 kB. doi:10.1021/jm00075a027

Stolaroff, MJ; Wells, CW. Preliminary results with new psychoactive agents 2C-T-2 and 2C-T-7. In Jahrbuch für Ethnomedizin und Bewußtseinsforschung (Yearbook of Ethnomedicine and the Study of Consciousness); Rätsch, C; Baker, J, Eds., 1 Jan 1993; Vol. 2, pp 99–117. 185 kB.

Huang, X; Nichols, DE. 5-HT2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits. Eur. J. Pharmacol., 1 Jan 1993, 238 (2–3), 291–296. 553 kB. doi:10.1016/0014-2999(93)90859-G

Jacob, P; Yu, L; Liang, G; Shulgin, AT; Benowitz, NL. Gas chromatographic-mass spectrometric method for determination of anabasine, anatabine and other tobacco alkaloids in urine of smokers and smokeless tobacco users. J. Chromatogr. Biomed. Applic., 1 Jan 1993, 619,49–61. 736 kB. doi:10.1016/0378-4347(93)80445-A

Shulgin, AT. Appendix 4: Annotated Bibliography. In E is for Ecstasy; Saunders, N, Nicholas Saunders, 14 Neal‘s Yard, London, 1 Jan 1993; pp 223–302.

Shulgin, AT. Controlled Substances. A Chemical & Legal Guide to the Federal Drug Laws, 2nd ed., Ronin Publishing, Berkeley, CA, 1 Jan 1992.

Huang, X; Marona-Lewicka, D; Nichols, DE. p-Methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent. Eur. J. Pharmacol., 1 Jan 1992, 229 (1), 31–38. 702 kB. doi:10.1016/0014-2999(92)90282-9

Jacob, P; Shulgin, AT; Yu, L; Benowitz, NL. Determination of the nicotine metabolite trans-3′-hydroxycotinine in urine of smokers using gas chromatography with nitrogen-selective detection or selected ion monitoring. J. Chromatogr. Biomed. Applic., 1 Jan 1992, 583, 145–154. 608 kB. doi:10.1016/0378-4347(92)80547-4

Macor, JE; Blake, J; Fox, CB; Johnson, C; Koe, BK; Lebel, LA; Morrone, JM; Ryan, K; Schmidt, AW; Schulz, DW; Zorn, SH. Synthesis and serotonergic pharmacology of the enantiomers of 3-[(N-methylpyrrolidin-2-yl)methyl]-5-methoxy-1H-indole: Discovery of stereogenic differentiation in the aminoethyl side chain of the neurotransmitter serotonin. J. Med. Chem., 1 Jan 1992, 35 (23), 4503–4505. 427 kB. doi:10.1039/jm00101a032

Tomaszewski, Z; Johnson, MP; Huang, X; Nichols, DE. Benzofuran bioisosteres of hallucinogenic tryptamines. J. Med. Chem., 1 Jan 1992, 35 (11), 2061–2064. 591 kB. doi:10.1021/jm00089a017

Oberlender, R; Pfaff, RC; Johnson, MP; Huang, X; Nichols, DE. Stereoselective LSD-like activity in d-lysergic acid amides of R- and S-2-aminobutane. J. Med. Chem., 1 Jan 1992, 35 (2), 203–211. 1143 kB. doi:10.1021/jm00080a001

Macor, JE; Fox, CB; Johnson, C; Koe, BK; Lebel, LA; Zorn, SH. 1-(2-Aminoethyl)-3-methyl-8,9-dihydropyrano[3,2-e]indole: A rotationally restricted phenolic analog of the neurotransmitter serotonin and agonist selective for serotonin (5-HT2-type) receptors. J. Med. Chem., 1 Jan 1992, 35 (20), 3625–3632. 1944 kB. doi:10.1021/jm00098a005

Peroutka, SJ; McCarthy, BG; Guan, X. 5-Benzyloxytryptamine: a relatively selective 5-hydroxytryptamine1D/1B agent. Life Sci., 1 Jan 1991, 49 (6), 409–418. 556 kB. doi:10.1016/0024-3205(91)90582-V

By, AW; Duhaime, R; Lodge, BA. The synthesis and spectra of 4-ethoxyamphetamine and its isomers. Forensic Sci. Int., 1 Jan 1991, 49 (2), 159–170. 494 kB. doi:10.1016/0379-0738(91)90075-T

Nichols, DE; Johnson, MP; Oberlender, R. 5-Iodo-2-aminoindan, a nonneurotoxic analogue of p-iodoamphetamine. Pharmacol. Biochem. Behav., 1 Jan 1991, 38 (1), 135–139. 456 kB. doi:10.1016/0091-3057(91)90601-W

Shulgin, AT; Shulgin, A; Jacob, P. Central nervous system (CNS) activity of two new psychoactive compounds (Letter to the editor re: 2C-T series). J. Psychoactive Drugs, 1 Jan 1991, 23 (1), 95–96. 2571 kB. doi:10.1080/02791072.1991.10472583

Wilson, WL. The identification and analysis of Canadian designer drugs. J. Forensic Sci. Soc., 1 Jan 1991, 31 (2), 233–237. 538 kB. doi:10.1016/S0015-7368(91)73147-2

Steele, TD; Brewster, WK; Johnson, MP; Nichols, DE; Yim, GKW. Assessment of the role of α-methylepinine in the neurotoxicity of MDMA. Pharmacol. Biochem. Behav., 1 Jan 1991, 38 (2), 345–351. 723 kB. doi:10.1016/0091-3057(91)90289-E

Nichols, DE; Oberlender, R; McKenna, DJ. Stereochemical aspects of hallucinogenesis. In Biochemistry and Physiology of Substance Abuse, Vol. 3; Watson, RR, Ed., CRC Press, Boca Raton, FL, 1 Jan 1991; . 44166 kB.

Johnson, MP; Huang, X; Nichols, DE. Serotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a nonneurotoxic 3,4-methylenedioxymethamphetamine (MDMA) analogue. Pharmacol. Biochem. Behav., 1 Jan 1991, 40 (4), 915–922. 845 kB. doi:10.1016/0091-3057(91)90106-C

Shulgin, AT. Designer drugs. Where we are, and where we are going. J. Forensic Sci. Soc., 1 Jan 1991, 31 (2), 231–232. 364 kB. doi:10.1016/S0015-7368(91)73146-0

Oberlender, R; Nichols, DE. Structural variation and (+)-amphetamine-like discriminative stimulus properties. Pharmacol. Biochem. Behav., 1 Jan 1991, 38 (3), 581–586. 586 kB. doi:10.1016/0091-3057(91)90017-V

Huang, X; Johnson, MP; Nichols, DE. Reduction in brain serotonin markers by α-ethyltryptamine (Monase). Eur. J. Pharmacol., 1 Jan 1991, 200 (1), 187–190. 420 kB. doi:10.1016/0014-2999(91)90686-K

McKenna, DJ; Guan, AM; Shulgin, AT. 3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine. Pharmacol. Biochem. Behav., 1 Jan 1991, 38 (3), 505–12. 783 kB. doi:10.1016/0091-3057(91)90005-M

Nash, JF; Nichols, DE. Microdialysis studies on 3,4-methylenedioxyamphetamine and structurally related analogues. Eur. J. Pharmacol., 1 Jan 1991, 200 (1), 53–58. 714 kB. doi:10.1016/0014-2999(91)90664-C

Johnson, MP; Conarty, PF; Nichols, DE. [3H]Monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues. Eur. J. Pharmacol., 1 Jan 1991, 200 (1), 9–16. 1107 kB. doi:10.1016/0014-2999(91)90659-E

Lodge, BA. Canadian designer drugs. J. Psychiatry Neurosci., 1 Jan 1991, 16 (5), 239–240. 239 kB.

Shulgin, AT; Shulgin, A. PiHKAL: A Chemical Love Story, Transform Press, Berkeley, CA, 1 Jan 1991.

Johnson, MP; Frescas, SP; Oberlender, R; Nichols, DE. Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: Similarities to 3,4-(methylenedioxy)methamphetamine (MDMA). J. Med. Chem., 1 Jan 1991, 34 (5), 1662–1668. 975 kB. doi:10.1021/jm00109a020

Nichols, DE; Snyder, SE; Oberlender, R; Johnson, MP; Huang, X. 2,3-Dihydrobenzofuran analogues of hallucinogenic phenethylamines. J. Med. Chem., 1 Jan 1991, 34 (1), 276–281. 833 kB. doi:10.1021/jm00105a043

Shulgin, AT. Future Drugs: The Next 10 Years. Drug Policy Letter, 1 Jan 1991, 8–10. 6000 kB.

Dal Cason, TA. An evaluation of the potential for clandestine manufacture of 3,4-methylenedioxyamphetamine (MDA) analogs and homologs. J. Forensic Sci., 1 May 1990, 35 (3), 675–697. 2235 kB. doi:10.1520/JFS12874J

Dowd, CS; Herrick-Davis, K; Egan, C; DuPre, A; Smith, C; Teitler, M; Glennon, RA. 1-[4-(3-Phenylalkyl)phenyl]-2-aminopropanes as 5-HT2A partial agonists. J. Med. Chem., 10 Aug 2000, 43 (16), 3074–3084. 271 kB. doi:10.1021/jm9906062

Seggel, MR; Yousif, MY; Lyon, RA; Titeler, M; Roth, BL; Suba, EA; Glennon, RA. A structure-affinity study of the binding of 4-substituted analogues of 1-(2,5-dimethoxyphenyl)-2-aminopropane at 5-HT2 serotonin receptors. J. Med. Chem., 1 Mar 1990, 33 (3), 1032–1036. 807 kB. doi:10.1021/jm00165a023

Jacob, P; Jones, RT; Benowitz, NL; Shulgin, AT; Lewis, ER; Elias-Baker, BA. Cocaine smokers excrete a pyrolysis product, anhydroecgonine methyl ester. Clin. Toxicol., 1 Jan 1990, 28 (1), 123–125. 182 kB. doi:10.3109/15563659008993484

Stolaroff, MJ. Letter to the editor (re: 2C-T-2 & 2C-T-7). J. Psychoactive Drugs, 1 Jan 1990, 22 (3), 379. 1090 kB. doi:10.1080/02791072.1990.10472568

Johnson, MP; Mathis, CA; Shulgin, AT; Hoffman, AJ; Nichols, DE. [125I]-2-(2,5-Dimethoxy-4-iodophenyl)aminoethane ([125I]-2C-I) as a label for the 5-HT2 receptor in rat frontal cortex. Pharmacol. Biochem. Behav., 1 Jan 1990, 35 (1), 211–217. 724 kB. doi:10.1016/0091-3057(90)90228-A

Johnson, MP; Nichols, DE. Comparative serotonin neurotoxicity of the stereoisomers of fenfluramine and norfenfluramine. Pharmacol. Biochem. Behav., 1 Jan 1990, 36 (1), 105–109. 521 kB. doi:10.1016/0091-3057(90)90133-3

Shulgin, AT. How similar is substantially similar? J. Forensic Sci., 1 Jan 1990, 35 (1), 8–10. 410 kB. doi:10.1520/JFS12796J Rhodium.

Jacob, P; Shulgin, AT; Benowitz, NL. Synthesis of (3′R,5′S)-trans-3′-hydroxycotinine, a major metabolite of nicotine. Metabolic formation of 3′-hydroxycotinine in humans is highly stereoselective. J. Med. Chem., 1 Jan 1990, 33 (7), 1888–1891. 590 kB. doi:10.1021/jm00169a009

Johnson, MP; Nuang, X; Oberlender, R; Nash, JF; Nichols, DE. Behavioral, biochemical and neurotoxicological actions of the α-ethyl homologue of p-chloroamphetamine. Eur. J. Pharmacol., 1 Jan 1990, 191 (1), 1–10. 1250 kB. doi:10.1016/0014-2999(90)94090-K

Nichols, DE; Brewster, WK; Johnson, MP; Oberlender, R; Riggs, RM. Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA). J. Med. Chem., 1 Jan 1990, 33 (2), 703–710. 1078 kB. doi:10.1021/jm00164a037

Nichols, DE; Oberlender, R. Structure-activity relationships of MDMA and related compounds: a new class of psychoactive agents? In Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA; Peroutka, S, Ed., Kluwer Academic Publishers, Norwell, MA, 1 Jan 1990; pp 105–131. 5442 kB.

Shulgin, AT. History of MDMA. In Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA; Peroutka, S, Ed., Kluwer Academic Publishers, Norwell, MA, 1 Jan 1990; pp 1–20. 3840 kB.

Shulgin, AT. Forensic Toxicology, University of California, BEHS 183, Kinko‘s, Berkeley, CA, 1 Jan 1990.

Glennon, RA; Chaurasia, C; Titeler, M. Binding of indolylalkylamines at 5-HT2 serotonin receptors: Examination of a hydrophobic binding region. J. Med. Chem., 1 Jan 1990, 33 (10), 2777–2784. 1248 kB. doi:10.1021/jm00172a016

Nichols, DE; Oberlender, R; Burris, K; Hoffman, AJ; Johnson, MP. Studies of dioxole ring substituted 3,4-methylenedioxyamphetamine (MDA) analogues. Pharmacol. Biochem. Behav., 1 Jan 1989, 34 (3), 571–576. 680 kB. doi:10.1016/0091-3057(89)90560-1

Johnson, MP; Nichols, DE. Neurotoxic effects of the alpha-ethyl homologue of MDMA following subacute administration. Pharmacol. Biochem. Behav., 1 Jan 1989, 33 (1), 105–108. 399 kB. doi:10.1016/0091-3057(89)90437-1

Steele, TD; Nichols, DE; Yim, GKW. MDMA transiently alters biogenic amines and metabolites in mouse brain and heart. Pharmacol. Biochem. Behav., 1 Jan 1989, 34 (2), 223–227. 477 kB. doi:10.1016/0091-3057(89)90303-1

Nichols, DE; Oberlender, R. Structure-activity relationships of MDMA-like substances. In Pharmacology and Toxicology of Amphetamine and Related Designer Drugs. NIDA Research Monograph 94; Asghar, K; Souza, ED, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office, Washington, DC, 1 Jan 1989; pp 12–40. 282 kB.

Gerdes, JM; Mathis, CA; Shulgin, AT. Synthesis of (±)-1-[2,5-dimethoxy-4-(β-fluoroethyl)phenyl]-2-aminopropane - an approach to F-18-labeled serotonin receptor probes (Meeting abstract 394-ORGN). Amer. Chem. Soc. Abs., 25 Sep 1988, 196, 394–ORGN.

Shulgin, AT. Development of a drug database: Hypercard is valuable in the construction of an intuitively usable and quickly distributed source of reference material (California Association of Criminalists 71st semi-annual seminar). J. Forensic Sci. Soc., 1 Jul 1988, 28 (4), 268–268. 490 kB. doi:10.1016/S0015-7368(88)72845-5

Shulgin, AT. An Annotated Bibliography Of The Scientific Literature Referring To MDMA (including a sampling of the popular literature), Alexander T. Shulgin, 1 Jul 1988.

Shulgin, AT. The Controlled Substances Act: A resource manual of the current status of the federal drug laws, Alexander T. Shulgin, 1 Apr 1988.

Lyon, RA; Titeler, M; Seggel, MR; Glennon, RA. Indolealkylamine analogs share 5-HT2 binding characteristics with phenylalkylamine hallucinogens. Eur. J. Pharmacol., 19 Jan 1988, 145 (3), 291–297. 533 kB. doi:10.1016/0014-2999(88)90432-3

Shulgin, AT. DIPT: The distortion of music. High Frontiers/Reality Hackers, 1 Jan 1988, 6, Winter, 27. 54 kB.

Gerdes, JM; Mathis, CA; Shulgin, AT. Synthesis of 1-[2′,5′-dimethoxy-4′-(p-β;-fluoroethyl)phenyl]-2-aminopropane: Studies related to 18F-labeled serotonin receptor ligands. Tetrahedron Lett., 1 Jan 1988, 129 (50), 6537–6540. 268 kB. doi:10.1016/S0040-4039(00)82391-6

Jansen, KLR; Prast, CJ. Psychoactive properties of mitragynine (kratom). J. Psychoactive Drugs, 1 Jan 1988, 20 (4), 455–457. 2807 kB. doi:10.1080/02791072.1988.10472519

Jacob, P; Benowitz, NL; Shulgin, AT. Recent studies of nicotine metabolism in humans. Pharmacol. Biochem. Behav., 1 Jan 1988, 30 (1), 249–253. 490 kB. doi:10.1016/0091-3057(88)90453-4

Nichols, DE; Lloyd, DH; Johnson, MP; Hoffman, AJ. Synthesis and serotonin receptor affinities of a series of enantiomers of α-methyltryptamines: Evidence for the binding conformation of tryptamines at serotonin 5-HT1B receptors. J. Med. Chem., 1 Jan 1988, 31 (7), 1406–1412. 1085 kB. doi:10.1021/jm00402a026

Glennon, RA; Titeler, M; Lyon, RA; Slusher, RM. N,N-Di-n-propylserotonin: Binding at serotonin binding sites and a comparison with 8-hydroxy-2-(di-n-propylamino)tetralin. J. Med. Chem., 1 Jan 1988, 31 (4), 867–870. 600 kB. doi:10.1021/jm00399a031

Arvidsson, L; Johansson, AM; Hacksell, U; Nilsson, JLG; Svensson, K; Hjorth, S; Magnusson, T; Carlsson, A; Lindberg, P; Andersson, B; Sanchez, D; Wikström, H; Sundell, S. N,N-Dialkylated monophenolic trans-2-phenylcyclopropylamines: Novel central 5-hydroxytryptamine receptor agonists. J. Med. Chem., 1 Jan 1988, 31 (1), 92–99. 1162 kB. doi:10.1021/jm00396a014

Buchanan, JF; Brown, CR. ‘Designer drugs’. A problem in clinical toxicology. Med. Toxicol. Adverse. Drug. Exp., 1 Jan 1988, 3 (1), 1–17. 1882 kB.

Jacob, P; Benowitz, NL; Shulgin, AT. Synthesis of optically pure deuterium-labelled nicotine, nornicotine and cotinine. J. Labelled Compd. Radiopharm., 17 Aug 1987, 25 (10), 1117–1128. 593 kB. doi:10.1002/jlcr.2580251009

Sargent, TW; Shulgin, AT; Mathis, CA. Rapid brain scanning pharmaceutical. U S. Patent 4,647,446, 3 Mar 1987. 619 kB.

Stone, DM; Johnson, M; Hanson, GR; Gibb, JW. A comparison of the neurotoxic potential of methylenedioxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives. Eur. J. Pharmacol., 10 Feb 1987, 134 (2), 245–248. 316 kB. doi:10.1016/0014-2999(87)90555-8

Shulgin, AT. Reference information on MDMA. Analog: Australian Forensic Drug Analysis Bulletin, 1 Jan 1987, 9 (4), 10.

McKenna, DJ; Mathis, CA; Shulgin, AT; Sargent, T; Saavedra, JM. Autoradiographic localization of binding sites for 125I-DOI, a new psychotomimetic radioligand, in the rat brain. Eur. J. Pharmacol., 1 Jan 1987, 137 (2–3), 289–290. 232 kB. doi:10.1016/0014-2999(87)90239-1

Shulgin, AT; Jacob, P; Benowitz, NL; Lau, D. Identification and quantitative analysis of cotinine-N-oxide in human urine. J. Chromatogr. Biomed. Applic., 1 Jan 1987, 423, 365–372. 540 kB. doi:10.1016/0378-4347(87)80365-1

Shulgin, AT. The ‘social-chemistry’ of pharmacological discovery. Social Pharmacology, 1 Jan 1987, 1 (3), 279–290. 3421 kB.

Johnson, MP; Hoffman, AJ; Nichols, DE. Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur. J. Pharmacol., 16 Dec 1986, 132 (2–3), 269–276. 559 kB. doi:10.1016/0014-2999(86)90615-1

Brown, CR; McKinney, H; Osterloh, JD; Shulgin, AT; Jacob, P; Olson, KR. Severe adverse reaction to 3,4-methylenedioxymethamphetamine (MDMA). Vet. Hum. Toxicol., 1 Oct 1986, 28 (5), 490. 239 kB.

Shulgin, AT. The Controlled Substances Act— Scheduled drugs and their illegal synthesis. Amer. Chem. Soc. Abs., 7 Sep 1986, 192, 10–CHAL.

Shulgin, AT. History and analysis of the current federal controlled substances act of 1970 (California Association of Criminalists 67th semi-annual seminar). J. Forensic Sci. Soc., 1 Sep 1986, 26 (5), 371–371. 779 kB. doi:10.1016/S0015-7368(86)72520-6

Mathis, CA; Shulgin, AT; Sargent, T. Synthesis of 122I- and 125I-labelled meta-dimethoxy-N,N-dimethyliodophenylisopropylamines. J. Labelled Compd. Radiopharm., 1 Feb 1986, 23 (2), 115–125. 445 kB. doi:10.1002/jlcr.2580230202 Rhodium.

Shulgin, AT; Shulgin, LA; Jacob, P. A protocol for the evaluation of new psychoactive drugs. Meth. Find. Exp. Clin. Pharmacol., 1 May 1986, 8 (5), 313. 7938 kB.

Shulgin, AT. The background and chemistry of MDMA. J. Psychoactive Drugs, 1 Jan 1986, 18 (4), 291–304. 13190 kB. doi:10.1080/02791072.1986.10472361

Nichols, DE. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: Entactogens. J. Psychoactive Drugs, 1 Jan 1986, 18 (4), 305–313. 10675 kB. doi:10.1080/02791072.1986.10472362

Mathis, CA; Shulgin, AT; Yano, Y; Sargent, T. [18F]-Labelled N,N-dimethylamphetamine analogues for brain imaging studies. Appl. Radiat. Isot., 1 Jan 1986, 37 (8), 865–872. 502 kB. doi:10.1016/0883-2889(86)90284-4

Jacob, P; Benowitz, NL; Yu, L; Shulgin, AT. Determination of nicotine N-oxide by gas chromatography following thermal conversion to 2-methyl-6-(3-pyridyl)tetrahydro-1,2-oxazine. Anal. Chem., 1 Jan 1986, 58 (11), 2218–2221. 7064 kB. doi:10.1021/ac00124a022

Nichols, DE; Hoffman, AJ; Oberlender, RA; Jacob, P; Shulgin, AT. Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: Representatives of a novel therapeutic class. J. Med. Chem., 1 Jan 1986, 29 (10), 2009–2015. 1024 kB. doi:10.1021/jm00160a035

Nichols, DE. Studies of the relationship between molecular structure and hallucinogenic activity. Pharmacol. Biochem. Behav., 1 Jan 1986, 24 (2), 335–340. 542 kB. doi:10.1016/0091-3057(86)90362-X

Nichols, DE; Hoffman, AJ; Oberlender, RA; Riggs, RM. Synthesis and evaluation of 2,3-dihydrobenzofuran analogues of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane: Drug discrimination studies in rats. J. Med. Chem., 1 Jan 1986, 29 (2), 302–304. 441 kB. doi:10.1021/jm00152a022

Menachery, MD; Lavanier, GL; Wetherly, ML; Guinaudeau, H; Shamma, M. Simple isoquinoline alkaloids. J. Nat. Prod., 1 Jan 1986, 49 (5), 745–778. 1488 kB. doi:10.1021/np50047a001

Trudeau, GB. Ecstasy: Whither the future? In Doonesbury Deluxe; , Henry Holt and Company, 19 Aug 1985; . 3328 kB.

Mathis, CA; Budinger, TF; Sargent, T; Shulgin, AT; Kung, HF. Generator produced I-122 labeled amines and diamines for brain blood flow measurements in neurologic disorders ( Proc. of the 32nd Annual Meeting of The Society of Nuclear Medicine. Poster session 442). J. Nucl. Med., 1 May 1985, 26 (5), P105. 178 kB.

Mathis, CA; Sargent, T; Shulgin, AT; Yano, Y; Budinger, TF; Lagunas-Solar, M. Synthesis and evaluation of meta-substituted I-122-labeled dimethoxy-N,N-dimethylamphetamines for brain imaging studies ( Proc. of the 32nd Annual Meeting of The Society of Nuclear Medicine. Scientific paper 287). J. Nucl. Med., 1 May 1985, 26 (5), P69. 177 kB.

Lemaire, D; Jacob, P; Shulgin, AT. Ring substituted beta-methoxyphenethylamines: a new class of psychotomimetic agents active in man. J. Pharm. Pharmacol., 1 Jan 1985, 37 (8), 575–7. 1767 kB. doi:10.1111/j.2042-7158.1985.tb03072.x

Mathis, CA; Sargent, T; Shulgin, AT. Iodine-122-labeled amphetamine derivative with potential for PET brain blood-flow studies. J. Nucl. Med., 1 Jan 1985, 26 (11), 1295–1301. 1182 kB.

Hoffman, AJ; Nichols, DE. Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. J. Med. Chem., 1 Jan 1985, 28 (9), 1252–1255. 583 kB. doi:10.1021/jm00147a022

Repke, DB; Grotjahn, DB; Shulgin, AT. Psychotomimetic N-methyl-N-isopropyltryptamines. Effects of variation of aromatic oxygen substituents. J. Med. Chem., 1 Jan 1985, 28 (7), 892–896. 711 kB. doi:10.1021/jm00145a007

Shulgin, AT. What is MDMA? PharmChem Newsletter, 1 Jan 1985, 14 (3), 3–11. 952 kB.

McKenna, DJ. Monoamine odixase inhibitors in Amazonian hallucinogenic plants: Ethnobotanical, phytochemical, and pharmacological investigations. Ph. D. Thesis, University of British Columbia, BC, Canada, 26 Apr 1984. 12211 kB.

Sargent, T; Shulgin, AT; Mathis, CA. New iodinated amphetamines by rapid synthesis for use as brain blood flow indicators. J. Labelled Compd. Radiopharm., 1 Jan 1984, 19 (11–12), 1307–1308. 84 kB. doi:10.1002/jlcr.2580191102

McKenna, DJ; Towers, HHN. Biochemistry and pharmacology of tryptamines and beta-carbolines: A minireview. J. Psychoactive Drugs, 1 Jan 1984, 16 (4), 347–358. 10809 kB. doi:10.1080/02791072.1984.10472305

Jacob, P; Savanapridi, C; Yu, L; Wilson, M; Shulgin, AT; Benowitz, NL; Elias-Baker, BA; Hall, SM; Herning, RI. Ion-pair extraction of thiocyanate from plasma and its gas chromatographic determination using on-column alkylation. Anal. Chem., 1 Jan 1984, 56 (9), 1692–1695. 577 kB. doi:10.1021/ac00273a036

Nichols, DE; Jadhav, KP; Oberlender, RA; Zabik, JE; Bossart, JF; Hamada, A; Miller, DD. Synthesis and evaluation of substituted 2-phenylcyclobutylamines as analogues of hallucinogenic phenethylamines: Lack of LSD-like biological activity. J. Med. Chem., 1 Jan 1984, 27 (9), 1108–1111. 617 kB. doi:10.1021/jm00375a004

Sargent, T; Shulgin, AT; Mathis, CA. Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography. J. Med. Chem., 1 Jan 1984, 27 (8), 1071–1077. 1859 kB. doi:10.1021/jm00374a023 Rhodium.

Jacob, P; Shulgin, AT. Sulfur analogues of psychotomimetic agents. 3. Ethyl homologues of mescaline and their monothioanalogues. J. Med. Chem., 1 Jan 1984, 27 (7), 881–887. 1213 kB. doi:10.1021/jm00373a013

Oberlender, RA; Kothari, PJ; Nichols, DE; Zabik, JE. Substituent branching in phenethylamine-type hallucinogens: A comparison of 1-[2,5-dimethoxy-4-(2-butyl)phenyl]-2-aminopropane and 1-[2,5-dimethoxy-4-(2-methylpropyl)phenyl]-2-aminopropane. J. Med. Chem., 1 Jan 1984, 27 (6), 788–792. 764 kB. doi:10.1021/jm00372a015

Glennon, RA; Young, R; Jacyno, JM. Indolealkylamine and phenalkylamine hallucinogens: Effect of α-methyl and N-methyl substituents on behavioral activity. Biochem. Pharmacol., 1 Apr 1983, 32 (7), 1267–1273. 591 kB. doi:10.1016/0006-2952(83)90281-2

Shulgin, AT. Twenty years on an ever-changing quest. In Psychedelic Reflections; Grinspoon, L; Bakalar, JB, Eds., Human Sciences Press, New York, 1 Jan 1983; pp 205–212. 1649 kB.

Meyer, BN; Helfrich, JS; Nichols, DE; McLaughlin, JL; Davis, DV; Cooks, RG. Cactus alkaloids. LIII. Coryphanthine and O-methyl-candicine, two new quaternary alkaloids from Coryphantha greenwoodii. J. Nat. Prod., 1 Jan 1983, 45 (5), 688–639. 442 kB. doi:10.1021/np50029a017

Jacob, P; Shulgin, AT. Sulfur analogs of psychotomimetic agents. 2. Analogs of (2,5-dimethoxy-4-methylphenyl)- and of (2,5-dimethoxy-4-ethylphenyl)isopropylamine. J. Med. Chem., 1 Jan 1983, 26 (5), 746–752. 1054 kB. doi:10.1021/jm00359a021

Kline, TB; Benington, F; Morin, RD; Beaton, JM; Glennon, RA; Domelsmith, LN; Houk, KN; Rozeboom, MD. Structure-activity relationships for hallucinogenic N,N-dialkyltryptamines: photoelectron spectra and serotonin receptor affinities of methylthio and methylenedioxy derivatives. J. Med. Chem., 1 Jan 1982, 25 (11), 1381–1383. 378 kB. doi:10.1021/jm00353a021

Kline, TB; Benington, F; Morin, RD; Beaton, JM. Structure-activity relationships in potentially hallucinogenic N,N-dialkyltryptamines substituted in the benzene moiety. J. Med. Chem., 1 Jan 1982, 25 (8), 908–913. 845 kB. doi:10.1021/jm00350a005

Hathaway, BA; Nichols, DE; Nichols, MB; Yim, GKW. A new, potent, conformationally-restricted analogue of amphetamine: 2-amino-1,2-dihydronaphthalene. J. Med. Chem., 1 Jan 1982, 25 (5), 535–538. 563 kB. doi:10.1021/jm00347a011

Nichols, DE; Lloyd, DH; Hoffman, AJ; Nichols, MB; Yim, GKW. Effects of certain hallucinogenic amphetamine analogues on the release of [3H]-serotonin from rat brain synaptosomes. J. Med. Chem., 1 Jan 1982, 25 (5), 530–535. 804 kB. doi:10.1021/jm00347a010

Jacob, JN; Nichols, DE. Isomeric cyclopropyl ring-methylated homologues of trans-2-(2,5-dimethoxy-4-methylphenyl)cyclopropylamine, an hallucinogen analogue. J. Med. Chem., 1 Jan 1982, 25 (5), 526–530. 732 kB. doi:10.1021/jm00347a009

Glennon, RA; Liebowitz, SM. Serotonin receptor affinity of cathinone and related analogues. J. Med. Chem., 1 Jan 1982, 25 (4), 393–397. 665 kB. doi:10.1021/jm00346a012

Shulgin, AT; Jacob, P. 1-(3,4-Methylenedioxyphenyl)-3-aminobutane: A potential toxicological problem. Clin. Toxicol., 1 Jan 1982, 19 (1),109–110. 77 kB. doi:10.3109/15563658208990371

Cheng, AC; Shulgin, AT; Castagnoli, N. Studies on the chemical reactivity of the quinone methide derived from the oxidative cyclization of α-methyl-3,4-dihydroxyphenylalanine ethyl ester. J. Org. Chem., 1 Jan 1982, 47 (27), 5258–5262. 710 kB. doi:10.1021/jo00148a007

Shulgin, AT. Chemistry of psychotomimetics. In Handbook of Experimental Pharmacology. Psychotropic Agents, Part III: Alcohol and Psychotomimetics, Psychotropic Effects of Central Acting Drugs; Hoffmeister, F; Stille, G, Eds., Springer-Verlag, Berlin, 1 Jan 1982; Vol. 55 (3), pp 3–29. 29651 kB.

Shulgin, AT; Jacob, P. Potential misrepresentation of 3,4-methylene-dioxyamphetamine (MDA). A toxicological warning. J. Anal. Toxicol., 1 Jan 1982, 6 (2), 71–75. 5581 kB. doi:10.1093/jat/6.2.71

Pummangura, S; McLaughlin, JL; Davis, DV; Cooks, RG. Cactus alkaloids. XLIX. New trace alkaloids (dehydrosalsolidine and heliamine) from the Saguaro, Carnegiea gigantea, and confirmation by MIKES (MS\MS). J. Nat. Prod., 1 Jan 1982, 45 (3), 277–282. 457 kB. doi:10.1021/np50021a008

Nichols, DE. Structure-activity relationships of phenethylamine hallucinogens. J. Pharm. Sci., 1 Jan 1981, 70 (8), 839–849. 1424 kB. doi:10.1002/jps.2600700802

Shulgin, AT; Carter, MF. N,N-diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity. Commun. Psychopharmacol., 1 Jan 1981, 4 (5), 363–369. 1166 kB.

Repke, DB; Ferguson, WJ; Bates, DK. Psilocin analogs II. Synthesis of 3-[2-(dialkylamino)ethyl]-, 3-[2-(N-methyl-N-alkylamino)ethyl]-, and 3-[2-(cycloalkylamino)ethyl]indol-4-ols. J. Heterocycl. Chem., 1 Jan 1981, 18 (1), 175–179. 368 kB. doi:10.1002/jhet.5570180131

Shulgin, AT. Profiles of psychedelic drugs. 11. Bufotenine. J. Psychoactive Drugs, 1 Jan 1981, 13 (4), 389. 848 kB. doi:10.1080/02791072.1981.10471899

Shulgin, AT. Profiles of psychedelic drugs. 10. DOB. J. Psychoactive Drugs, 1 Jan 1981, 13 (1), 99. 775 kB. doi:10.1080/02791072.1981.10471457

Jacob, P; Shulgin, AT. Metallation-sulfidation: A convenient method for the synthesis of aryl alkyl sulfides and of unsymmetrical diaryl sulfides. Synth. Commun., 1 Jan 1981, 11 (12), 957–968. 160 kB. doi:10.1080/00397918108065755

Jacob, P; Shulgin, AT. The synthesis of hydroxybenzaldehydes from bromobenzaldehydes via lithiated Schiff’s bases. preparation of 5-hydroxypiperonal and related compounds. Synth. Commun., 1 Jan 1981, 11 (12), 969–977. 131 kB. doi:10.1080/00397918108065756 Rhodium.

Domelsmith, LN; Eaton, TA; Houk, KN; Anderson, GM; Glennon, RA; Shulgin, AT; Castagnoli, N; Kollman, PA. Photoelectron spectra of psychotropic drugs. 6. Relationships between physical properties and pharmacological actions of amphetamine analogues. J. Med. Chem., 1 Jan 1981, 24 (12), 1414–1421. 963 kB. doi:10.1021/jm00144a009

Jacob, P; Shulgin, AT. Sulfur analogues of psychotomimetic agents. Monothio analogues of mescaline and isomescaline. J. Med. Chem., 1 Jan 1981, 24 (11), 1348–1353. 953 kB. doi:10.1021/jm00143a017

Kothari, PJ; Hathaway, BA; Nichols, DE; Yim, GKW. Synthesis and serotonin-like activity of 2-amino-5,8-dimethoxy-6-methyl-1,2-dihydronaphthalene. J. Med. Chem., 1 Jan 1981, 24 (7), 882–884. 464 kB. doi:10.1021/jm00139a022

Pummangura, S; McLaughlin, JL; Schifferdecker, RC. Cactus alkaloids. XLVII. β-Phenethylamines from the “Missouri Pincushion”, Coryphantha (Neobessya) missouriensis. J. Nat. Prod., 1 Jan 1981, 44 (5), 614–616. 261 kB. doi:10.1021/np50017a022

Shulgin, AT. Hallucinogens. In Burger’s Medicinal Chemistry, 4th ed., Part III; Wolff, ME, Ed., Wiley & Co., 1 Jan 1981; pp 1109–1137. 4695 kB.

Braun, U; Shulgin, AT; Braun, G. Centrally active N-substituted analogs of 3,4-methylenedioxyphenylisopropylamine (3,4-methylenedioxyamphetamine). J. Pharm. Sci., 1 Jan 1980, 69 (2), 192–195. 513 kB. doi:10.1002/jps.2600690220

Cannon, JG; Perez, JA; Pease, JP; Long, JP; Flynn, JR; Rusterholz, DB; Dryer., SE. Comparison of biological effects of N-alkylated congeners of beta-phenethylamine derived from 2-aminotetralin, 2-aminoindan, and 6-aminobenzocycloheptene. J. Med. Chem., 1 Jan 1980, 23 (7), 745–749. 731 kB. doi:10.1021/jm00181a009

Standridge, RT; Howell, HG; Tilson, HA; Chamberlain, JH; Holava, HM; Gylys, JA; Partyka, RA; Shulgin, AT. Phenylalkylamines with potential psychotherapeutic utility. 2. Nuclear substituted 2-amino-1-phenylbutanes. J. Med. Chem., 1 Jan 1980, 23 (2), 154–162. 1125 kB. doi:10.1021/jm00176a010

Kantor, RE; Dudlettes, SD; Shulgin, AT. 5-Methoxy-alpha-methyltryptamine (alpha,O-dimethylserotonine) a hallucinogenic homolog of serotonin. Biol. Psychiat., 1 Jan 1980, 15, 349–352. 873 kB.

Braun, U; Shulgin, AT; Braun, G. Prüfung auf zentrale Aktivität und Analgesia von N-substituierten Analogen des Amphetamin-Derivates 3,4-Methylendioxyphenylisopropylamin. Arzneim. Forsch., 1 Jan 1980, 30 (5), 825–830. 1504 kB.

Weintraub, HJR; Nichols, DE; Makriyannis, A; Fesik, SW. Conformational energy differences between side chain alkylated analogues of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane. J. Med. Chem., 1 Jan 1980, 23 (3), 339–341. 452 kB. doi:10.1021/jm00177a030

Shulgin, AT. Introduction. In Moksha: Writings on Psychedelics and the Visionary Experience 1931–1963; Huxley, A; Horowitz, M; Palmer, C, Chatto and Windus Ltd, London, 1 Jan 1980; pp xvii–xix. 511 kB.

Woolverton, WL; Shybut, G; Johanson, CE. Structure-activity relationships among some d-N-alkylated amphetamines. Pharmacol. Biochem. Behav., 1 Jan 1980, 13 (6), 869–876. 783 kB. doi:10.1016/0091-3057(80)90221-X

Shulgin, AT. Profiles of psychedelic drugs. 9. LSD. J. Psychedelic Drugs, 1 Jan 1980, 12 (2), 173–174. 1025 kB. doi:10.1080/02791072.1980.10471571

Shulgin, AT. Profiles of psychedelic drugs. 8. Psilocybin. J. Psychedelic Drugs, 1 Jan 1980, 12 (1), 79. 1595 kB. doi:10.1080/02791072.1980.10471557

Nichols, DE; Kostuba, LJ. Steric effects of substituents on phenethylamine hallucinogens. 3,4-(Methylenedioxy)amphetamine analogues alkylated on the dioxole ring. J. Med. Chem., 1 Jan 1979, 22 (10), 1264–1267. 606 kB. doi:10.1021/jm00196a022

Glennon, RA; Gessner, PK. Serotonin receptor binding affinities of tryptamine analogues. J. Med. Chem., 1 Jan 1979, 22 (4), pp 428–432. 731 kB. doi:10.1021/jm00190a014

Glennon, RA; Kier, LB; Shulgin, AT.